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Abstract 
Background  
Safety and efficacy data on many medicines used in children are surprisingly scarce. As a 
result, children are sometimes given ineffective medicines or medicines with unknown 
harmful side effects. Better and more relevant clinical trials in children are needed to 
increase our knowledge of the effects of medicines and to prevent the delayed or non-use of 
beneficial therapies. Clinical trials provide reliable evidence of treatment effects because they 
perform controlled testing of interventions on human subjects. Trials in children are more 
challenging to conduct than trials in adults because of the paucity of funding, unique needs of 
children and particular ethical and safety concerns. Although current initiatives and 
regulations are improving the number and quality of trials in children, there are still 
deficiencies that need to be addressed to radically accelerate equitable access to evidence-
based therapies in children.  
 
This thesis is one of the first major attempts to comprehensively look at the equity, quality 
and relevance of clinical trials in children to inform better evidence-based child healthcare 
and outcomes worldwide. There is a growing recognition that more, better, and more 
relevant trials need to be conducted in children to drive improvements in child health. To 
enhance treatment, healthcare and outcomes in children requires us to understand the 
current context of trials in children, the challenges, disparities and strategies that could 
inform improvements. We hypothesised that there may be a poor match between the health 
problems that children face and the trials that are being conducted. Clinical trials are 
necessary to address unmet therapeutic needs and the disease burden of children globally. 
However, few trials are conducted in the LMICs where the majority of the global burden of 
disease resides. We, thus aimed to describe stakeholder beliefs and experiences of 
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conducting trials in children in LMICs to inform strategies for improving the number and 
relevance of trials in LMICs.  
 
Empiric studies of published trials involving children have shown methodological flaws and 
high risk of bias but it is unclear if this reflects editorial processes or true problems in design 
and conduct. We aimed to ascertain the completeness of the reporting of key domains in 
the conduct of clinical trials involving children by evaluating the protocols of pharmacological 
interventions for trials submitted to the Human Research Ethics Committees (HRECs) of 
Children’s Hospitals in Australia. The last decade has seen dramatic changes in the 
regulatory landscape to support more trials involving children, but child-specific challenges 
and inequitable conduct across income regions persist. We conducted a study to describe 
the attitudes and opinions of stakeholders towards trials in children, to inform additional 
strategies to promote more high-quality, relevant trials in children across the globe. 
 
Methods 
A number of different methods were used which best suited the thesis research questions. 
All trials on the World Health Organisation (WHO) International Clinical Trials Registry 
Platform (ICTRP) registered from 2005 to 2013 were reviewed. The disease-specific focus of 
registered clinical trials for children by income region was compared to the global burden of 
disease for 2011 using WHO disability-adjusted life-year (DALY) data. We conducted a 
systematic review of qualitative studies of stakeholders’ perspectives on conducting clinical 
trials among children in LMICs to inform strategies for more, better trials relevant to child 
health in LMICs. In the study checking for completion of the trial protocols, Ethics Offices in 
all Australian paediatric hospitals were invited to participate. De-identified trial protocols 
submitted for review in 2012 were evaluated using checklists based on CONSORT 
(CONsolidated Standards of Reporting Trials), the Cochrane risk of bias tool and Good 
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Clinical Practice guidelines. The international study of key informant semi-structured 
interviews were conducted with stakeholders (researchers, regulators and sponsors) 
purposively sampled from LMICs and high-income countries. The transcripts were 
thematically analysed. 
 
Findings  
The analyses of the trials on the WHO ICTRP showed that children account for 25% of the 
global disease burden, but represent only 15% (29 899/203 726) of registered trials. 
Although the number of trials in children registered annually has increased over time (from 
3174 in 2005 to 3392 in 2013), the proportion of trials involving children has decreased 
(from 18% to 13%). Despite 98% of the paediatric illness burden being in LMIC, only 22% of 
all trials in child health are conducted in those countries. There was moderate correlation 
between the number of trials and the burden of each disease within each region (Spearman’s 
correlation r=0.6, P=0.007 and r=0.55, P=0.015 in low-middle and high-income regions, 
respectively). There were mismatches of trials focus compared with disease burden. For 
example, respiratory diseases and neoplasms were over-represented and congenital and 
neonatal conditions were under-represented. 
 
The analyses of registered trials identified the inequities of trials in children. This was 
particularly prevalent in LMICs and we explored the contributory factors further by 
conducting a systematic review of stakeholder’s views of trials in children in LMICs. In this 
systematic review, 39 studies involving 3110 participants (children [n=290], parents or 
caregivers [n=1609], community representatives [n=621], clinical or research team [n=376], 
regulators [n=18] and sponsors [n=15]) across 22 countries were included. We identified 
five themes: centrality of community engagement (mobilising community, representatives 
pivotal role, managing expectations, retaining involvement); cognisance of vulnerability and 
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poverty (therapeutic opportunity, medical mistrust); contending with power differentials 
(exploitation, stigmatisation, disempowerment); translating to local context (cultural beliefs, 
impoverishment constraints, ethical pluralism) and advocating fair distribution of benefits 
(healthcare, sponsor obligation, collateral community benefits).  
 
Our narrative review of the literature on clinical trials in children showed that the study 
design of trials in children is complex and the protocol of trials therefore requires careful 
planning. In our assessment of completion of scientific components of paediatric trial 
protocols, four hospitals participated and 69 trials were included. Four of 8 hospitals agreed 
to participate and 69 protocols were analysed. The domains most frequently reported were 
clustered around the background and trial plan (planned interventions for each group (99%), 
specific objectives (97%), and scientific background (96%)). Domains that were reported 
least frequently were clustered around the statistical analysis plan (66%), the justification for 
a new trial based upon a systematic review of the published literature (48%), and child-
specific domains (48%).  
 
The interviews of the multinational stakeholders explored more in-depth the challenges 
identified in the narrative and systematic reviews, the analysis of registered trials and the 
completion of reporting domains in paediatric trial protocols. In the interview study, 35 
stakeholders from 10 countries participated. We identified five major themes: addressing 
pervasive inequities (paucity of safety and efficacy data, knowledge disparities, volatile 
environment, double-standards, contextual relevance, market-driven forces, industry 
sponsorship bias, prohibitive costs); contending with infrastructural barriers (resource 
constraints, dearth of paediatric trial expertise, logistical complexities); navigating complex 
ethical and regulatory frameworks (“draconian” oversight, ambiguous requirements, 
exploitation, excessive paternalism and unwarranted exclusion, precariousness of coercion 
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vs. volunteerism); respecting uniqueness of children (paediatric research paradigms, child-
appropriate approaches, family-centred empowerment); and driving evidence-based child health 
(advocacy, opportunities, treatment access, best practices, research prioritisation). 
 
Conclusions 
Overall, children continue to be under-represented in trials, particularly children from 
LMICs where disease burden is greatest. Trial activity correlates moderately with disease 
burden among the world’s children. Redressing these disparities requires prioritisation of 
child healthcare needs. Stakeholders believe that conducting trials in children in LMICs is 
complex due to social disadvantages, economic scarcity, idiosyncratic cultural beliefs and 
historical disempowerment which contribute to inequity, mistrust and fears of exploitation. 
They suggested effective community engagement in recruiting, building research capacity and 
designing trials that are pragmatic, ethical and relevant to the healthcare needs of children in 
LMICs to help improve equity and health outcomes of this vulnerable population. 
 
The design of trials in children across all income settings could be enhanced. In the study 
evaluating the completeness of reporting in protocols we found that protocols of clinical 
trials involving children assessed by Ethics Committees are generally comprehensive, but 
many key domains in trial design and conduct are not reported. There is widespread 
recognition of how problems in the design and conduct of clinical trials may lead to 
misleading conclusions. Stakeholders acknowledged that changes in the regulatory 
environment have encouraged more trials in children, but they contended that inequities, 
political, regulatory, and resource barriers continue to exist. Embedding trials as part of 
routine clinical care, addressing the unique needs of children, and streamlining regulatory 
approvals were suggested. Increasing international collaboration, establishing sustainable 
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centralised trials infrastructure, and aligning research to child health priorities were 
proposed to encourage more high-quality trials that address global child healthcare needs.  
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Chapter 1: Introduction and overview of the thesis 
 
1.1 Background and rationale 
Improving child health is a global concern. There are several contributory factors to child 
mortality including lack of access to healthcare and medicines, multiple social determinants as 
well as a scarcity of evidence to support safe and effective prescribing. Reliable evidence of 
treatment effects is essential to inform child healthcare and can be obtained from clinical trials 
by rigorous controlled testing of interventions. There is a need to evaluate the issues and 
challenges of performing clinical trials in children to help inform strategies for better 
evidence-informed care and outcomes in children. Children have unique therapeutic needs as 
they are developmentally and physiologically different from adults. They can also respond 
differently to medicines, which have the potential to impact their growth and maturation and 
affect them psychosocially. Many medicines prescribed for children have not been adequately 
evaluated for safety, dosing, efficacy and administration [1-3]. This can present challenges 
with medicine licensing, labelling and access in children. It is often necessary to prescribe 
medicines off-licence (not licensed with the regulatory authority) and off-label (not a labeled 
indication), which can risk exposing children to unintended adverse reactions or suboptimal 
therapies [4, 5]. It is essential for children to participate in clinical trials to enable the 
development of  empirically-verified, age-specific therapies and interventions [6]. Data from 
trials in children would therefore support licensing, labelling and access of medicines in the 
paediatric population. 
 
The dearth of paediatric trials denies children equitable access to evidence-based healthcare. 
This scarcity of appropriate testing of medicines in children is due to multiple factors, which 
require further in-depth exploration to inform improvements. Paediatric trials have novel 
Chapter 1: Introduction and overview of thesis 
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complexities due to the safety concerns of testing medicines in children, ethical considerations 
such as informed consent, lower prevalence of disease, the need to test different age groups, 
the possibility of late adverse effects,  the requirement for tailored study designs and the need 
for child-appropriate medicine formulations [4, 7]. Historically, clinical trials have focused on 
adults where there is a higher burden of illness and greater returns on investment [7].  Fewer 
trials in children is also related to the lack of economic incentives for the pharmaceutical 
industry to conduct trials of medicines in children as this market is not likely to compensate 
for the arduous and expensive drug development phases. Obtaining data on the current status 
of trials in children in comparison to adults and the paediatric disease burden is useful 
information for regulators, policy-makers and funding bodies in charge of allocating research 
funds aligned to health priorities. 
 
About 85% of research is estimated to lead to waste, due to inappropriate research questions, 
poor study designs and lack of transparency and completeness of reporting and 
implementation of findings [8]. There are reports that published paediatric trials are judged to 
be poorly designed with a high risk of bias which could threaten the internal validity of trial 
results, with possible consequences of harming children and overestimating trial effects [9, 
10]. It is also important to ascertain if the weak evidence-base in child healthcare is due to the 
scarcity of robust safety and efficacy data which can be improved by clinically-relevant trials, 
or if it is related to the design, conduct and reporting of trials. If it is related to the trial, this 
will warrant the development of guidance and standards to support the training and education 
of all paediatric trial stakeholders. To increase the value of research and reduce research 
waste, new interventions should be of value in a wide population group where burden of 
disease is greatest. Global investments in health research and development indicate 
inequitable access with only 10% of funds spent in low- and middle-income countries 
(LMICs) [11]. There are concerns that there is a critical lack of evidence-based child 
Chapter 1: Introduction and overview of thesis 
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healthcare in LMICs magnified by the scarcity of resources [12, 13]. A comparison of clinical 
trials in children conducted in the LMICs and high-income countries with the paediatric 
disease burden will help determine if they are matched to inform the child health research 
agenda locally and worldwide. 
 
The last decade has seen clinical trials in children undergoing an evolution with heightened 
awareness and advocacy that children are not little adults and require high-quality evidence to 
support clinical care [14]. The need for timely medicinal product development in children has 
been identified internationally by health care providers, researchers, professional and 
regulatory authorities and the public with some legislation and initiatives underway to 
improve trials in children. The impact of these initiatives to support trials in children and the 
success and challenges need investigation. Children are our future and have a right to 
evidence-informed healthcare. Improving evidence-based child healthcare through clinical 
trials is “everybody’s business” and is an important topic for further research [15].  
 
1.2 Objectives  
 
The issues of equity, quality and relevance of trials in child health in the current context are 
not clear. This theme of the thesis is very broad, thus selected components of the entire topic 
mainly focussing on the current status, challenges, gaps and enablers of clinical trials in 
children were chosen to be explored. The objectives of this thesis were to gather evidence to 
clarify some of the unresolved issues of equity, quality and relevance to inform improvements 
of clinical trials in children. The aims of this thesis were to: 
1.2.1 Provide a comprehensive narrative overview of what is written in the literature about 
clinical trials of medicinal products in children over the last decade. 
Chapter 1: Introduction and overview of thesis 
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1.2.2 Compare registered trials in children to the paediatric disease burden of the LMICs and 
high-income countries. 
1.2.3 Describe stakeholder beliefs and experiences of conducting trials in children in LMICs 
to inform strategies for improving the number and relevance of trials in LMICs. 
1.2.4 Evaluate the completeness of protocols of paediatric trials of pharmacological 
interventions submitted to the HRECs among Australian Children’s Hospitals, and to identify 
areas for improvement.  
1.2.5 Describe the attitudes and opinions of multinational researchers, regulators and sponsors 
of trials in children that could inform local and international strategies to improve trials in 
children. 
 
 1.3 Overview of chapters 
 
This thesis comprises 7 chapters (Figure 1.1) including this introduction chapter. Five papers 
will be presented that use quantitative and qualitative research methods to explore different 
aspects of equity, quality of trial design, conduct and reporting and appropriateness of the 
trials in addressing global paediatric disease burden and child health priorities. The contents 
of Chapter 2 are published and chapter 4 is accepted for publication. Chapter 3 is submitted 
for publication and Chapters 5 and 6 are to be submitted.   
 
Chapter 2 is a systematic literature search of MEDLINE and Embase databases of 
pharmaceutical intervention trials in children as a topic. The search was conducted over the 
last decade to capture the major changes and developments with regard to clinical trials in 
children during this period. The search strategy appears in Appendix A1. This comprehensive 
narrative review describes the dearth of safety and efficacy evidence in children and the 
urgency to conduct more, high-quality trials of relevance to child healthcare.  It also discusses 
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the importance of strong advocacy to increase paediatric evidence-based care and initiatives 
such as paediatric legislation, incentives and paediatric research networks. Study design and 
conduct issues in children such as pharmacokinetic studies, trial registration and publication, 
small sizes for paediatric studies, attitudes to children’s participation in trials and appropriate 
medicine formulations for children are also described. The ethical issues in children such as 
informed consent and assent and payment for participation are included. 
 
Each of these original  research presented in Chapters 3 to 6 contribute new understanding to 
the overarching theme of the thesis of equity quality and relevance of clinical trials in 
children. 
In Chapter 3, findings related to equity in Chapter 2 are built upon and the relevance of 
paediatric trials to disease burden is also examined. The registered clinical trials in children 
on the World Health Organisation (WHO) International Clinical Trials Registry Platform 
were reviewed. The disease-specific focus of registered clinical trials for children was 
compared to the global burden of disease by LMICs and high-income countries to determine 
whether these were matched. The WHO disability-adjusted life-year (DALY) was used to 
estimate the burden of disease or health in children. The number of trials in children was 
compared with those in adults.  
 
Chapter 4 continues the theme of equity and relevance of trials in children, but also examines 
issues related to quality of trials in children in LMICs. This is a systematic review of 
qualitative studies of children’s, parents’, researchers’, regulators’, sponsors’ and the public’s 
perspectives on conducting clinical trials among children in LMICs to inform strategies for 
more, better trials relevant to child health in LMICs. Findings were analysed using thematic 
synthesis, which inductively generated new analytical themes from the findings of the 
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included primary studies. 
  
In Chapter 5, we build on the theme of the quality of trials in children from Chapters 2 and 4. 
We evaluated the completeness of reporting of the scientific components of protocols of trials 
in children submitted to Ethics Committees of Australia Children’s Hospitals to identify gaps 
that could be improved. De-identified data on the protocols for trial characteristics and 
completion of scientific domains related to the background, rationale, objective(s), design, 
methodology, statistical considerations, organisation of a trial and risk of bias were extracted 
using a consolidated checklist to identify areas for improvement. 
 
Chapter 6 builds on Chapters 2, 3, 4, 5 looking at equity, quality and relevance of paediatric 
trials. It is a multinational qualitative study where key informant researchers, regulators and 
sponsors of trials in children were interviewed to elicit their attitudes and opinions on 
challenges and enablers of trials in children. Grounded theory and thematic analysis was used 
to group similar concepts into themes and subthemes relating to barriers and enablers of trials 
in children in the current clinical trials landscape. Relationships and patterns between themes 
were identified to develop a thematic schema encompassing the key findings.  
 
Chapter 7 concludes this thesis with a summary of the main findings, strengths and potential 
limitations, implications for clinical practice and policy making, and future research related to 
the equity, quality and relevance of trials in children. 
 
Rationale for subsequent chapters: Chapter 2 is an extensive review of clinical trials in 
children. Chapter 3 then focuses on registered trials in children by analysing trials on the 
WHO portal by income regions. In Chapter 4 we further explored issues surrounding 
conducting trials in LMICs by a systematic analysis of published literature of qualitative 
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studies looking at trials in children in LMICs. Chapter 5 is an analysis of the scientific 
components of trial protocols submitted to Ethics Committees. Chapter 6 explored the 
viewpoints of stakeholders by a qualitative analysis of perspectives from stakeholders 
obtained through interviews. Chapter 7 is the discussion and conclusion of the overarching 
theme of the thesis: equity, quality and relevance of clinical trials in children. 
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Chapter 2: Literature review - clinical trials in children 
 
2.1 Abstract  
Safety and efficacy data on many medicines used in children are surprisingly scarce. As a 
result children are sometimes given ineffective medicines or medicines with unknown 
harmful side effects. Better and more relevant clinical trials in children are needed to increase 
our knowledge of the effects of medicines and to prevent the delayed or non-use of beneficial 
therapies. Clinical trials provide reliable evidence of treatment effects by rigorous controlled 
testing of interventions on human subjects. Paediatric trials are more challenging to conduct 
than trials in adults because of the paucity of funding, uniqueness of children and particular 
ethical concerns. Although current regulations and initiatives are improving the scope, 
quantity and quality of trials in children, there are still deficiencies that need to be addressed 
to radically accelerate equitable access to evidence-based therapies in children. 
 
2.2 Imperative to conduct trials in children  
Since the acknowledgement of children as “therapeutic or pharmaceutical orphans” in the 
1960s [1-3] there has been a worldwide recognition of the need to conduct trials of medicines 
used in children as a mechanism to improve the health of children [4-7]. Significant advances 
in child health have resulted from the conduct of paediatric trials. Well-known trials of polio 
vaccines and the subsequent rapid translation into practice were instrumental in the successful 
and almost complete eradication of polio [8, 9]. Recent advances in multicentre cancer trials 
in children have increased childhood cancer 5-year survival from 28% in the late 1960s to 
79% by 2005 [10-13]. Regrettably, these stories of remarkable benefits cannot be extended to 
many other childhood conditions [14] because of the dearth of relevant trials.  
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Prescribing in children is often based on extrapolation from trials in adults due to the lack of 
paediatric data. Children are not “little adults,” but are a heterogeneous group, ranging from 
preterm neonates to post-pubertal adolescents [15-17]. Their disease presentation may have a 
different natural history than adults and they may also suffer from diseases which do not 
occur in adults [18-20]. Children have complex physiological, developmental, psychological 
and pharmacological characteristics that vary from adults and these features are also different 
across the newborn to adolescent age range [21]. They may metabolise certain medicines 
differently from adults resulting in sub-optimal therapy, unexpected responses, adverse drug 
reactions and toxicity which may affect development and future reproductive capacity [22-
24].  
 
Relying on adult safety and efficacy data when prescribing in children can have unpredictable 
and tragic effects [4, 17, 25]. For example, faster metabolism of cyclosporin in children could 
lead to sub-therapeutic levels because of under-dosing [26]. Prescribing tetracycline in 
children during the period of mineralisation of developing teeth results in severe enamel 
dysplasia [27]. Children may experience paradoxical hyperactivity with phenobarbital which 
is not experienced in adults due to differences in pharmacodynamics [26]. In neonates, 
because of the immaturity of the liver, reduced medicine clearance resulted in the Gray baby 
syndrome with chloramphenicol [28, 29]; hepatotoxicity, hypotension, renal failure and death 
with the solvent propylene glycol which was in E-Ferol
® 
[30] and “gasping syndrome” from 
metabolic acidosis with formulations containing benzyl alcohol [15]. Thalidomide, was used 
for morning sickness in pregnant women with devastating effects on foetal development, 
resulting in thousands of children being born with phocomelia [31]. 
 
More trials are needed, especially in areas of high clinical need. A study in 2007 showed that 
the number of randomised controlled trials in adults published in five high-impact general 
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medical journals has nearly doubled over 20 years, while the number of paediatric trials has 
not increased [32]. Despite about 27% of the world’s population being children [33], 
paediatric trials constitute only 16.7% of the total number of trials registered on the World 
Health Organisation (WHO) portal [34].  In a study of trials registered on clinicaltrials.gov on 
selected medical conditions, only 12% were paediatric trials although children contributed to 
almost 60% of the total disease burden [35]. The WHO Global Burden of Disease study in 
2002 estimated 11.4 million deaths in children under 10 years of age with 91% of these in 
children less than 5 years [36]. Fewer trials are conducted in younger children where it is most 
needed [37]. Only 7% (42) of all paediatric trials published in 2007 were in neonates [38, 39]. 
There are a disproportionately small number of trials in children in low-income countries [40, 
41]. Over 89% of children live in low and lower-middle income countries, but only about a 
quarter of the 604 trials of medicinal products in children published in 2007 were conducted 
in these countries [38].  
 
The pharmaceutical industry funds a greater proportion of trials in adults (65%) than children 
[35, 42]. Industry may be reluctant to conduct trials in children due to decreased commercial 
interest, increased cost and greater risk of liability [20, 43-45]. The more restrictive regulatory 
oversight for paediatric trials [23, 46] which includes the recommendation for provision of 
medicines post-trial to participants where there is proven therapeutic benefit [47, 48], may 
further discourage industry from conducting trials in children. Funding for paediatric trials 
therefore often rely on non-profit organisations, which has limited funding. The government 
favours trials in adults because of political and economic pressures [17, 35]. 
 
2.3 Study design and conduct of paediatric trials 
There are special considerations when designing any of the four phases of clinical trials in 
children [49, 50]. Phase I trials, which test the safety and pharmacokinetics of a new 
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intervention for the first time, are discouraged in children due to the unknown effects of the 
intervention [51, 52]. However, Phase I trials are more acceptable in children with severe or 
life-threatening conditions where there are no proven treatment or when standard therapies 
have failed [51, 52]. Phase I trials can only occur when there are appropriate pre-clinical 
safety and efficacy data available from animal studies, modelling or other predictive studies 
[53]. Phase II trials, which study the safety and efficacy of the intervention [51], are 
sometimes conducted in children. Generally, medicinal products testing in children are 
deferred until the trials reach phase III which evaluate efficacy, acceptability and adverse 
effects [54]. Although the intent of the deferral is to protect children from exposure to 
unnecessary harms, it also means a delay to the access of children to potentially useful 
medications [54]. Phase III trials (randomised controlled trials) compare the investigational 
intervention with standard therapy, another effective therapy or placebo to estimate unbiased 
treatment effects [54-56]. Control groups and placebos are used when there are no established 
alternative therapies [54, 57-59]. Phase IV post marketing trials are infrequently conducted in 
children. However, the Food and Drug Administration (FDA) Paediatric Research Equity Act 
(PREA) require paediatric trials of marketed medicines [60]. 
 
2.3.1 Pharmacokinetic studies   
Pharmacokinetic studies (which generally occur in Phase I) are important in the different 
paediatric age ranges. Challenges with pharmacokinetic studies include the lack of expertise 
in paediatric population pharmacokinetic or pharmacodynamic analysis; problems associated 
with the number, volume and timing of sampling; and the absence of sensitive micro-
analytical techniques to accurately determine the drug concentration of very small volume 
specimens [61]. If the disease progression is similar between children and adults, an initial 
dose extrapolated from adult data may be adequate, followed by pharmacokinetic studies to 
determine the most appropriate paediatric dose [62]. Another approach is to conduct single 
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dose paediatric studies in the different age groups if medicines are known to have linear 
pharmacokinetics in adults [63]. In paediatric pharmacokinetic studies, innovative trial design 
techniques for reducing the number and volume of samples required are sometimes used. 
These techniques use sparse and scavenged pharmacokinetic samples with population 
pharmacokinetic methods using non-linear mixed effects [61, 63]. Opportunistic trials, which 
collect pharmacokinetic samples from children receiving treatment as part of routine clinical 
care, is another low-risk and high-yield design that is efficient and acceptable to parents and 
ethics committees [61]. Pharmacogenomic methods are also being developed for investigating 
drug disposition, efficacy and safety [46]. 
 
2.3.2 Trial registration and publication 
Public registration of clinical trials is especially important to protect participants from 
unnecessary, duplicative studies, to improve transparency and overcome publication and 
selective outcome reporting bias [37, 64-66]. Prospective registration of trials is strongly 
advocated internationally by regulatory authorities, ethics committees and journals as a 
condition of publication [67]. However, a review of published paediatric randomised 
controlled trials showed that some were poorly reported [42] and had incomplete reporting of 
adverse drug reactions [68]. Disappointingly, a considerable number of paediatric trials that 
were conducted as a result of the paediatric exclusivity legislations were not published [69]. 
For paediatric trial results to be translated into clinical practice, prompt and accessible 
publication of unbiased results including negative results helps to improve public trust and 
confidence in paediatric research [70-72].  
 
2.3.3 Small trials sizes for paediatrics 
The recruitment of children in trials is more difficult than for adults [45, 47] because of the 
lower burden of disease in children [46, 73, 74]. Most paediatric trials have small sample 
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sizes  [35, 38, 41] with only 38% of 736 paediatric trials published from 1996 to 2002 having 
a sample of more than 100 [40]. The small sample size, heterogeneity of response of children 
to treatments and rarity of certain important outcomes contribute to the problem of inadequate 
power [75]. Underpowered trials may provide inconclusive results and fail to detect modest 
but clinically relevant outcomes including adverse effects [17, 21, 54, 71]. This may waste 
resources and the efforts of children’s participation in trials [76]. To address the small sample 
sizes in children, there have been major achievements in developing statistical methods and 
collaborative specialist multinational groups and paediatric clinical trials networks that pool 
their data and resources [77-82]. 
 
2.3.4 Attitudes to participation in trials  
There has been a general reluctance about involving children in trials particularly by parents 
and doctors because of fears of harming children by exposing them to uncertain treatment 
effects [45, 72, 83]. In particular, parents were anxious about their child being treated as a 
“guinea pig” and were concerned that investigators may have conflicting interests and do not 
have their child’s health as a priority [45, 84]. However, in a neonatal study, 75% of parents 
believed that their doctor would not approach them to do research if it might place babies in 
real danger and 50% reported that they trusted their doctor and would agree to participate in a 
trial if suggested by their doctor [85]. Practitioners interviewed in a study in 2011 were 
apprehensive and averse to recruiting children for trials due to the trial burdens which 
included the overwhelming amount of information they had to provide to the families [72]. 
Assisting practitioners to understand families’ perceptions of trials and providing ‘moral’ 
support may improve recruitment of children [72]. In contrast, parents who reported a positive 
recruitment experience, viewed participation in a trial as an “exciting” opportunity, felt a 
sense of comfort and safety, acknowledged the value of research and desired to be informed 
about a trial if their child was eligible [72]. Other  positive aspects of parents’ experiences 
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include the altruistic desire to help future children, the opportunity to access new therapies, 
increased access to health care professionals and medical information, better medical care for 
their child, meeting other parents in a similar situation, and feeling a sense of hope when no 
other effective therapies are available [72-74, 86, 87]. The high level of threat and need for 
hope may account for the generally high rates of recruitment to neonatology and childhood 
cancer trials [83]. There are also perceived benefits for children participating in trials. 
Children often enjoy being part of a trial, interacting with other participants, being able to 
contribute to helping other children and are empowered about their treatment [84]. 
 
There has been some work on developing strategies to aid parents in the decision making 
process for trial participation [88].  Some strategies include improving the readability of the 
consent [89]. Masty et al conceptualised a “goodness-of-fit” approach to informed consent for 
paediatric trials that encouraged investigators to create consent procedures that took into 
account the research context, the child’s cognitive and emotional maturity, and the family 
system [90]. The James Lind Library has been created to help the public understand that trials 
are fair tests of treatments in health care [91]. 
 
The use of placebo is poorly understood by parents who do not understand the rationale for 
using placebo to determine whether the intervention is effective or necessary. Parents fear 
assignment of their child to the placebo arm or to the treatment arm which is later proven to 
be less effective [45, 92, 93]. This concern may be compensated for by providing the proven 
effective treatment to all participants at the conclusion of the study. Alternative randomisation 
methods should also be considered which may be more acceptable to parents. In a 
conventionally randomised trial, parents’ views were evenly divided on accepting the 
controversial Zelen randomisation where randomisation occurs prior to discussion with the 
family and only if the child is allocated the experimental treatment arm is consent sought [94]. 
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In a survey investigating different types of consent to hypothetical neonatal resuscitation 
trials, parents wished to be responsible for making the  informed decisions and were more 
comfortable with prospective consent than deferrals, waivers or ‘opt-out’ options [95].  
 
The burdens of trial participation for children are different to adults, for example, children’s 
aversion to needles makes obtaining blood samples challenging. To address this burden and 
protect children from unnecessary testing, the volume of blood sampling generally allowed in 
paediatric trials is less than 3% of the estimated circulating blood volume over a 2 to 8 week 
period [20, 96, 97]. Alternative appropriate sampling techniques, for example, finger or heel 
pricks or salivary samples may be preferred as it minimizes discomfort for children [15, 20, 
96, 97]. There is a strong advocacy that paediatric trials requires the same dedicated time and 
attention to educate families and participants, ensuring appropriate child friendly environment 
and adapting treatments to their special needs that is generally accepted as routine clinical 
care [98, 99]. The use of pragmatic trials where there are no additional burdens of testing and 
monitoring beyond the requirements of routine clinical care [37-40] may also alleviate some 
of these concerns, including the use of placebos [55]. Participation may also be improved by 
having trained investigators who understand the complexities of conducting trials in children, 
appropriate facilities that meet the needs of children and a designated trials coordinator to 
facilitate recruitment and trial conduct [45, 93, 100]. Increasingly the importance of engaging 
children and families in the recruitment, consent and design of trials has also been recognised 
[99]. 
 
2.3.5 Appropriate medicine formulations in trials 
The development of appropriate formulations for children has been slow. This may be due to 
historical disasters such as the formulation of sulphanilamide as an elixir which used 
diethylene glycol without animal toxicity testing resulting in poisoning and deaths in the 
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1930s [101, 102]. Consequently, risk averse companies may be reluctant to develop paediatric 
formulations due to the potential harmful effects of excipients used in the products and the 
low market share of these products. To encourage the pharmaceutical industry to develop 
paediatric appropriate formulations, the 2003 FDA Best Pharmaceuticals for Children Act 
(BPCA) [103] and European Union Paediatric regulations was endorsed.  
 
Administration of medicines in children is complex and the trial design needs to consider the 
child’s developmental abilities and the medicine’s acceptability and tolerability as this will 
impact on compliance.  Children are fearful of injectable medicines and if an alternative route 
of administration is not available, the provision of local anesthetic gels or patches will 
decrease discomfort. The requirements of child friendly formulations may differ in resource 
limited settings where there may be a lack of refrigeration facilities which may impact on the 
stability and efficacy of the medicine [104]. When there is a lack of paediatric appropriate 
formulations, the use of adult dose forms such as tablets and capsules can be problematic for 
younger children who cannot swallow tablets as crushing tablets or opening capsules and 
dispersing in liquids may compromise the palatability and bioavailability of the medicine and 
affect the trial results [96]. The inclusion of extemporaneous preparation guidelines in 
paediatric trials which use solid oral dosage forms, will improve the accuracy and 
reproducibility of the preparation [73]. Skin patches or flexible oral solid dosage forms such 
as dispersible tablets or powders, melts (wafers, sublingual) and sprinkles may be more 
suitable across various settings [102].   
 
2.3.6 Outcome measures 
As children grow and mature through the developmental stages, it may not be suitable to use 
the same outcome measures when comparing children of different ages and stages [16]. Some 
outcomes such as pain, nausea, dizziness, level of sedation or visual and auditory responses 
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[42] are difficult to measure and report in young children. When designing how to measure 
these outcomes, researchers need to consider using age-appropriate tools such as the face pain 
scale [57, 105]. Because of differences in body composition in different age groups, 
pharmacokinetic studies have sometimes resulted in incomplete and incorrect conclusions 
[96]. Trials that include different paediatric ages may need appropriate dose adjustments by 
weight or body surface area [96, 106]. Researchers are increasingly recognising the 
importance of qualitative outcome measures that are relevant to the child and family, 
including the impact of the illness and treatment on the quality of life [16]. When measuring 
quality of life outcomes, consideration needs to be given about whether to use proxy response 
by parents or reporting by the child or both [107], as these may differ. Involving parents and 
children in the selection of outcome measures that are important to them is recommended [16, 
21]. 
 
2.4 Ethics of paediatric clinical trials 
There is a dilemma in finding a balance between the obligation to conduct trials to protect 
children from the risk of using untested medicines and to protect children against unknown 
risks and harms which may occur with trial participation [27, 39, 108, 109]. The ethical 
principles of respect for persons, beneficence, non-maleficence and justice in trials involving 
children are the same as adults. There are additional ethical challenges because children lack 
the capacity to understand the risks involved in trials and depend upon adults to make 
decisions for them [110].  In a review of 739 paediatric trials from 1996 to 2002, 523 (71%) 
reported adverse drug reactions, but only 13 (2%) of the trials had safety monitoring 
committees [4]. Since then, trial governance are becoming more stringent with a requirement 
for an independent safety monitoring board with paediatric expertise, who can appreciate the 
uniqueness and unpredictability of responses in children [76, 111]. Long-term follow up in 
children is particularly important as many adverse effects may present later in life [17, 44]. 
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2.4.1 Informed consent and assent 
Informed consent for participation in paediatric trials is more complex than adult studies 
because consent is by proxy from the parents or guardian, who have a duty to protect the 
child’s welfare [112]. Parents are uncomfortable with this responsibility because they are 
making a decision for their child [87]. Mason and Allmark  propose that parents’ consent in 
trials is vital to socially recognise parental roles, but does not offer added protection for 
neonates to that provided by appropriate research ethics, safety monitoring and governance 
procedures and parents’ knowledge of these measures would improve decision making [113]. 
A review by Shilling and Young indicated that parents are keen to take responsibility for the 
decision to enrol their child in a trial, but are also fearful of making the 'wrong' decision’ [83]. 
They also reported that individual parent’s understanding of the threat of the child's condition 
and the trial risks depends on their personal values and experiences, their child’s medical 
condition and the type of the trial [83]. Suggestions to address some of these parental 
concerns identified in this review include positive interactions at recruitment with the 
flexibility to tailor discussions to the needs and circumstance of individual parents [83].  The 
study by Woolfall et al in 2013 suggest that the investigating team involved in recruitment 
need to be aware of parents’ priorities and the sorts of misunderstandings that can arise with 
parents [86]. A goodness-of-fit approach is described by Masty and Fisher whereby consent 
procedures are tailored to the research, the cognitive and emotional maturity of the child, the 
family system, the participants’ priorities and well-being and are focussed on the issues that 
are of concern to potential participants and helping them achieve understanding of a trial [90]. 
To improve recruitment of children, the study by Woolfall et al also recommended providing 
tailored trial information on aspects that parents considered important in making a decision 
for their child participating in a trial [86]. Also providing information about the trial not only 
to parents but also to children in an age-appropriate method to improve comprehension, show 
respect, preserve trust and enable cooperation [98, 114]. The most frequently cited 
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suggestions from interviews and focus groups for improving informed consent related to 
allowing parents more time to make their decision, the amount and type of information 
provided, organisation of the consent meeting, communication style, and providing additional 
materials [115]. Although consent by parents or guardians is a legal requirement for trials, the 
autonomy of children should be respected and investigators need to also include them in 
decision making as much as they are capable [27, 87, 116]. Children’s dissent should also be 
respected, particularly if their dissent is different from their usual response to the same 
procedure in normal clinical care. 
  
2.4.2 Payment for participation 
Although it is common practice to compensate trial participants for travel, parking, meal 
allowance and accommodation [54], payments for participation in trials is more controversial 
in children [117]. The types of payment can be in the form of reimbursement for direct trial-
related expenses, compensation for the time and inconvenience of trial participation, 
appreciation after participation to thank them for their involvement and incentives to reward 
enrolment above actual out-of-pocket expenses [112, 117]. While the European Union (EU) 
advocates banning of all incentive payments to children [118], this is common practice in the 
United States (US) where almost 25% of paediatric trials offer payment [117]. The ethical 
concern about large incentive payments is that it might entice and distort the judgement and 
decision of the parent or child about the risks of trial participation [112, 118]. However, non-
payment for direct expenses and inconvenience of trial participation may create unnecessary 
financial obstacles for participation and risks hindering essential paediatric research [45, 117-
119]. The ethics committees, investigators and sponsors need to ensure that payment for trial 
participation of children is fair by keeping payments reasonable [98, 120].  
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2.5 Advocacy for trials 
The 1989 ‘Convention on the Rights of the Child’ ‘recognise the right of the child to the 
enjoyment of the highest attainable standard of health’ [121].  This includes the right to have 
research evidence for treatments commonly used in children. It is a reasonable requirement 
for the developmental pipeline of new interventions to include children in trials when use in 
children is anticipated [54, 122]. Several rigorous guidelines including the Belmont Report 
[123], Declaration of Ottawa on Child Health [124], Declaration of Helsinki and International 
Conference on Harmonisation (ICH) E11 [15, 125] address the need for paediatric trials and 
protection of the rights and welfare of children. Many countries have also developed their 
own regulations, guidelines and standards for the inclusion of children in trials [22, 54, 57, 
126-128]. 
 
2.5.1 Paediatric legislations 
Most medicines used by children internationally are unlicensed or off-label, with no 
randomised controlled trial data in more than 50% of interventions used in children as 
compared to adults [44, 71, 129-131]. The US was the first to initiate legislative changes in 
1997 to encourage more trials in children to improve the evidence-base for medicines in 
children [28, 51], followed by the EU in 2007 [7, 132-135] (Figure 2.1). Their expectations 
were for the pharmaceutical industry to evaluate the safety and efficacy of medicines used by 
children in all appropriate paediatric age groups, to ensure that product labels contain the 
known paediatric data, to develop paediatric appropriate formulations and to provide a 
Paediatric Investigation Plan for testing in children at the time of medicine application 
submission [122]. Both regulations have mandatory requirements with an incentive of a six-
month extension of patent protection to encourage the pharmaceutical industry to conduct 
paediatric trials. These incentives resulted in an increase in the number of paediatric trials 
[136-138]. By March 2008, more than 49,000 children were enrolled in trials and the FDA 
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had granted exclusivity to 150 medicines and granted requests for 842 studies which were 
mostly for new indications of existing medicines [134]. The FDA “New Paediatric Labelling 
Information Database” provides information of new paediatric trials that resulted in new or 
enhanced safety data in children [137, 139]. In a retrospective analysis of the applications for 
Paediatric Investigation Plan and Waivers submitted to the European Medicines Agency 
(EMA), from 2007 to 2009, there has only been a slight increase in the proportion of 
paediatric trials from 8.2% of all trials in 2007 to 9.4% in 2009 [140]. The main therapeutic 
areas of applications were endocrinology (13.4%), oncology (11%), infectious diseases 
(10.8%) and cardiovascular diseases (7.1%) [140]. This pattern reflected the commercial 
interest of the pharmaceutical industry to evaluate medicines with a high market value and 
which are commonly prescribed in adults rather than addressing the priority health needs of 
children [140, 141]. Many frequently prescribed, essential medicines that are off-patent and 
have a small market-share in children have yet to be investigated [39, 142, 143]. This is 
because incentives for the development of off-patent medicines in both the US and EU is 
small and voluntary and public funding is inadequate [142].  
 
The pharmaceutical industry does not appear to be interested in transferring the benefits of 
approved paediatric appropriate medicines in the US and EU to other countries. This may be 
due to the lack of economic incentives and the high costs associated with amending the labels 
of existing medicines with new paediatric data or registering new medicines. Therefore, there 
needs to be an efficient, harmonised process globally through collaboration of government, 
pharmaceutical industry and the medical community to ensure that the development of 
paediatric medicine is optimally aligned with priority healthcare needs [45, 142]. Canada and 
Japan has implemented modest paediatric regulation reforms [142]. Other countries need to 
adopt regulations and incentives for promoting paediatric medicines research with sustained 
government and societal support. 
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Figure 2.1 Timeline of paediatric regulations in the US and EU 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
2.5.2 International paediatric trials initiatives 
Global priorities of the WHO Millennium Development Goals include the 'Make medicines 
child size' initiative and the World Health Assembly “Better Medicines for Children" 
Resolution WHA60.20 in 2007 to improve knowledge, access, research and development of 
paediatric medicines [144, 145]. Another WHO initiative is the Paediatric medicines 
Regulator's Network (PmRN) which involves National Medicines Regulatory Authorities 
(NMRAs) which aims to harmonise the regulation of manufacture, license and research of 
medicines for children [144]. 
 
  1979   1994         1997        1998               2002        2003                       2007            2012 
FDA 
regulations: 
drug label to 
include 
paediatric use 
subsection 
based on 
adequate well-
controlled 
studies 
Final Rule revising 
Paediatric Use 
Subsection 
(21CFR201.57): more 
paediatric data on the 
label based on adult 
studies plus paediatric 
pharmacokinetics and 
safety data  
FDA Modernization 
Act of 1997 
(FDAMA): 
voluntary 
•paediatric 
exclusivity 
•written request 
introduction 
•6 month extension 
of patent 
Final Paediatric Rule:  
 assess paediatric safety 
and effectiveness of 
•all new molecular 
entities and all 
supplemental New Drug 
Applications 
•request studies for 
marketed drugs and 
biological products  
Best Pharmaceuticals for 
Children Act (BPCA): 
voluntary, replaced FDAMA 
•established programme 
and funding for study of 
off-patent drugs 
•Institute of Medicine 
reviews federal paediatric 
regulations  
Paediatric 
Research 
Equity Act 
(PREA):  
replaces the 
1998 Final 
Paediatric Rule  
 
FDA amendments Act 
(FDAAA): 
Re-authorisation of 
BPCA and PREA. 
Establishment of 
paediatric review 
committee (PeRC) 
•safer and more 
effective treatments 
  
FDA Safety and 
Innovation Act 
(FDASIA) 
paediatric 
provisions: 
strengthens BPCA, 
PREA, Paediatric 
Medical Device 
Safety and 
Improvement Act 
EU Paediatric regulation (1901/2006):  
•6 month marketing authorisation 
extension for new drugs 
•Paediatric-Use Marketing Authorisation 
(PUMA): 10 years data protection for a 
new indication for off-patent medicines 
•July 2008, requirement of Paediatric 
Investigation Plan 
•2009, rules apply to new indications, 
formulations, routes of administration 
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International paediatric trial networks have been established in many countries to address 
some of the challenges by improving the infrastructure and research capacity. The US and EU 
created networks with specialised expertise in conducting trials in children and have dedicated 
funding for paediatric research and training [142]. The US National Institute of Child Health 
and Human Development (NICHD) Pediatric Trial Network (PTN) was launched in 
September 2010 with US $95 million for 7 years to conduct paediatric trials on off-patent 
medicines [146]. This network provides an appropriate environment for performing safe and 
effective trials in children as recommended by the Best Pharmaceuticals for Children Act 
(BPCA) drug development program in a variety of therapeutic areas [146]. In 2012, the 
network in collaboration with the FDA has commenced paediatric studies on 30 drugs [147]. 
 
The Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)] was 
established in March 2011 in collaboration with research networks, investigators and centres 
with recognised expertise in conducting paediatric trials [148]. This network is working 
towards developing the necessary competences and avoiding unnecessary duplication of 
paediatric studies; educating parents or carers and children about trials and encouraging their 
participation; raising awareness among healthcare professionals of the necessity for trials in 
children of all ages, supporting their involvement in such studies and engaging in dialogue 
with ethics committees on paediatric trials issues [148]. The National Institute for Health 
Research (NIHR) Medicines for Children Research Network (MCRN) in the UK was 
established in 2005. This network has been more successful because of funding from the 
government [99]. The Standards for Research in (StaR) Child Health is an international 
initiative founded in 2009 to improve the quality of the design, conduct, and reporting of 
paediatric trials by promoting the use of internationally developed research standards to 
enhance their reliability and relevance [5, 149-151].  
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Professional bodies and research organisations internationally have also recognised the 
imperative to conduct paediatric trials. These include the International Pediatric Association 
(IPA) [152], the American National Institute of Health (NIH) [153, 154] and Academy of 
Paediatrics (AAP) [54], the UK Medical Research Council (MRC) [155] and Royal College 
of Paediatrics and Child Health (RCPCH) [156]  and the European Agency for the Evaluation 
of Medicinal Products (EMEA) [125].  
 
International collaborative disease specific groups have been formed to address the logistical 
and methodological difficulties in conducting trials of diseases with a low prevalence [80]. 
Examples of successful disease specific groups include the Children’s Oncology Group 
(COG) [77], Paediatric Rheumatology International Trials Organisation (PRINTO) [79] and 
Paediatric European Network for the Treatment of AIDS (PENTA) [81]. As a result of 
collaboration, the Children’s Oncology Group has developed a research culture in the 
participating institutions which accepts protocol-driven trials as part of standard care [13]. It 
has also facilitated rigorous protocol development and review, centralisation of pathology 
review, central database and safety monitoring of toxicity and response, internal auditing to 
ensure compliance to Good Clinical Practice and involvement of established investigators 
with oncology paediatric expertise [45, 157]. The Paediatric Rheumatology International 
Trials Organisation (PRINTO) has a Scientific Advisory Council, International and National 
Coordinating Centres to facilitate logistics and scientific elements of multicenter, 
multinational studies [80]. PRINTO’s achievements include developing standardised 
treatment outcome measures, training young researchers, access to network facilities for the 
conduct trials and establishing a website for families to access health information [80]. All 
these global initiatives can be adopted by other disease specific groups to support the 
collaborative efforts to increase the number of clinically relevant paediatric trials. 
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2.6 The way forward  
Although progress has been slow, paediatric clinical trials has undergone a renaissance with 
international recognition of the importance of trials in children. However, there continues to 
be deficiencies including inadequate funding and conflicts of interest with trials still being 
driven by financial and political incentives. Health policy makers need to consider the needs 
of children by setting priorities, developing infrastructure and providing sufficient funding 
[158] that is sustainable to accelerate the progress of equitable healthcare. The future health of 
children hinges on the success of paediatric trials. Greater advocacy and collaboration 
between all major stakeholders including regulatory authorities, pharmaceutical industries, 
scientific community, clinicians and the public at national and international level is crucial to 
this success. Investment into better evidence-based treatments for our children is an 
investment into a better future for all. 
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3.1 Abstract         
Objective: To compare registered clinical trials in children to the paediatric disease burden in 
low-and middle-income countries (LMICs) and high-income countries.  
Methods: All trials on the World Health Organization (WHO) International Clinical Trials 
Registry Platform registered from 2005 to 2013 were reviewed. The disease-specific focus of 
registered trials for children was compared to the global burden of disease for 2011 using 
WHO disability-adjusted life-year data. 
Results: Children account for 25% of the global disease burden, but represent only 15% (29 
899/203 726) of registered trials. Although the number of trials in children registered annually 
has increased over time (from 3174 in 2005 to 3392 in 2013), the proportion of trials 
involving children has decreased (from 18% to 13%). Despite 98% of the paediatric illness 
burden being in LMIC, only 22% of all trials in child health are conducted in those countries. 
More trials were registered in high-income than in LMICs for the majority of the disease 
categories. There was moderate correlation between the number of trials and the burden of 
each disease within each region (Spearman’s correlation r=0.6, P=0.007 and r=0.55, P=0.015 
in LMICs and high-income countries, respectively).  
Conclusions: Overall, children continue to be under-represented in clinical trials, particularly 
children from LMICs where disease burden is greatest. Trial activity correlates moderately 
with disease burden among the world’s children. Stakeholders need to embrace an evidence-
informed approach of prioritising trials to specifically address healthcare needs of children 
and improve the disparities. 
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What is known on this topic 
 Many medicines in children have not been tested for safety and efficacy, particularly 
in low-and middle-income countries, but this has not been properly enumerated. 
 Clinical trials in children are important to inform evidence-informed child healthcare. 
 There are initiatives to register and conduct more trials in children, however 
investigations on whether the scope of all trials registered worldwide matches relevant 
child health therapeutic areas to inform the research agenda in children is scarce.  
 
What this study adds 
 Children account for 25% of the global disease burden, but represent only 15% of the 
total trials registered worldwide.  
 Less than a quarter (22%) of the total registered trials in children were in the LMICs, 
despite 89% of the world’s children living in this region and contributing to 98% of 
the global paediatric disease burden.  
 There is mismatched focus of trials in relation to disease burden, which should be 
prioritised according to the therapeutic needs of children, and where the disease impact 
is greatest. 
 
3.2 Introduction 
The majority of the disease burden and mortality among children occurs in low-and middle- 
income countries (LMICs), while most of the paediatric research expertise and resources is 
concentrated in high-income countries [1]. The World Health Organization’s (WHO) 
Millennium Development Goals aim to close the gap in inequitable healthcare delivery and 
improve outcomes for children globally [2, 3]. New research underpinning such ambitious 
goals, particularly trials to support the safe and effective use of interventions, is required.  
 
Chapter 3: Disease burden - research match? Registered trials in child health from low-middle and high-income countries  
43 
 
Descriptive studies suggest that there are fewer trials in children, especially in resource-
limited settings [4-8]. A comparison of the distribution of current trials conducted among 
children against child health needs is required to inform strategies for prioritising research. 
The WHO International Clinical Trials Registry Platform (ICTRP), a global initiative linking 
national trial registers, was established in 2006 to improve transparency and access to trial 
registration data [9, 10].  The aim of our study was to compare registered trials in children to 
the paediatric disease burden in low-middle and high-income countries.  
 
3.3 Methods 
3.3.1 Inclusion criteria 
All trials on the WHO ICTRP from 1 January 2005 to 31 December 2013 were selected 
because most major journals required trial registration from 2005 [10, 11]. The WHO portal 
provides access to a comprehensive central database of trial records that meet the WHO 
International Standards for Clinical Trial Registries. The portal has a facility to allow for 
identification of on-going and completed child-specific trials, defined as “any research study 
that prospectively assigns human participants or groups of humans to one or more health-
related interventions to evaluate the effects on health outcomes” [9] in  participants from birth 
to 18 years inclusive. 
 
3.3.2 Data extraction 
Data were extracted from January 22-27, 2014. Double data extraction was performed 
independently with data re-extracted when discordant values were obtained. The number of 
registered trials rather than the number of records of trials was extracted, avoiding 
overestimation of trials that had multiple registrations. Registered trials in children by the 
country of recruitment were determined by limiting ‘search for clinical trials in children.’ The 
total number was determined by combining the trials from low-middle and high-income 
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countries. Trials in adults were determined by subtracting the number registered in children 
from the total number of trials.   
 
The data on the number of trials were extracted yearly from 2005 until 2013. Characteristics 
of child-specific trials extracted according to income regions included the disease-specific 
scope, intervention, and primary sponsorship. Intervention was classified using an adapted list 
from clinicaltrials.gov [12-14]. An adapted Australian New Zealand Clinical Trials Registry 
(ANZCTR) list was used to classify the primary sponsor [15]. For industry sponsorship, we 
searched for ‘commercial or pharmaceutical’ and the top 25 pharmaceutical companies names 
[16]. 
 
3.3.3 Disease-specific scope 
The WHO Global Health Estimates  summary tables disease categories were used [17]. Health 
condition refers to an illness, disorder, injury or any health issue [12]. The disease category 
was specified in the ‘condition’ field on the portal. Malignant and other neoplasms were 
combined as one category. Synonymous terms for diseases were combined during data 
extraction.  
 
3.3.4 Location  
Recruiting countries were defined as low-and middle-income or high-income according to the 
World Bank list of economies, July 2012.[18] The groups are low-and middle-income 
(combined for low-income: $1025 or less, lower-middle income: $1026–4035, upper-middle 
income: $4036–12475) and high-income ($12476 or more) [18]. Individual countries from the 
income regions were selected in the ‘countries of recruitment’ field and data were extracted 
for all the countries combined for that region.  
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3.3.5 Disease burden 
The population and disease burden in children was estimated from the World Bank data of 
2011[18, 19]. The WHO disability-adjusted life-year (DALY) data for 2011 was used to 
estimate the burden of disease [17]. DALYs were calculated as the sum of the Years of Life 
Lost (YLL) due to premature mortality in the population and the Years Lost due to Disability 
(YLD) for people living with the health condition or its consequences [9]. One DALY may be 
regarded as one lost year of ‘healthy’ life due to disease [9, 20]. Pre-defined age groups were 
used for the population and DALY data in the Global Health Estimates summary tables. An 
approximate estimate of DALYs for children 018 years was determined by combining 
DALYs for persons 027 days, 159 months, 514 years, and 4/15 of 1529 years [9, 20, 21].  
 
3.3.6 Statistical analysis 
For every Global Health Estimate disease category, we calculated the DALYs for each income 
region using the world paediatric DALYs. The proportion of trials in each therapeutic area 
within each region was compared to the proportion of DALYs in that therapeutic area or 
region using one-sample Wald tests for binomial proportions and 95% confidence intervals 
calculated. Within each region, the associations between the number of trials and the DALYs 
for the various therapeutic areas were calculated using Spearman correlations. Statistical 
analyses was performed using the SAS software, version 9.3 (SAS Institute, Cary, North 
Carolina). 
 
3.4 Results 
3.4.1 Number and location of trials 
In 2011, 24% (2319/9730 million) of the world’s population were children. However, only 
15% (29 899/203 726) of all trials registered worldwide between 2005 and 2013 were 
conducted in children. Despite a steady increase in the number of registered trials in children 
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worldwide, from 3174 in 2005 to 3392 in 2013, as a proportion of the total number of trials, 
this has decreased from 18% (3174/17 274) in 2005 to 13% (3392/25 822) in 2013 (Figure 1).  
 
Most (89%) of the world’s children live in LMICs, but only 22% of the 29 899 registered 
trials involve these countries. For the period 2005 to 2013, the total number of trials in 
children from LMICs has increased from 405 to 1033, compared to high-income countries 
where it has decreased from 2769 to 2359 (Figure 1). Over these nine years, the proportion of 
registered trials in children in the LMICs has increased from 13% (405/3174) to 30% 
(1033/3392). 
 
3.4.2 Characteristics of registered trials in children 
3.4.2.1 Types of intervention and sponsorship 
Drug therapy was the main intervention type, comprising 31% (9357/29 899) of the total trials 
in children (Table 1) with the majority 77% (7233/9357) in high-income countries.  
The same number of biological or vaccine trials (1918) were conducted in children in both 
income regions. Universities were the major sponsor of trials conducted in children worldwide 
with only 17% sponsored by the pharmaceutical industry.  
 
3.4.3 Comparison of trials and disease burden for Global Health Estimate disease 
categories  
 
Children contributed to 25% of the global disease burden, but only 15% (29 899/203 726) of 
the total number of registered trials. There was a significant mismatch in the 22% of trials 
(95% CI 21.7 22.7) relative to 98% of disease burden (p< 0.001) among children in LMICs 
compared to high-income countries (Table 2).  
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There was moderate correlation between the number of trials and the burden of each disease 
within each region (Spearman’s correlation r=0.6, P=0.007 and r=0.55, P=0.015 and LMICs 
and high-income countries, respectively). Worldwide, neonates comprise only 05% of the 
pediatric population, but neonatal conditions account for 24% of the global disease burden in 
children, with LMICs contributing about 99% of this burden. Only 4% of the registered trials 
in children were in neonatal conditions and another 3% in congenital anomalies.   
 
Within the LMICs, the number of trials for most conditions was under-represented relative to 
disease burden (Table 1 and Figure 2). Most trials 1143 (17%) were in infectious and parasitic 
diseases which contributed the greatest burden of disease with 256 million DALYs (28%), 
followed by 622 (9%) trials in respiratory diseases with 15·9 million DALYs (2%), and 435 
(7%) trials in neonatal conditions with a high disease burden of 223.8 million DALYs (24%).  
 
In contrast, in high-income countries, most trials in children were over-represented relative to 
the disease burden. Most trials involved respiratory diseases 2386 (10%) with 1.5 million 
DALYs (7%), neoplasms 1969 (8%) trials with 0.7 million DALYs (3%), infectious and 
parasitic disease 1314 (6%) trials with 1.2 million DALYs (5%) and mental or behavioral 
1192 (5%) trials with the highest disease burden of 4.9 million DALYs (22%). 
 
3.5 Discussion 
Mismatches in the proportion of registered trials in children in comparison to adults, the 
geographic location by national income, and disease burden were shown in our study. 
Interventions are not frequently studied in the children most at risk, or in countries and 
therapeutic areas of need. Disproportionately fewer trials are registered in children compared 
to adults, in LMICs compared to high-income countries, and in diseases which have a high 
burden in children. 
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Our finding that there are fewer registered trials in children compared to adults has been 
extensively highlighted over the last decade [20-24]. However, we observed that the gap is 
increasing and there are now approximately five times more trials in adults compared to 
children, with the number of trials in children plateauing. The reasons behind this observation 
are likely to be complex and include small prevalence of diseases in children, safety concerns 
of involving children, changing needs of populations (such as demographics, decreasing child 
mortality and ageing population), market-driven forces and the ethical and regulatory burden 
[25, 26].  
  
Our analysis showed that registered trials in children by income regions were still moderately 
correlated to the disease burden [21]. The mismatched focus of trials to disease burden in all 
settings is possibly driven by political influences, responsive agendas of the pharmaceutical 
industry to economic incentives, and the academic interest of investigators [26]. Within the 
LMICs countries, children contributed proportionately more to disease burden, compared to 
the high-income countries. However, there is gross inequity as less than a quarter (22%) of the 
total registered trials in children were in the LMICs, despite 89% of the world’s children 
living in this region and contributing to 98% of the global pediatric disease burden [27]. The 
disproportionately small number of trials in LMICs is likely to be due to less research 
infrastructure and investment in research, the additional complexities and challenges 
associated with poverty, and the prioritisation given to urgent acute care [28-32]. Classical 
trial designs may sometimes be inappropriate in LMICs and more effort should be spent on 
innovative trial designs or alternative methods like pharmacokinetic studies that may be more 
efficient. Although our study shows the continuing inequity in opportunities to participate in 
trials, based upon income, the gap between the regions appears to be narrowing [33]. We 
observed that trials in children in the LMICs have more than doubled over the last nine years, 
compared to the proportion within high-income countries. This is likely driven by 
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globalisation, cost imperatives, increased awareness, philanthropic effort and a greater 
commitment to evidence-based medicine [30, 34, 35].   
 
Our findings confirm that the leading paediatric diseases in both regions are very different, 
with the focus being communicable diseases related to poverty in the LMICs, and non-
communicable diseases of affluent lifestyle in the high-income countries [36-38]. Over 50% 
of trials in infectious and parasitic diseases are being conducted in high-income countries 
while LMICs carry almost 100% of the burden. These trials in high-income countries are 
possibly focused on rarer infections and are small studies, while those in LMICs are larger 
studies of important diseases such as malaria or diarrhoeal disease. Another contributory 
factor is that vaccines and biological trials are simultaneously trialed in both income regions, 
possibly because of global prioritisation of infectious diseases and the large sample size 
required to  determine vaccine safety [19, 33, 39]. This is encouraging as medicines should be 
trialed in different pediatric populations to allow for indigenous data, as pharmacogenomic 
differences may not generate reproducible effects. Although there is concern that some 
interventions in children that are successful in high-income countries may not be affordable or 
accessible in LMICs, this should not exclude their participation as their circumstances may 
change and poverty is not uniform in these countries [29, 40].  
 
Neonatal conditions and congenital anomalies are among the leading causes of disease burden 
and mortality in both income regions [41, 42]. However, our study corroborates other findings 
demonstrating that neonates, as a group, are grossly under-studied, possibly due to the narrow 
spectrum of neonatal diagnoses, ethical challenges, safety concerns, greater complexity and 
long timelines for completion [43, 44]. Mental and behavioral diseases had fewer trials as 
interventions are more likely to be non-randomised studies of non-drug interventions which 
are inherently more complex. The disease-specific focus of some of the trials (for example, 
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neoplasms) may also be due to health ministries’ prioritisation, successful international 
collaborative research networks, sustainable funding, and emotional appeal [45, 46].  
 
Some of the strengths of our study include reporting on data from the WHO portal which 
contained data from 16 clinical trial registers from 16 countries at the time of the study. We 
have used DALYs data for 2011, which is more updated than previous analysis and the 
established Global Health Estimate categories for health conditions. Our study has highlighted 
the gaps and current disease focus of trials in children and has provided the current trend of 
trials in children that can inform priority areas for clinical research. However, there were 
potential limitations to this study. There may have been trials that were not registered on the 
WHO primary registers and would have been excluded. There may have been non-conformity 
among registry records and incomplete fields.
 
Different clinical challenges in newborns, 
infants and children may require different trial evidence and comparing the number of trials in 
certain diseases such as congenital neonatal conditions to respiratory illness may not be 
appropriate. Disease conditions may be over- or under-represented according to the number of 
trials, but there are other measures of trial “effort”. The restrictions of the portal did not make 
it possible to extract other data, such as sample size, facilitate subgroup analyses of 
commercial versus non-commercial trials, or identifying trials with mixed populations of 
adults and children and we recommend further enhancements to the portal.   
 
Our study has shown that there is scope for the trial data on the registries to be linked to the 
countries’ burden of disease to identify the unmet healthcare needs in children. This is 
valuable to stakeholders, both locally and internationally to inform the paediatric research 
agenda and canvass for greater investment in trials to primarily meet the need for evidence-
based care of children and ensure universal health coverage. Global research priorities should 
reflect the global burden of disease in children, while national health priorities should be 
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considered within countries. The evidence gained supports the recommendation for a WHO 
global observatory on health research and development to help align research investment with 
the demands of child health and restore the current inequities in the most disadvantaged 
children in LMICs [27].  
 
3.6 Conclusions 
Worldwide, children continue to be under-represented in trials, particularly in LMICs where 
disease burden is greatest. The numbers of trials in specific diseases correlates only 
moderately with the proportion of disease burden in children. There were mismatches of trial 
focus with disease burden, like respiratory diseases and neoplasms which were over-
represented and congenital and neonatal anomalies that were under-represented. Our analysis 
provides a benchmark for targeting more trials in children in diseases of greatest burden and 
neglected therapeutic areas, in appropriate settings to inform policy and clinical practice. 
Stakeholders both locally and internationally need to embrace an evidence-informed approach 
of prioritising trials to specifically address the healthcare needs of children and improve the 
disparities within global child healthcare. 
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Table 3.1 Characteristics of registered trials in child health (2005−2013) 
 
                                  Region 
Characteristic Low-middle income 
countries (%) 
High-income      
countries (%) 
Total (%) 
  n=6636 (22.2) n=23263 (77.8) n=29899 (100) 
 Intervention Type      
   Drug 2124 (32.0) 7233 (31.1) 9357 (31.3) 
   Biological/vaccine 1918(28.9) 1918 (8.2)  3836 (12.8) 
   Behavioral 484 (7.3)  3159 (13.6) 3643 (12.2) 
   Procedure/surgery 479 (7.2) 2025 (8.7)  2504 (8.4) 
   Radiation 355 (5.3) 2069 (8.9) 2424 (8.1) 
   Genetic 272 (4.1) 1543 (6.6)  1815 (6.1) 
   Nutrition/dietary supplement 450 (6.8) 1057 (4.5)  1507 (5.0) 
   Device 221 (3.3) 1275 (5.5) 1496 (5.0) 
   Physical therapy 207 (3.1) 1101 (4.7)  1308 (4.4) 
 
 
   Other/unclassified 150 (2.3) 1883 (8.1) 2033 (6.8) 
Sponsor      
    University 2115 (31.9) 7012 (30.1) 9127 (30.5) 
   Commercial sector/industry 1316 (19.8) 3714 (16.0) 5030 (16.8) 
   Hospital 651 (9.8) 3958 (17.0) 4609 (15.4) 
   Individual 102 (1.5) 533 (2.3) 635 (2.1) 
   Foundation/charity/society 84 (1.3) 464 (2.0) 548 (1.8) 
   Government funding body  172 (2.6) 184 (0.8)  356 (1.2 ) 
   Collaborative group 27 (0.4) 132 (0.6) 159 (0.5) 
   Other/unclassified 2169 (32.7) 7266 (31.2) 9435 (31.6) 
 Disease Condition Global Health Estimate   
 
   Respiratory diseases 622 (9.4) 2386 (10.3) 3008 (10.1) 
   Infectious and parasitic diseases 1143 (17.2) 1314 (5.6) 2457 (8.2) 
   Malignant and other neoplasms 207 (3.1) 1969 (8.3)  2176 (7.3) 
   Mental and behavioural disorders 215 (3.2) 1192 (5.1) 1407 (4.7) 
   Respiratory infections 410 (6.2) 947 (4.1) 1357 (4.5) 
   Neonatal conditions 435 (6.6) 847 (3.6) 1282 (4.3) 
   Musculoskeletal diseases 253 (3.8 ) 995(4.3 ) 1248 (4.2) 
   Sense organ diseases 209 (3.1) 922 (4.0) 1131 (3.8) 
   Diabetes mellitus 147 (2.2) 843 (3.6) 990 (3.3) 
   Neurological conditions 173 (2.6) 710 (3.1) 883 (3.0) 
   Congenital anomalies 124 (1.9) 759 (3·3) 883 (3.0) 
   Maternal conditions 245 (3.7) 637(2.7) 882 (2.9) 
   Cardiovascular diseases 99 (1.5) 706 (3.0) 805 (2.7) 
   Nutritional deficiencies 307 (4.6 ) 400(1.7) 707 (2.4) 
   Endocrine, blood, immune disorders 106 (1.6) 550 (2.4) 656 (2.2) 
   Digestive diseases 115 (1.7 ) 419 (1.8) 534 (1.8) 
   Genitourinary diseases 61 (0.9 ) 338(1.5) 399 (1.3) 
   Oral conditions 65 (1.0) 141 (0.6) 206 (0.7) 
   Skin diseases 25 (0.4) 109 (0.5) 134 (0.4) 
   Other/unclassified 1675 (25.4) 7079(30.4) 8754 (29.3) 
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Table 3.2 Number of trials in the Top 10 disease contributors to disability in children 
stratified by income region (20052013) 
 
Global Health Estimate disease   
category 
Region 
DALYs 
(millions)   
World 
 DALYs 
 millions) 
Region  
DALYs/World  
DALYs (%) 
Number  
of trials 
(region) 
 
Number  
of trials 
(world) 
Proportion  
of trials (region/ 
world) (%) 
Low and-middle-income countries 
Total 929.9 952.0 97.7 6636 29899 22.2 
  Infectious and parasitic diseases 256.4 257.6 99.5 926 2240 41.3 
  Neonatal conditions 223.8 226.4 98.8 435 1282 33.9 
  Respiratory infections 124.9 125.5 95.5 410 1357 30.2 
  Nutritional deficiencies 55.3 55.9 99.0 307 707 43.4 
  Congenital anomalies 49.5 51.6 96.0 124 883 14.0 
  Mental and behavioural disorders 36.6 41.5 88.2 215 1407 15.3 
  Respiratory diseases 15.9 17.4 91.6 622 3008 20.7 
  Neurological conditions 14.8 15.6 94.6 173 883 19.6 
  Cardiovascular diseases 14.4 14.9 96.3 99 805 12.3 
  Endocrine, blood, immune disorders   14.3 15.4 93.1 106 656 16.2 
High-income countries 
Total 22.1 952.0 2.4 23263 29899 77.8 
  Mental and behavioural disorders 4.9 41.5 11.8 1192 1407 84.7 
  Neonatal conditions 2.7 226.5 1.2 847 1282 66.1 
  Congenital anomalies 2.1 51.6 4.2 759 883 86.0 
  Respiratory diseases 1.4 17.4 8.0 2386 3008 79.3 
  Infectious and parasitic diseases 1.2 257.6 0.5 1314 2240 58.7 
  Musculoskeletal diseases 1.2 8.3 14.5 995 1248 79.7 
  Endocrine, blood, immune disorders 1.1 15.4 6.9 550 656 83.8 
  Neurological conditions 0.8 15.6 5.4 710 883 80.4 
  Neoplasms 0.7 10.7 6.3 1969 2176 90.5 
  Respiratory infections 0.6 125.5 0.5 947 1357 69.8 
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Figure 3.1 Number of registered trials in (a) children and adults and (b) children by income 
region (20052013) 
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Figure 3.2 Association between disease burden and the number of registered trials in 
children (20052013) for the Global Health Estimate disease categories within (a) Low-and 
middle-income countries and (b) High-income countries 
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Chapter 4: Stakeholder views of clinical trials in children in 
low-and middle-income countries: a systematic review 
 
4.1 Abstract         
Context: Clinical trials are necessary to improve the healthcare of children, but only one-
quarter are conducted in the low-middle income countries (LMICs) where 98% of the global 
burden of disease resides.  
Objective: To describe stakeholder beliefs and experiences of conducting trials in children in 
LMICs to inform strategies for improving the number and relevance of trials in LMICs. 
Data sources: Electronic databases were searched to August 2014. 
Study selection: Qualitative studies of stakeholder perspectives on conducting clinical trials 
among children in LMICs. 
Data extraction: Findings were analysed using thematic synthesis. 
Results: Thirty-nine studies involving 3110 participants (children [n=290], parents or 
caregivers [n=1609], community representatives [n=621], clinical or research team [n=376], 
regulators [n=18] and sponsors [n=15]) across 22 countries were included. We identified five 
themes: centrality of community engagement (mobilising community, representatives pivotal 
role, managing expectations, retaining involvement); cognizance of vulnerability and poverty 
(therapeutic opportunity, medical mistrust); contending with power differentials (exploitation, 
stigmatisation, disempowerment); translating to local context (cultural beliefs, 
impoverishment constraints, ethical pluralism) and advocating fair distribution of benefits 
(healthcare, sponsor obligation, collateral community benefits). 
Limitations: Studies not published in English-language were excluded. 
Conclusions: Conducting trials in children in LMICs is complex due to social disadvantage, 
economic scarcity, idiosyncratic cultural beliefs and historical disempowerment which 
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contribute to inequity, mistrust and fears of exploitation. Effective community engagement in 
recruiting, building research capacity and designing trials that are pragmatic, ethical and 
relevant to the healthcare needs of children in LMICs may help to improve equity and health 
outcomes of this vulnerable population. 
 
4.2 Introduction 
Globally, the 2000 Millennium Development Goals and other initiatives have seen 
progressive improvements in child health [1, 2]. Although research has contributed positively 
by promoting therapeutic advances in healthcare of children, there are still inequities evident 
across different income settings [3]. The “10/90 gap” suggests that only 10% of global health 
research funds are invested into medical conditions that account for 90% of the global disease 
burden, which resides mainly in the low-and middle-income countries (LMICs) [4, 5]. 89% of 
children live in LMICs and contribute 98% to the global burden of disease, and yet only one-
quarter of trials are done in this setting [6-8].  
 
Conducting clinical trials in children in LMICs is reported to be more complex and they may 
be of lower methodological quality than trials in high-income countries [7]. Specific 
challenges include the risk of exploitation, scarce resources, deficient ethical and regulatory 
framework and logistical constraints [9].Qualitative research can help to explain social 
phenomena and provides an understanding of people’s values, beliefs, and attitudes [10]. 
Thematic synthesis of multiple qualitative studies can generate more comprehensive insight 
across different stakeholder groups and settings.  
 
The aim of this systematic review was to describe the perspectives and experiences of 
conducting clinical trials in children in LMICs among key stakeholders including children, 
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parents or caregivers, community representatives, clinical and research team, regulators and 
sponsors to inform strategies to improve locally relevant research in children from LMICs. 
 
4.3 Materials and Methods 
We followed the Enhancing Transparency of Reporting the Synthesis of Qualitative Research 
(ENTREQ) reporting guideline for systematic review of qualitative studies, as endorsed by 
the EQUATOR (Enhancing the Quality and Transparency Of health Research) network [11, 
12]. 
 
4.3.1 Data sources and searches 
The searches were conducted in MEDLINE and Embase from inception to 3
rd
 August 2014. 
The search strategy is provided in Appendix B1. Google Scholar and reference lists of 
relevant articles and reviews were also searched. PDJ screened the titles and obtained full 
texts of potentially relevant studies, which were assessed for eligibility. CSH independently 
reviewed the search results to ensure that all studies that met the inclusion criteria were 
included. 
 
4.3.2 Study selection criteria 
Qualitative studies on stakeholders (children, parents or caregivers, community 
representatives, clinical or research team, regulators, sponsors) experiences and perspectives 
on conducting trials in children (aged 0-18 years) in LMICs (as classified by the World Bank) 
were included. Articles were excluded if they were quantitative surveys, reviews or 
commentaries or only reported on trials conducted in the adult population. Non-English 
articles were excluded to prevent potential misinterpretation of the information. 
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4.3.3 Quality of reporting appraisal 
For each study, the comprehensiveness of reporting was independently appraised by two 
reviewers (PDJ and CSH) using the Consolidated Criteria for Reporting Qualitative Health 
Research (COREQ) framework, which included criteria relating to the research team, 
methods, study context, analysis and interpretations [13]. These provide contextual details for 
readers to evaluate the credibility, dependability and transferability of the study findings to 
other settings [13]. Any differences in assessment were discussed and resolved.     
 
4.3.4 Data Extraction and Synthesis 
Thematic synthesis was used to inductively generate analytical themes from the findings of 
the included studies [10]. All text under the ‘‘results or findings’’ or ‘‘conclusion or 
discussion’’ section of each article were extracted. The text were entered verbatim into 
HyperRESEARCH (ResearchWare, INC.2009, version 3.0.3, Randolph, MA) software for 
coding textual data. PDJ performed line-by-line coding of all relevant text and data. Similar 
concepts were categorised into themes. The themes were revised as new concepts were 
identified. To ensure that coding captured all relevant issues and reflected the primary data, 
two reviewers (CSH and PHC) independently reviewed the preliminary themes and analytical 
framework and discussed the addition or revision of themes with PDJ and AT. This form of 
investigator triangulation ensured that the coding framework and themes reflect the full 
breadth of data. Conceptual relationships between the themes were mapped to develop an 
overarching analytical thematic schema.  
 
4.4 Results 
4.4.1 Literature search and study characteristics 
Overall, 39 studies involving more than 3110 participants were found to be eligible and 
included (Figure 4.1). Participants were children [n=290], parents or caregivers [n=1609], 
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community representatives [n=621], clinical and research team [n=376], regulators [n=18] 
and sponsors [n=15] (Box 4.1).  
 
Box 4.1 Clinical trials in children stakeholders 
 
 
Children: adolescents, youth, children 
 
Parents or caregivers: mothers, fathers, caregivers, family members, adults in community 
  
Community representatives: community health workers (CHW)/village reporters, 
leaders/chiefs/elders/ community advisory board members, education officers/ teachers/ school 
principals, community based organisations, women group leaders, traditional birth 
attendants/healers, HIV counselors, clergy, opinion leaders, civil society, media, mayors 
 
Clinical or research team: health care providers, principal investigators (PI), project managers, 
fieldworkers (FW), field supervisors/managers, researchers, research nurses, community facilitators, 
head of clinical trials, research coordinators/assistants, research institutes/universities 
  
Regulators: political officials, policy makers, ethical review bodies, research coordinating bodies 
 
Sponsors: government, non-government organizations, pharmaceutical industry, other funding 
bodies 
 
One study did not report the number of participants. The study characteristics are provided in 
Table 4.1. The studies were conducted across 22 countries with the majority in Africa. The 
perspectives were predominantly focused on trials within the specialty of infectious diseases, 
particularly human immunodeficiency virus (HIV), tuberculosis and malaria. Data were 
collected using in-depth, structured or semi-structured interviews, focus groups, open-ended 
surveys and observations.  
 
4.4.2 Comprehensiveness of reporting 
Reporting was variable with studies providing details on 3 to 21 of the 31 items of the 
COREQ framework (Table 4.2).  All studies included participant quotations, 30/39 studies 
described the participant selection strategy, 27/39 provided the questions or topic guides, and 
27/39 reported recording of the interview. Researcher triangulation (multiple researchers 
involved in coding and analysis) was described in 24 studies. Theoretical saturation (when 
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little or no new concepts are identified in subsequent data collection) was described in only 7 
studies. Member checking (obtaining feedback from participants on the preliminary findings) 
was reported in one study. 
 
4.4.3 Descriptive synthesis 
We identified five major themes: centrality of community engagement, cognizance of 
vulnerability and poverty, contending with power differentials, translating to local context and 
advocating fair distribution of benefits. Selected quotations for each theme are provided in 
Table 4.3. Conceptual links among themes are depicted in Figure 4.2.  
 
4.4.3.1 Centrality of community engagement  
Mobilising community  
The need for community engagement to build trust and foster acceptance of trials was 
emphasized by all stakeholders [14-17]. They believed that culturally appropriate strategies 
were necessary to educate the community about new interventions and encourage active 
participation in research. Community leaders in Ghana suggested using traditional community 
gatherings which included cultural activities like drumming and dancing [16]. Many desired 
“genuine, fair and effective” [18] dialogue with community members to improve trial design 
and conduct, strengthen ethical practice and demonstrate respect for community values.  
 
Recognising the pivotal role of leaders and representatives 
Stakeholders believed that investigators need to navigate and respect hierarchical decision-
making structures in the community [14, 19]. Endorsement by “chiefs” and understanding 
their role as “gatekeepers and mediators” was considered necessary to “allay suspicion, to 
nurture trust, and to establish the researchers’ credibility” [16]. Involving trusted  “grass-root” 
[17]  intermediaries like community workers was deemed vital in “opening the way” [20] for 
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researchers. Employing fieldworkers with knowledge of local customs was supported to 
facilitate recruitment of participants [16]. Researchers recognised that community 
representatives’ could potentially enable or undermine the trial goals [15]. 
 
Managing different expectations 
The transfer of material benefits such as healthcare resources was expected by the community 
and was believed to encourage participation, but this could undermine intrinsic motivation 
[19, 21]. Tensions arose as volunteer community workers were dissatisfied with their poor 
incentives compared to the payment of the fieldworkers employed on the trial [17, 20]. 
Community workers expectation to enroll participants for payment differed from researchers 
who felt that community workers should not be directly involved in consenting participants to 
avoid conflict of interest [18, 19]. Some recommended having mediators e.g. community 
advisory boards, to address community and researchers’ expectations more effectively [19, 
22]. 
 
Retaining community intermediaries’ involvement 
Retention of community workers was deemed critical for a trial to be successful, but potential 
barriers included dissatisfaction with remuneration, limited scope of responsibilities, heavy 
workload, work-related travel, familial opposition and negative attitudes of parents towards 
them [23, 24]. Community workers were motivated to participate because of recognition and 
appreciation, altruism, humanitarian and religious reasons, but recommended appropriate 
compensation and incentives to improve retention [14, 23].  
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4.4.3.2 Cognizance of vulnerability and poverty 
Vital therapeutic opportunity 
For parents, hope for free, quality medical care for children and their family was the driving 
force for participation in trials [25]. Some parents feared that refusal to participate would 
result in denial of medical care [22, 26]. The Gambian community appreciated having post-
trial access to treatment [27] and mothers in Malawi valued the clinical testing provided in the 
trials [25]. Parents had a “therapeutic misconception” [28] that all trial interventions were 
beneficial, for example, believing that participating in the HIV trials would prevent their child 
from getting HIV [28, 29]. Altruism also motivated participation to contribute to science and 
provide hope for new therapies for future generations and the under-privileged [30, 31].  
 
Medical mistrust 
The community’s mistrust of medical research was a barrier that researchers believed needed 
to be addressed sensitively [15, 22]. A major concern in Africa was the perceived dangers of 
taking blood samples. The community believed the blood was sold “because our blood is of 
higher quality than that of the white people” [32]. Parents were anxious that “the trial was a 
disguise for witchcraft or Satanism,” [33] “children’s body parts would be removed and sold” 
[33]  or the “white people” will infect them with HIV or tuberculosis [20]. Parents in Puerto 
Rico were reluctant to enroll their children in a placebo-controlled trial because they “would 
not trust what is being injected to their children” [34]. The need to sign consent forms were 
regarded with suspicion and some perceived it was to absolve researchers of liability [14, 21].  
 
4.4.3.3 Contending with power differentials 
Potential for exploitation  
Most stakeholders believed impoverishment rendered these communities “powerless” and 
vulnerable to exploitation [27]. Regulators raised concerns about LMICs being easy 
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recruitment sites in multinational trials where researchers “parachute in, parachute out” [27, 
35]. There were concerns of inducement and conflict of interest because some leaders and 
trial staff were perceived to exercise their authority to “exert pressure” on the community to 
participate [14]. Regulators felt that providing benefits or large monetary payments to 
participants may lead to commodification of research, but sponsors believed that participant 
payments should be equitable and not based on the country’s economy [22, 36]. Researchers 
were afraid of being involved with the media whom they perceived as exploitative, “vultures” 
and always “raping their work” [22]. 
 
Fearing discrimination and stigmatisation 
In South Africa stakeholders advocated for fairness in community and participant selection 
because of the perceived discrimination where vulnerable “black people were targeted as 
research participants” [22]. Participants feared stigmatisation and humiliation, that their 
participation would be misconstrued as them having HIV in the context of the trial [26, 37, 
38]. Parents in a malaria vaccine trial feared becoming a “laughing stock” by non-participants 
and desired that results of ineffective interventions remain confidential [15]. 
 
Disempowerment hampering informed consent 
Stakeholders believed that disempowerment, poor education and difficulty in translating 
scientific concepts were barriers to informed decision-making [34, 39, 40]. They 
recommended that consent forms be simplified, presented in a culturally and linguistically 
appropriate format with verification of parental comprehension [37]. Parents’ implicit trust in 
doctors was a concern as the doctor’s recommendation of the trial may be misinterpreted as 
endorsement that the intervention is effective [29]. In patriarchal African and Indian societies, 
women were believed to have minimal decision-making power, [28, 41] although in some 
countries such as Malawi, women made decisions autonomously [25, 28, 41]. There were 
Chapter 4: Stakeholder views of clinical trials in children in low-and middle-income countries: a systematic review  
70 
 
conflicting views on children’s decision-making capacity.Some reported children being 
persuaded to participate [22, 38].  
 
4.4.3.4 Translating research to local context 
Respecting beliefs and cultural practices  
Cultural beliefs that conflicted with the trial were a challenge for researchers. For example 
parents felt that the requirement for contraception to prevent pregnancy in the vaccine trial 
“will encourage girls to have sexual intercourse before getting married,” or “could cause 
infertility” [34]. In some communities, illness was believed to be due to physical or spiritual 
happenings and herbalists and religious leaders were trusted to protect their child’s health 
which discouraged participation in trials [32]. The confidentiality measures required in trials 
was perceived by the community to be a contravention of their cultural practices and was 
misinterpreted that the trial was unethical or shameful [22]. Researchers also recognised that 
culturally accepted practices could conflict with ethical principles. For example, in Ghana, 
presenting the paramount chiefs with gifts at the initial trial visit was customary but this could 
be seen as an inducement [16].   
 
Understanding constraints of impoverishment 
Researchers advocated that international sponsors need to understand the severe economic 
scarcity when planning trials and to ensure interventions are feasible and sustainable in 
LMICs [37, 42]. Parents reported sharing therapeutic interventions with non-participants. The 
community in Malawi recommended that for the bottle-feeding intervention in the HIV trial to 
be sustained, the “sterilizing paraphernalia” needed to be provided as they could not afford 
them [29].  
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Ethical pluralism 
In international trials, some supported the “universality of ethics” [22] while others argue that 
ethical standards varied across cultures [21, 42]. Researchers felt that rigorous international 
requirements of documentation were too ambitious for LMICs [15, 43]. Some believed that 
trials needed to produce locally relevant results and should not have “an island of excellent 
investigation where that’s not your standard of care” [42]. African researchers were concerned 
that if international standards were not strictly applied locally their research quality will be 
unacceptable in the global arena [42]. For example serious adverse events required all co-
existing medical conditions and symptoms related to poverty, for example malnutrition to be 
reported. 
 
4.4.3.5 Advocating fair distribution of benefits  
Supporting health care and societal needs 
Stakeholders encouraged the “sharing and mutuality” [20] of research-related benefits with 
participants to prevent exploitation and promote the societal value of international health 
research [20, 35]. However, they recognised that the governance framework around provision 
and accountability of these benefits was inadequate [22, 44]. Stakeholders felt that “tangible 
benefits to host communities have been insufficient and unfairly so” [16]. Many stakeholders 
supported trials as a means to help address healthcare inequities including poor access and 
affordability of therapeutic products for children and to promote social justice [35].   
  
Sponsor obligation 
Regulators and researchers argued that sponsors had a moral responsibility to ensure 
availability of the proven interventions after trial completion and to improve research and 
healthcare capacity [22]. For example, in Kenya, the secondary benefits of a malaria vaccine 
trial included improved local health facilities, provision of medical equipment and up-skilling 
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of medical personnel [40]. Community members perceived that the primary role of sponsors 
was to provide access to treatment and better quality medical care [27, 44]. Reimbursement of 
out-of-pocket trial expenses and providing ancillary medical care were considered distinct to 
sharing benefits arising from the research.  
 
Collateral community benefits 
While researchers felt that trial participants, and those who did not participate (including 
those who withdrew) should have access to the intervention, [22] some parents felt this was 
unfair and only participants should benefit from the trial intervention [22, 27, 28].  Sponsors 
in The Gambia elected to treat non-participants and siblings of participants to maintain overall 
community goodwill [32]. Tensions emerged when benefits differed between studies or when 
there was poor clarity or disagreements on eligibility for reimbursement [40]. Researchers 
proposed that direct collateral community benefits should be primarily medical rather than 
monetary and should be maximised through engagement of the country’s ministry of health 
[40]. 
 
4.5 Discussion 
Conducting trials in children in LMICs is regarded as a complex and arduous process by a 
broad range of stakeholders including children, parents or caregivers, community members, 
clinical or research teams, regulators and sponsors due to the difficult financial scarcity and 
cultural contexts that have been shaped historically by disadvantage and exploitation. This 
disempowerment also contributed to the communities’ mistrust of trials and fears of 
stigmatisation. Stakeholders felt that trials should be adapted to the local context with 
consideration of the resource constraints, cultural beliefs and ethical pluralism. Facilitators of 
trials were a perceived opportunity to access medical care among parents and the community, 
engaging the community, addressing expectations and fair distribution of research benefits.  
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The primary motivation of parents to participate in trials across all income settings is the 
opportunity of better medical care for their child, however in LMICs, participation in trials 
was often the only option to access treatment [3, 45]. The parents’ implicit trust in doctors’ 
recommendations to enroll children in trials was apparent, which may contrast to parental 
reluctance in high-income countries [45]. Involving parents and families in the protocol 
design is encouraged universally, however, this is more difficult in  LMICs where there are 
specific misconceptions of  trials [3]. Rumors such as “blood and organ stealing” as well as 
belief in witchcraft as a cause of illness and traditional medicines as a cure were often 
regarded as more important and relevant than biomedical risks [15]. These rumors and fears 
of stigmatisation for participation may be constructively addressed by contextualisation, 
community education to improve health literacy and engaging community representatives to 
help build trust by fostering mutual understanding, respect and equity [21, 33, 46-48].  
Community engagement is a dynamic process and a constantly changing set of negotiated 
relationships to address expectations and challenges tailored to the local setting [49, 50].  
Stakeholders recommended ethnographic research in preparation for commencing a trial 
within a community, to improve feasibility, methodological rigor and acceptability of trial 
protocol, while safeguarding the health and interests of child participants [29, 37].  Feedback 
of the trial findings to the participant and the community is complex, but was recognised as a 
key component of continuing social interactions and is encouraged in all trials [28, 51]. 
 
The underlying principle of consent being free, autonomous and informed is the cornerstone 
of trials universally [52-54]. However, findings from this literature review reaffirm 
observations that meaningful decision-making is further compromised in LMICs by 
disempowerment, cultural idiosyncrasies, extensive illiteracy and or decision-making styles 
[39, 41, 53]. Thus the western ethical principles of informed consent and child assent, 
autonomy and individualism needs to be contextualised [32, 41, 55]. Many of the 
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controversial ethical issues such as the use of placebo, the appropriate local standard of care 
and  resource constraints in complying with the rigorous trial requirements we reported in this 
literature review is part of the international agenda [50, 54, 56, 57]. Some stakeholders 
reported that ethical approval and oversight of trials in children was also inadequate [7]. The 
rigid ethical-legal framework of children’s participation in trials, arising from paternalism and 
poor awareness was recognised as a barrier that unnecessarily excludes children from trials 
[22, 38]. This systematic review’s results show that there is scope for a common international 
ethical framework to be applied in LMICs with ethical reasoning of the moral application of 
these principles in these contexts [30, 58]. Researchers supported the development of a 
pragmatic ethical framework for children’s involvement in trials that are appropriate in 
LMICs [15, 59, 60].   
 
Communities in LMICs place a greater emphasis on tangible research benefits and 
remuneration which some stakeholders believed may be coercive and cloud objective 
assessment of potential risks to participants [61, 62]. Many were troubled that poverty 
compounded by lack of medical care, unawareness of medical rights and language barriers 
rendered children and communities more vulnerable to exploitation in trials [29, 37, 63]. 
Stakeholders reported potential vertical exploitation, where community intermediaries are 
encouraged by researchers to take advantage of their social relationships to coerce participants 
and horizontal exploitation where intermediaries influenced participation in order to increase 
their remuneration [64].  Some were concerned that the pharmaceutical industry may exploit 
LMICs by conducting trials primarily for the benefit of wealthy countries [42].  Therefore, 
some stakeholders supported research which investigates less expensive ways of using proven 
treatments for treating conditions specific to local child health priorities [42]. 
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This systematic review’s results reaffirm the on-going discourse of children and communities 
needing to benefit from the research to promote justice and equity [35]. Although benefit 
sharing and defining fair research-related benefits are standard ethical concerns in global 
health research, we found that its practical implementation is complex with less attention on 
the consequences of delivering on promises of benefits in LMICs [22, 56, 65]. Controversy 
and contention still exists internationally concerning the ethics of monetary compensation to 
parents and investigators [22, 66]. However, findings from this literature review showed that 
there are poorer governance structures and greater concerns of inducement or coercion in 
LMICs. More empiric work is needed to guide appropriate and ethical distribution of research 
benefits in LMICs [40, 44]. There is speculation that the lack of commercial incentives to the 
pharmaceutical industry (the major driver and sponsor of trials) to conduct trials in children of 
diseases specific to LMICs, may have contributed to a much lower allocation of resources to 
trials in LMICs relative to the tremendous burden of disease and addressing this gap is on the 
global health research and development agenda [4, 67, 68]. Stakeholders advocated for 
communities to receive concrete benefits to compensate for years of disadvantage and 
ostracism echoing the international ethics discussions  that encourages sponsor investment in 
developing health research capacity [69].  
 
The experiences and the practical and ethical concerns of stakeholders identified in this 
literature review can inform the design and conduct of clinical trials in children in LMICs. 
Our synthesis reflects the diversity and full breadth of data reported in the primary studies and 
we recognize that the majority of the findings were focused on the problems, challenges, and 
issues for research in LMICs. Further studies may be conducted to elicit stakeholder 
perspectives on the initiatives, approaches and positive developments that exist or would be 
effective in encouraging more, high-quality trials of clinical relevance in children in LMICs. 
Some studies were conducted in local languages and transcripts were translated into English, 
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which could be a potential limitation if linguistic and cultural nuances were not fully 
conveyed in the primary study [70]. Also, some of the interviews in the primary studies were 
conducted by the research institute or trial staff, rather than independent interviewers which 
may have limited the full range of issues and experiences that stakeholders, were willing to 
share. Studies not published in English were excluded to avoid misinterpretation of results.  
This systematic review focused on clinical trials in children in LMICs; however some issues 
are common for high-income countries as well as in the adult population. 
 
4.6 Conclusion and future directions 
The clinical trials paradigm is complex in LMICs as it is hampered by impoverishment, 
disempowerment, inequity and idiosyncratic cultural beliefs that have created mistrust in 
clinical research with fears of exploitation. Key facilitators are engaging the community in 
mobilising and designing trials that are pragmatic, ethical and relevant to the healthcare needs 
of children in these diverse settings. Fair distribution of research benefits, including 
investment in research infrastructure and regulatory frameworks, will help restore trust lost by 
the past social injustices and promote more, quality trials to improve the future of these 
historically disadvantaged children. 
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Study by 
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Bangladesh 
Rahman et al. 
2010[24]                 
Newborn care Foundation/ 
charity/society, 
government 
69     0 0 Qualitative design Open-ended questions, 
in-depth interviews, 
focus group 
 Recruitment and 
retention of 
Community Health 
Workers 
Ghana 
Abbey et al. 
2014[23] 
 
Fever 
 
Foundation/ 
charity/ society 
35 0 0 35 0 0 0 Mixed methods/  
   ecological 
behaviors 
model  
Face-to-face interviews, 
focus groups,  informal 
discussions; field 
reports 
Iterative Retention of 
Community Health 
Workers  
Febir et al. 
2013[70] 
 
Malaria Foundation/ 
charity/society, 
government 
159 0 144 10 5 0 0 Qualitative design Focus groups, in-depth 
interviews; cross-
sectional survey 
Thematic 
analysis 
Knowledge and 
perception of malaria 
vaccines 
Tindana et al.  
2006[71]                       
Non-specific Government 90 0 70 10 10 0 0 Qualitative design In-depth semi-structured 
interviews, focus 
groups 
Thematic 
analysis 
Informed consent 
process 
Tindana et al.  
2011[16]                 
Non-specific Foundation/ 
charity/society 
136 0 24 104 8 0 0 Qualitative design In-depth interviews,  
focus groups 
 Community 
engagement in 
biomedical research 
Haiti 
Coreil et al. 
1998[37] 
 
HIV Government  239 0 167 72 0 0 0 Ethnography Focus groups, 
in-depth interviews 
Content and 
thematic 
analysis 
Cultural  feasibility of 
trial 
India 
DeCosta et al. 
2004[41]              
Non-specific Hospital, university, 
government 
57 57 0 0 0 0 0 Qualitative design Structured interviews  Informed consent and 
motivation for  
participation  
Kenya 
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Angwenyi et al. 
2013[17] 
 
Infection Government, 
   industry trust 
33 25 0 0 8 0 0 Mixed methods/ 
multi-method 
social science 
In-depth interviews, 
focus groups; 
observations 
Thematic 
analysis 
Practical and ethical 
implications of 
involving 
   Community Health 
Workers 
Angwenyi et al. 
2014[14] 
 
Malaria Government, 
  industry trust 
57 0 19 8 30 0 0 Mixed methods  In-depth interviews, 
focus groups; surveys, 
observations, 
document reviews 
Framework 
analysis 
Informed consent and 
community 
engagement 
activities 
Chantler  et al. 
2013[20] 
 
Infection University, industry 
trust 
 
119 0 27 74 18 0 0 Ethnography Observations, 
interviews, focus 
groups 
Thematic 
analysis 
Community 
engagement of paid 
volunteers 
Gikonyo et al. 
2008[15]  
 
Malaria Government, 
industry trust 
203 0 198 0 5 0 0 Qualitative design Structured interviews, 
focus groups 
 Informed consent 
practices 
Gikonyo et al. 
2013[28] 
 
Malaria Government, 
industry trust 
~40 0    0 0 Ethnography Observation, meeting 
minutes; interviews, 
focus groups 
 Feedback of trial 
findings to 
participants  
Kamuya et al.  
2013[18]                      
Non-specific Government, 
industry trust  
 
24 0 0 24 0 0 0 Qualitative design Focus group, in-depth 
interviews; reports, 
self-administered 
questionnaires 
 Engaging communities 
to strengthen 
research ethics 
Lairumbi et al. 
2011[35]                         
Non-specific Government, 
industry trust  
52 0 0  27 15 10 Qualitative design Face-to-face, in-depth 
interviews 
Grounded 
theory 
Understanding of  
   benefit sharing in 
health research 
Lairumbi et al. 
2012[44]
a
                               
Non-specific Government, 
industry trust  
52 0 0  27 15 10 Qualitative design Face-to-face, in-depth 
interviews 
Grounded 
theory 
Research benefits 
expected by 
participants 
 
Molyneux et al. 
2004[36]                             
Non-specific Government, 
industry trust 
142 0 89 50 3 0 0 Qualitative design Observation; 
hypothetical case 
vignettes, informal and 
 Understanding of 
informed consent 
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semi-structured group 
interviews  
Molyneux et al. 
2005[21]
a
                                  
Non-specific Government, 
industry trust 
 
 
142 0 89 50 3 0 0 Qualitative design Observation; 
hypothetical case 
vignettes, informal and 
semi-structured group 
interviews  
Content 
analysis 
Informed consent 
process 
Molyneux et 
al.2005a
 a
 [72]                              
Non-specific Government, 
industry trust 
142 0 89 50 3 0 0 Qualitative design Observation, 
hypothetical case 
vignettes, focus 
groups, interviews 
Content  
analysis 
Notion and practice of 
informed consent 
Molyneux et al. 
2012[40]  
Perfusion, HIV,TB, 
respiratory 
infections, 
malaria,  
immunology 
Government, 
industry trust 
87 0 0 0 87 0 0 Qualitative design Case vignettes, in-depth 
interviews, focus 
group, consultative 
workshop; e-mail 
survey 
 Benefits’ and payments 
for research 
participants 
Okello et 
al.2013[19] 
 
Malaria Foundation/ 
charity/society, 
government, 
industry trust,  
42 0   20 0 0 Qualitative design Observation, in-depth 
interviews, focus 
groups 
 Challenges of consent 
and community 
engagement in a 
school-based trial 
Vreeman et al. 
2012[61]                    
Non-specific Government 108 0 60 48 0 0 0 Qualitative design Traditional community 
assemblies/focus 
group 
 Community 
perspectives 
   on informed consent 
and research 
participation 
Lebanon 
Nabulisi et al. 
2011[73] 
Meningitis University 33 0 33 0 0 0 0 Qualitative design In-depth interviews Thematic 
analysis 
Parental motivation for 
participation 
 
Malawi 
Corneli et al. 
2007[29] 
HIV Government 133 0 100 33 0 0 0 Formative Semi-structured 
interviews, focus 
Content 
analysis 
Community 
engagement 
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 group, observations informing design of 
protocols 
Masiye et al. 
2008[25] 
Malaria Government 81 0 81 0 0 0 0 Qualitative design Focus groups  Motivation for 
participation and role 
of relatives in 
decision making 
Piwoz et al. 
2006[74]              
HIV Government 19 0 0 0 19 0 0 Formative In-depth interviews Content 
analysis 
Feasibility of 
intervention to 
inform trial design 
Multinational 
Hyder and 
Wali.2006[43]
c
                   
Non-specific Government 
 
78 0 0 0 78 0 0 Qualitative design Focus groups, in-depth 
interviews; open 
ended questions in 
survey 
 
 Developing countries 
researcher 
perspectives of 
informed consent 
and collaborative 
research 
Kass et al. 
2005[39]
d 
                      
Infectious disease Government  26 0 26 0 0 0 0 Qualitative design In-depth interviews Thematic 
analysis 
Participant 
motivations, 
understanding 
   and voluntariness   
Puerto Rico 
Perez-Guerra et 
al. 2012[34]                            
Dengue Industry 
 
 
313 111 145 39 18 0 0 Grounded theory Interviews, focus groups Content 
analysis 
Community views of 
placebo-controlled 
dengue vaccine trial 
South Africa 
Essack et al. 
2010[22]                   
HIV Government 31 0 0 16 7 3 5 Qualitative design Semi-structured in-
depth interview 
 Ethical challenges in 
HIV vaccine trials 
Jaspan et al. 
2008[38] 
HIV Government 200 57 51 92 0 0 0 Qualitative design Focus group Thematic 
analysis 
Ethical issues of 
adolescent 
involvement in HIV 
vaccine trials 
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Jaspan et al. 
2010[26]
a
                        
 
HIV Collaborative 
group, 
   government 
 
200 57 51 92 0 0 0 Qualitative design Focus groups 
 
Thematic 
analysis 
Attitudes towards the 
inclusion of 
adolescents in HIV 
vaccine trials 
Mahomed et 
al.2008[31]  
Tuberculosis Foundation/ 
charity/society, 
government,  
industry 
72 40 32 0 0 0 0 Qualitative design Focus group; self-
administered survey 
Content 
analysis 
Knowledge and 
attitudes of 
adolescent to 
tuberculosis trials 
Tanzania 
Liheluka et al. 
2013[75] 
Malaria  Industry 55 0 49 6 0 0 0 Qualitative design In-depth interviews,  
focus group 
Thematic 
analysis 
Secondary health 
benefits of malaria 
vaccine trials 
The Gambia 
Fairhead et al. 
2006[32]   
Pneumonia, 
meningitis 
Government 
 
>60 0   10 0 0 Ethnography Observations, narrative 
and semi-structured 
interviews 
Thematic 
analysis 
Engagement of parents 
in vaccine trial 
Geissler et al. 
2008[27]  
Malaria Foundation/ 
charity/society 
93 0 80 0 13 0 0 Qualitative design Semi-structured 
interviews 
 Relational ethics and 
material exchanges 
Leach et al. 
1999[30] 
Influenza Government  189 0 189 0 0 0 0 Qualitative design Semi-structured 
interview 
 Informed consent 
procedure 
Uganda 
Crane 2010[42] 
 
HIV Foundation/ 
charity/society 
5 0 0 0 5 0 0 Qualitative design Semi-structured 
interviews 
 Science and ethics in 
HIV transnational 
research in Africa 
Zambia 
Kingori et al. 
2010[33] 
Malnutrition University 
 
>30 0 >25 0 5 0 0 Qualitative design Face-to-face in-depth 
interviews, focus 
group 
 Misconception of 
clinical trials 
Zimbabwe 
Power et al. 
2004[63]
b
                      
Sexual health         Qualitative design Observation, in-depth 
interviews,  focus 
groups 
Thematic 
analysis 
Feasibility study 
targeting adolescent 
sexual health  
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a
 Excluded from the total number of participants as they have the same participants as another study in this review by same author 
b 
Number of participants not reported, thus not included in the total number of participants 
c 
Countries of study: China, India, Thailand, the Philippines, South Africa, Tanzania, Kenya, Brazil, Colombia, Mexico   
d
 Countries of study: Africa, Caribbean 
 not stated, unclear, or unable to ascertain 
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Table 4.2 Comprehensiveness of reporting in the included studies 
Item Studies reporting on the item n (%) 
Personal  characteristics    
  Interviewer/facilitator identified [14, 16-18, 20, 23, 27-37, 39-44, 61, 71, 73-75] 27(69) 
  Credentials [14, 17, 18, 20, 28, 29, 35, 37, 39-44, 71, 74] 16(41) 
  Occupation of interview/facilitator [14-18, 20, 26, 28, 30, 35, 39-44, 71, 73, 74] 19(49) 
  Gender [16-18, 20, 32, 33, 35, 36, 39, 40, 42, 44, 71, 73] 14(36) 
  Experience/training in qualitative research [14, 15, 17, 18, 23, 29-31, 35-37, 43, 44, 61, 71, 73-75] 18(46) 
Relationships with participants    
  Established relationships prior to study [17, 36, 40, 71] 4(10) 
  Participant knowledge of interviewer [36] 1(3) 
Participant selection   
  Selection method (e.g. snowball, purposive, 
  convenience)  
[14-18, 20, 22, 23, 25, 28-35, 39-44, 61, 70-75] 30(77) 
  Method of approach/ recruitment [15-17, 19, 21, 22, 25, 26, 29, 30, 32, 34, 35, 38-41, 43, 44, 61, 
70-75] 
26(67) 
  Sample size [14-44, 61, 70-75] 38(97) 
  Number/reasons for non-participation [23, 25, 30, 33, 34, 41, 70, 74, 75] 9(23) 
Setting   
  Venue of data collection [21, 25, 26, 30, 31, 34, 36, 39-42, 61, 70, 72, 73, 75] 17(44) 
  Presence of non-participants (e.g. clinical  staff)    [27, 30, 41] 3(8) 
  Description of the sample [14-17, 19-26, 28-35, 37-44, 61, 63, 70-72, 74, 75] 35(90) 
Data collection   
  Questions, prompts or topic guide [14-16, 22, 23, 25-27, 29, 30, 33-35, 37-44, 70-75] 27(69) 
  Repeat interviews/observations [14, 29, 72, 75] 4(10) 
  Audio/visual recording [14-17, 22, 23, 25, 26, 28-32, 34, 35, 37-40, 43, 44, 61, 63, 70, 
71, 73, 74] 
27(69) 
  Field notes [14, 16, 20, 22, 23, 29, 31, 32, 35, 37, 40, 41, 44, 61, 75] 15(38) 
  Duration of data collection (interview or focus group) [16, 22, 26, 31, 34, 38, 39, 61, 72, 75] 10(26) 
  Data (or theoretical) saturation [15, 22, 35, 44, 72, 73, 75] 7(18) 
  Participants received transcripts  [32] 1(3) 
  Methodological theory identified [14-17, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 39, 40, 43, 44, 
61, 63, 70, 71, 73-75] 
26(67) 
Data analysis   
Number of data coders [14-17, 20, 22, 23, 26, 28, 29, 31, 32, 35, 38-40, 44, 61, 71, 74, 
75] 
21(54) 
Researcher/expert triangulation (multiple 
researchers involved in coding and analysis) 
[14-16, 18, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 37, 38, 40, 42, 
44, 61, 71, 72, 74, 75] 
24(62) 
Derivation of themes or findings (e.g. inductive, 
constant comparison) 
[14-17, 20, 22, 23, 25-29, 31, 32, 34-41, 44, 61, 63, 70-75] 31(79) 
Protocol for translation  [14-17, 20, 22, 25, 26, 28-31, 35, 38, 39, 41, 44, 61, 63, 70, 71, 
74] 
22(56) 
Protocol for data preparation/ transcription [14-17, 20, 22, 23, 25, 26, 28, 29, 31-35, 37-40, 43, 44, 61, 63, 
70, 71, 73-75] 
29(74) 
Use of software (e.g. NVivo)  [14, 16, 17, 20, 22, 25, 28-30, 39, 41, 43, 61, 70, 75] 15(38) 
Member checking (participant feedback on findings)  [32] 1(3) 
Reporting   
Participant quotations provided or raw data 
provided (picture, diary entries) 
[14-44, 61, 63, 70-75] 39(100) 
Range and depth of insight into participant 
perspectives on clinical trials in children issues in 
LMICs 
[14-44, 61, 63, 70-75] 39(100) 
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Table 4.3 Themes and selected illustrative quotations 
Subthemes Participants quotations (italicized) and/or authors’ explanations
 
Contributing 
references 
Centrality of community engagement 
Assisting in 
mobilising 
community  
 
 “If you don't get them involved, you may in the end implement something that will be 
strange or something that they will not embrace at all. So it is better to get them involved 
to be able to source some information from them, to be able to get their view about the 
project to move to the next stage, because they always have important contributions to 
make to the project, to improve on what you have.” (NHRC research office) [16] 
“Taking advantage of the structures that are already there is what makes it successful. It 
doesn't have to be capital-intensive or anything.” (NHRC research officer) [16]  
[14-16, 18-21, 
24, 26, 31, 32, 
34, 36, 37, 43, 
61, 73] 
 
Recognising the 
pivotal role of 
representatives 
and leaders  
 
“If one hadn't gone through the right procedure… that is, seeing the district authorities and 
the paramount chiefs and the subsection chiefs and so forth, there might have been a lot 
more suspicion about what was going on, why we were doing this, who we were, do we 
have permission to do this. Essentially, this study would not have been accepted.” 
(External researcher) [16]  
“… we went to the meeting and the assistant chief said he doesn’t want to hear any rumors 
from anybody. He said he was an assistant chief and he had a child who was in the KEMRI 
study. He told people if they won’t enroll  in the study they should just keep quiet and 
anybody who will be heard spreading rumours will be arrested … After the assistant chief 
called the meeting, rumours stopped and for us who had already joined, we felt a bit 
better because rumours had stopped” (Female parent, late consenter) [14]  
‘‘It was not difficult at all; it was difficult to convince them to join the programme, but 
through the long time I stayed with them I got a special relation, an independent rapport 
with them, so that even if they do not want to join, they couldn’t say no..” (Fieldworker) 
[27] 
[14-16, 18-20, 
27, 32] 
 
 
Managing 
community and 
research 
expectations 
 
“So as we went round he [CHW] used to say ‘you my colleagues earn but for me I go round 
and get nothing. You have bicycles and we have nothing but when we go, we go together. 
It’s like I am helping you in your work yet no one looks after us.’ So that is one of the 
challenges. But honestly if I look at it fairly its true; . . . if he had gone to work [he would 
have] earned something for a living . . . so it becomes hard because he wants something 
from there and you see I can’t help them.” (Fieldworker) [17] 
“......you should not say I think this is for research, when another person is dying and you 
have the medicines, I think it’s not fair. Even if you have the equipment for research, it can 
be used for diagnostics if it’s so needed.” (Researcher) [35]  
[14-22, 26, 27, 
34-36, 40, 42, 
61, 73] 
Retaining 
community 
intermediaries 
participation 
 
 “Those who stopped complained of money saying they are suffering for nothing . . .’ ‘. . . 
during the durbar the community agreed to give us (CHWs) some incentive but up to now 
nothing. . .’ : ‘The Bible says we should love our neighbour like . . . we love ourselves, so 
whether the children vomit on me or not or I’m being paid or not I will still continue. . .’.  ‘I 
have become so popular and respected by the people in the community. .’ …. ‘I have 
become a friend to all children and mothers in the village. That is my benefit from this 
work’. (CHW) [23] 
“The trial community became a web of everyday relations well beyond the necessities of the 
trial: ‘‘We are there daytime, night time, afternoon time, any time you think of. After the 
first trial, we do not leave but stay… we have good friends. We still visit them, and they 
come to us.’’; ‘‘By the end you become part of the community; you do everything 
together. It was sad…to leave.’ (Fieldworker)’ [27] 
"My father is the sufferer...He used to be the alternate imam of the village. Now half of the 
people do not want to stand behind him in the prayers. They say his daughters work for 
NGOs, which is not right for a religious person." (CHW) [24] 
[17, 20, 23, 
24, 27, 34] 
 
Cognizance of vulnerability and poverty 
Therapeutic 
opportunity 
“What attracted us [was that] we knew our children will receive treatment for a whole year 
in every disease they suffer. If you have a problem and visit the people concerned, a call is 
made to the … [PI] he brings a vehicle and [the sick person] is carried away [to hospital]. 
In fact it’s something we should be happy about because nobody can bring you a vehicle 
that easily.” (Parent) [15] 
“One good thing about it is that, there is no money involved. The parents would also benefit 
from the treatment given. Drugs are so expensive and are not available in government 
hospitals.” (Mother) [41] 
 ‘I don’t see anything wrong with testing the vaccine on us . . . it’s us who are dying of AIDS’ 
(Female adolescent) [26] 
 ‘‘Doctors will not give us anything that is harmful’’. Another subject said, ‘‘Doctors are in a 
way godly. Who would know better than them?’’ [41]  
[14, 15, 21, 
22, 25-27, 29-
32, 34, 36, 37, 
39, 41, 70, 73]  
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Subthemes Participants quotations (italicized) and/or authors’ explanations
 
Contributing 
references 
Medical mistrust 
 
“I don't trust experimental vaccines and moreover these vaccines brought here to Africa by 
scientists cannot be trusted. Because these Europeans know we are poor people and so 
accept any terms and conditions, they are using Africans like guinea-pigs and Africa as a 
dumping place for so much waste. I know it's true that experiments have to be carried 
out by researchers on human beings, but I don't want my child to be involved. ” (Parent) 
[30] 
 ‘The sickness already reduces the blood so what if more is taken?’ ‘won’t that finish of the 
child?’ [36] 
“If I give them my child and the child dies, then they give money that will not bring my child 
back. We had to explain to her until she understood. And in fact, some refused at that 
stage when they heard of KEMRI giving ‘fidia’ [compensation], they said ‘we don’t want 
our children in it. You want to take our child and give that child to the devils”…’ (Male, 
fieldworker). [14]  
[14, 15, 21, 
22, 25-27, 29-
34, 36, 37, 41, 
70, 73, 75] 
 
 
Contending with power differentials 
Concerning 
potential for 
exploitation 
When asked, why the MRC had come to Africa, many said ‘‘to help’’, ‘‘because we Africans 
are vulnerable to diseases’’ and ‘‘because they can’t find these diseases in the UK’’, or 
‘‘because we are powerless people and they need to help us to know the diseases’’. 
….‘‘because Britain has more power than Africa’’, ‘‘it will be easier here than there’’ or 
even ‘‘in UK people are not willing to participate in trials.” [27]  
 “......they might be doing something else also without you knowing. If they are drawing 
blood samples, they’re telling you we are doing it for Malaria, but do anybody have 
control over it, that those blood samples are not going out and they are doing some 
genetic testing or they are doing something else on it? /.../ that is my fear and concern...” 
(Institutional Review Board) [35] 
 “… village elders tended to be coercive sometimes … you could go with them [to homes] and 
you know that … [research] participation is voluntary. But then for a village elder, because 
he wants the [research] agenda fulfilled then he says, ‘we want everybody who has an 
eligible child to join the study, or else we will make sure you are removed even from other 
government projects that are brought here’. So in such a place you [fieldworker] have to 
come back again and try to explain that this [research] is not a must, it’s voluntary” 
(Male, fieldworker) [14] 
[14, 22, 27, 
35, 40, 42, 61, 
63]  
Fearing 
discrimination and 
stigmatisation 
 ‘This might have unintended outcomes where people might feel that they are used, 
understand, . . . unfortunately we have a long history of apartheid where blacks were 
exploited’ (Male educator) [26]   
 “. . . the community will ask . . . ‘what is it that we do not want it to know if there is no 
danger involved in this research?’. You try to explain that there are things in a family, 
family situation that . . . only family members should know . . . that is where people would 
begin to be suspicious; and . . . confidentiality is good in that it saves the lives of the 
people who are participating in research and at the same time it is retarding in the 
community that is being encouraged to participate.” (Community Advisory board 
member) [22] 
 “The way [the FWs] are free with us; they can visit in the morning or evening to check on 
the kid. [So non-participants] have now started spreading rumours that they are not only 
KEMRI but our boyfriends.” (Mother) [15] 
[15, 22, 26, 
28, 29, 31, 33, 
37, 38, 61]  
Disempowerment 
hampering 
informed consent 
 
If the husband says [in a household visit] ‘oh yeah you go listen and join the study’, then 
they are more likely to … [since] they already have permission if I may say so. But if you 
just speak to them [women] in a baraza [public meeting] and then they go explain to their 
husbands, the response is not so good” (Trial staff) [14] 
"Research project? They build houses?" A translator for a woman whose child was in the 
placebo-controlled malaria trial explained, "She does not know what research is. She 
thought they have already done the research, and they are trying to implement the 
results of the research with these children." (Stakeholder) [39] 
“Your main concern is to get your child treated. They could even ask you to stand by a fire all 
day, and you’d do it!” (Mother) [72] 
[15, 19, 22, 
23, 25, 29-32, 
34, 36-39, 41, 
43, 61, 71-74]  
Adapting research to local context 
Respecting 
beliefs and 
cultural practices  
 
“……..somewhere in the north, when a child is born it is not brought out until after one month 
or so. So if we are looking at a vaccine targeting children of four weeks or less, that can 
possibly be a barrier to such children getting access to the vaccine” (Religious leader) [70] 
“...I was uncomfortable discussing topics like reproductive organs because according to our 
Shona culture it’s taboo.” (Teacher) [63] 
This was illustrated in the breast-feeding study regarding the issue of random assignment of 
mothers-infant dyads to breast- or bottle-feeding groups. Although randomization alone 
posed no ethical problems (assuming proper support of safe bottle-feeding was provided), 
[16, 22, 29, 
31, 33, 37, 63, 
70, 74]  
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Subthemes Participants quotations (italicized) and/or authors’ explanations
 
Contributing 
references 
such a procedure clearly clashed with prevailing cultural expectations that parents should 
choose an infant’s feeding method. [37] 
 “Time is such a big constraint because sometimes you go to inform the chief and he says, 
“Come back in 2 or 3 days.”…. you need to add about a month just to complete the 
community process.” (NHRC social scientist) [16] 
“It is part of our culture; whatever you are doing, if there is no tobacco, it is not proper.” 
(Elder) [16] 
Understanding 
resource 
constraints 
 
Additionally, the Haitian custom of sharing food with needy neighbors and housemates would 
have to be respected and taken into account, thus the provision of grain was 
recommended as a measure to discourage consumption of the baby formula by other 
family members. [37] 
 “My children are also malnourished. I would share the supplements with them so they can 
also have good health.”(Mother) [29] 
The paediatric wards at UTH during the conduct of this study were often congested. ‘Floor 
beds’, which were temporary beds, could be found on the wards due to the large number 
of patients and insufficient resources. [33] 
However, it was acknowledged that: “being completely altruistic and participating in research 
that is [going to] benefit society and future generations, is sometimes a little hard to expect 
from people who’re struggling to keep their family fed “ (Site staff) [22] 
[29, 31, 33, 
37, 42, 63, 70]  
 
Ethical pluralism  “Many of the people in the regulatory divisions in the US or the West have really conducted 
trials in the West. And they’re very good, but in resource-limited settings, they actually 
sometimes don’t understand the context of the patients being very sick, you as a researcher 
being their primary clinician so you’re dealing not only with the study component, but 
you’re also providing care and treatment. And so there are a lot more visits that go beyond 
the study visits that you have to take care of as a researcher. So there are a lot of severe, 
adverse events that are not related to the drug, but actually are severe, adverse events that 
are part and parcel of a child growing up in Africa with a high infant mortality rate, a lot of 
malaria and pneumonia, diarrhea. Just the common illnesses that all need to be reported as 
serious adverse events. You know, we’re not denying that they should be reported, but 
there is a heavy load on the staff that are doing the studies.” (Investigator) [42] 
 “My opinion is that we should use the standard of care here. Because it makes more sense if 
you are investigating whether something is useful, you should compare it with what is being 
done here rather than what is being done in the US, which will take a long time actually to 
be done here.” (Investigator) [42] 
“I said to them, ‘this is very good, but why are you giving a placebo to this other group? Do 
you know that the transmission is obviously proven? It’s there. So, can you really give 
placebo to this group?’ They said, ‘Yeah. But you know, in as far as we are concerned, there 
is no other study regarding this so we really want to give placebo to prove it.’ I said, ‘No 
way! There’s no way! You know that these mothers are at a disadvantage. The children are 
at a disadvantage. How do you say you are going to give placebo? You are deliberately 
infecting those children!’ Right? So we refused and that group was given nevirapine and 
this other group received the new drugs. So they did the study…‘It’s the science and the 
ethics. Tell me in Sweden, in the States, in Canada, in France, would this research pass the 
ethics committee? Would children American children, Canadian children, Swedish children, 
French, Norwegian children be deliberately exposed to milk that was HIV-infected and be 
given placebo? And compared with a group that was receiving anti-retroviral drugs? Would 
that pass your ethics committee?’ (Investigator) [42] 
‘Sometimes people don’t even look at the issues, you know, they might be interested in what 
they are going to get out of the trial in terms of money’ (Research Ethics Committee). …‘The 
problem is, if you start agonizing over inducements then you come out saying that if a 
person is poor we will give less to be in the trial than if they are rich.’ (Sponsor) [22] 
[15, 22, 27, 
30, 35, 36, 42, 
43, 72]  
 
Advocating fair distribution of benefits 
Supporting 
health care and 
societal needs 
“...we want to ensure that if you are carrying research within a particular community, you 
need to give them something back for instance a hospital or something, even if you are 
doing clinical research. It can be anything else that can benefit the community. Some sort of 
infrastructure, so that they can at least see that they are benefiting. Once you have done 
that, actually they will feel that they are part of the process...” (Civil Society Organization) 
[44] 
“... he likes to talk about ‘brain gain’ as opposed to ‘brain drain’. I mean the fact is, we are 
being able to provide interesting research work for lots of scientists.... but there are a lot of 
Doctors that are able to do what they want to do which is to stay in their own country and 
work in their own country” (Public private partnership1) [44] 
The effective and fast treatment offered to trial participants as well as non-participants. ……… 
[16, 27, 44, 
75] 
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Subthemes Participants quotations (italicized) and/or authors’ explanations
 
Contributing 
references 
“The death of children has been massively reduced in the pediatric ward.” (Health worker) 
[75] 
“Even if the parents or guardians do not have money they still get quality health service, this 
project does not segregate between rich people and poor people…” (48-year-old Female) 
[75] 
Sponsor 
obligation 
 
“...in the previous decade (the industry) was seen to just purely profit from human suffering 
and people had a very negative view of the Pharmaceutical Industry. And in the last 10 
years, we are sort of re-modeling our self and trying to make sure we project our self in a 
very responsible manner...” (Pharmaceutical company 1) [35] 
 “... I think you should be realistic, that nobody is going to come back and you may not be 
there to enforce that somebody should give back to the community...and once they find 
what they are looking for, they may just take off...” (Institutional Review Board) [35]  
[16, 22, 35, 
40] 
Collateral 
community 
benefits 
 ‘‘We cannot serve the entire community, but neither can we only serve volunteers and leave 
out their wives and children… these people are all related - but where would we end?’’ 
(Fieldworker) [27] 
 “We do not accept! We do not accept it at all! And if you do so, we will withdraw completely 
from the study! We want to be vaccinated: us, our children, our husbands and even our 
dogs!” “Maybe they [non-participants] are the ones that will be bitten by dogs and we will 
not get that vaccine . . .” (Mothers) [28] 
 ‘Even with fares; a study will give exact fare, another one will give extra - like one and a half 
the amount that people are charged, so sometimes it brings problems and you know 
sometimes they are in one study when they complete then maybe another child is in 
another study, so they are like, “why is it that I was given double fare and now you are 
giving me only one way”  (Clinical officer) [40] 
[22, 27, 28, 
32, 40] 
 
Italicized quotations are from study participants.  
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Figure 4.1 Flowchart of review of qualitative studies on the conduct of trials in children in 
low-and middle-income countries 
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Figure 4.2 Thematic schema of redressing inequities and disadvantaged circumstances 
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Chapter 5: Completeness of protocols of clinical trials in 
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5.1 Abstract 
Abstract 
 
Background: Empiric studies of published clinical trials involving children have shown 
methodological flaws and high risk of bias but it is unclear if this reflects editorial processes 
of true problems in design and conduct. We aimed to ascertain the completeness of the 
reporting of key domains in the conduct of clinical trials involving children by evaluating the 
protocols of pharmacological interventions for trials submitted to the Human Research Ethics 
Committees (HRECs) of Children’s Hospitals in Australia. 
Method: HRECs of all Children’s Hospital were invited to participate. De-identified trial 
protocols submitted for review in 2012 were evaluated using checklists based on CONSORT 
(CONsolidated Standards of Reporting Trials), the Cochrane risk of bias tool and Good 
Clinical Practice guidelines. 
Results: Four of 8 hospitals agreed to participate and 69 protocols were analysed. The 
domains most frequently reported were clustered around the background and trial plan 
(planned interventions for each group (99%), specific objectives (97%), and scientific 
background (96%)). Domains that were reported least frequently were clustered around the 
statistical analysis plan (66%), the justification for a new trial based upon a systematic review 
of the published literature (48%), and child-specific domains (48%).                                                                                         
Conclusions: Protocols of trials involving children assessed by Ethics Committees are 
generally comprehensive, but many key domains in trial design and conduct are not reported. 
Problems in the design and conduct of clinical trials may lead to misleading conclusions in 
the healthcare of children. There is a need for development, implementation and compliance 
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with standards in the design of trial protocols to help improve the quality of trials, minimize 
risk of harm and generate reliable results to inform evidence-based child healthcare.  
 
What’s known on this subject  
Published trials in children are often analysed as high or unclear risk of bias, but it is 
uncertain whether this reflects editorial practices or whether this does indicate important 
omissions in the design and conduct of clinical trials involving children. 
 
What this study adds  
Paediatric trial protocols are generally comprehensive, but over 20% have major gaps, 
focused on the statistical analysis plan including sample size, and data analysis methods, and 
a justification for why an additional trial is needed, based upon a systematic review.  
 
5.2 Introduction 
It is well established that randomised controlled trials (RCTs) may result in over-optimistic 
and misleading treatment effects when key elements in the design and conduct are either not 
reported or are reported and are not appropriate. These problems have been found more 
frequently in trials involving children [1-5]. However it is unclear whether these problems 
reflect editorial practices, where ‘methods’ elements are removed in favor of ‘content’ 
elements because of space constraints, for example, or whether these observations do reflect 
deficiencies in actual trial design and conduct.  
A  trial protocol is a research plan that describes the background, rationale, objectives, design, 
methodology, statistical considerations, and organisation of the trial and is an essential 
document for all trial stakeholders [6]. The Human Research Ethics Committee (HREC) is 
responsible for the ethical and scientific review of trial protocols according to stringent local 
and international guidelines, balancing research risks with potential benefits and contribution 
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to existing knowledge [7, 8]. The fundamental assessment of the scientific rigor of a trial 
protocol is of paramount importance in validating the results of the trial. A recent study of 
reviews by HRECs of pediatric multi-center drug trials recommended that applicants ensure 
that the trial documents are informative to researchers, regulators and consumers [9]. Almost 
all empiric studies of the quality of research have assessed published reports, but this may not 
reflect actual design and conduct. We aimed to evaluate how comprehensive protocols of 
pediatric trials of pharmacological interventions were, as submitted to the HRECs among 
Australian Children’s Hospitals, and to identify areas for improvement.  
 
5.3 Methods 
5.3.1 Study Design 
This is a retrospective cohort study of trial protocols of pharmacological interventions 
involving children submitted from 1 January to 31 December 2012 to the HRECs of 
Children’s Hospitals in Australia. The study was conducted over 18 months from June 2013 
to December 2014. Ethics approval to conduct the study was received from the HRECs of 
participating Children’s Hospitals. 
 
5.3.2 Practice Selection and Setting 
All Children’s Hospitals in Australia were invited to participate in the study. The inclusion 
criteria were, clinical trials (phase 1 to 1V) of drug or medicines, complementary or herbal 
medicines or devices containing a therapeutic agent, which were to be conducted in children 
aged 0-18 years or in a mixed population of children and adults and which were submitted to 
the HREC during 2012. Only the scientific components of the protocols were assessed and 
not the ethical aspects. 
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5.3.3 Study Procedures  
The study investigated the characteristics and reporting of the domains of trials submitted to 
HRECs using a standardised checklist. The checklist was piloted to establish feasibility, and 
completeness of quality assessment criteria. The data were extracted from all protocols 
submitted the first time for consideration by any HREC and relevant supporting 
documentation. All eight pediatric hospitals were invited to be part of the study with a 
nominated investigator, who was a member of the local HREC or its sub-committee, being 
responsible for data extraction. All data were de-identified.  
 
5.3.4 Data collection  
The World Health Organization (WHO) International Classification of Diseases (ICD) was 
used for classifying the disease or health condition studied [10]. Data on the background, 
rationale, objective(s), design, methodology, statistical considerations, and organisation of 
each trial were extracted using a consolidated checklist adapted from the CONSORT 
(CONsolidated Standards of Reporting Trials) and Cochrane risk of bias tool [11, 12]. A 
compilation of other protocol elements of importance to trials and in particular child-specific 
domains such as reporting disease prevalence in children and long-term safety monitoring 
informed by current International Conference on  Harmonisation Guideline for Good Clinical 
Practice guidelines (E6R1) [6] and WHO Paediatric clinical trials guidance for assessors [7] 
were also included [13]. Some of these items now appear on Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) [14] and proposals for CONSORT-
Children and SPIRIT-Children [15]. The Cochrane Collaboration’s risk of bias tool  contains 
seven domains and we assessed five of these (sequence generation, allocation concealment, 
blinding, incomplete outcome data (intention to treat analysis),  and “other sources of bias 
(trial limitations, addressing sources of potential bias, imprecision, and if relevant, 
multiplicity of analyses)” [12, 13]. Given that each trial was in protocol stage some items 
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such as attrition bias were not relevant and not considered. We checked all the trials after 
ethics approval to determine whether they were registered on the WHO International Clinical 
Trials Registry Portal [16]. 
 
5.3.5 Data analysis 
The data from the checklist was captured on a Microsoft Excel
®
 spreadsheet for analysis. 
Descriptive techniques were used to analyse the data. For each of the core domains (title, 
background and objectives, trial design, participants, recruitment, interventions, outcomes, 
harms or unintended effects, sample size, randomisation, blinding, statistical methods, trial 
registration, funding, reporting) the proportion of protocols that included or described the 
domain, was reported. The Cochrane risk of bias domains was reported as high, low or 
unclear risk of bias.  Frequency of reporting across the domains were displayed using a two-
dimensional radar plot generated in Microsoft Excel
®
. Adequate reporting of domains was 
defined pragmatically as more than 80%. 
 
5.4 Results 
5.4.1 Characteristics of study sites and included trials 
Four of the eight pediatric hospitals in Australia participated. Non-participation was due to 
institutional restrictions, resources and time constraints. Characteristics of the included trials 
appear in Table 5.1. Of the 69 protocols included in the study, 57 (83%) were RCTs, 47 
(68%) recruited children only, 58 (84%) were multi-center of which 34 (49%) recruited multi-
nationally and 51 (74%) were phase III trials. The main health conditions studied were 
respiratory (18), neoplasms (9), hematological and immunological (9), and infectious diseases 
(8). Eleven of the protocols did not include the proposed sample size that could be potentially 
be recruited by the site. The  planned site sample size of the 58 remaining trials ranged 
between 1 to 1920 participants, with 44 (76%) estimating a sample size of 100 or less and 24 
Chapter 5: Completeness of protocols of clinical trials in children submitted to ethics committees 
102 
 
(41%) a sample size of 10 or less. The main comparators for the RCTs were current standard 
patient care (25) and placebo (21). Of the 38 studies that stratified the randomisation, 13 were 
by age and 10 by gender. The main endpoints in most trials were efficacy (65) and safety (52). 
Only 6 trials planned to evaluate quality of life (QOL).   
 
5.4.2 Completeness in the reporting of trial domains 
Figure 5.1 and the supplementary Table in Appendix E1 show the frequency of reporting of 
the CONSORT criteria. The domains that were reported almost always (90%) were: funding, 
scientific background, specific objectives, description of trial design, study setting , eligibility 
criteria, interventions for each group to allow replication, description of similarity of 
interventions, intervention maximum dose or threshold levels, compliance measurement, pre-
specified outcome measures, blinding of personnel after assignment of interventions. The 
domains that were reported almost always (75-90%) included dates defining the periods of 
recruitment and follow-up, statistical methods to compare group outcomes, type of 
randomisation and details of any restriction, method used to generate the random allocation 
sequence, person who generated the random allocation sequence and enrolled assigned 
participants,  method used to implement the random allocation sequence, harms or unintended 
effects, sample size calculation and trial registration. The trial domains that commonly and 
often missed were: descriptive title, mechanism used to implement the random allocation 
sequence, methods for subgroup or adjusted analyses and explanation of interim analyses and 
stopping guidelines.  
 
The checklist of child-specific and other important items for trial protocols appears in Figure 
5.2 and the supplementary Table in Appendix E2. The domains that were almost always done 
(90%), maximum dose or threshold levels of intervention, compliance measurement and 
safety data on the therapeutic intervention. The domains that were frequently reported (75-
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90%) were: disease prevalence in children, impact of the disease in children, participant 
timeline, continuous safety monitoring and planned reporting of study results. The trial 
domains that were reported least frequently were: background systematic review justifying 
need for the study; dose adjustment by age, weight or body surface area, post-trial provisions 
of effective interventions, age and development specific outcomes, protocol modification 
conditions, long-term safety monitoring, and inclusion of a Data Safety Monitoring Board. 
 
5.4.3 Assessment of risk of bias 
The assessments of risk of bias that were most frequently reported were as follows: random 
sequence generation (88%), blinding of participants and personnel (87%), blinded outcome 
assessment (81%), allocation concealment (80%). Poorly described domains were: specified 
intention to treat analysis or incomplete outcome data (54%) and other bias (51%) (Figure 
5.2).  
 
5. 5 Discussion 
Our study was designed to determine the completeness of reporting of important domains in 
the design and conduct in trials of pharmacological interventions based upon trial protocols 
submitted to Ethics Committees of Children’s Hospitals in Australia. We found that in most 
trial protocols the core content domains were reported, in particular funding, scientific 
background, objectives, disease prevalence in children, planned interventions and risk of bias.  
However, there were incomplete reporting of domains mainly clustering around systematic 
review of the literature, impact of disease in children, age and development specific 
outcomes, and most elements of the statistical analysis plan. 
 
It is likely that the domains that were well reported such as funding and objectives reflects the 
standard templates or checklists that  investigators are required to use for submitting  trial 
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protocols to the Ethics Committees [8, 17]. The training and guidance provided to 
investigators also improves their familiarity with the content requirements of the protocol. 
Domains related to the research question and rationale was reported in 96% of the trials in our 
study. However, fewer than 50% of trial protocols provided evidence of having undertaken a 
systematic review of the existing literature to inform the primary research proposed. Evidence 
of a systematic review is important for reviewers to ensure that the trial is necessary, and has 
not been answered previously. As the ethics applications are often guided by the institutional 
templates, some of the templates may not have included the need for a systematic review of 
the literature. Thus a systematic review may not have been included in the submitted protocol 
even though it may have been conducted by the investigators.  
 
Most elements of statistical analysis were poorly reported in our study. Appropriate sample 
size calculations ensure that studies are adequately powered to provide conclusive findings 
and detect modest but clinically relevant outcomes including adverse effects [5, 18]. 
However, our results indicate that only 73% of the trial protocols addressed sample size. 
Calculation of an adequate sample size is also important to prevent research waste and 
unnecessarily subjecting children to poor research.  A priori subgroups (e.g. neonates, infants, 
preschoolers, children and adolescents) within the pediatric population may respond 
differently to therapies and need to be identified, with trials adequately powered to minimise 
the chances of a type II error occurring in these subgroups [5, 19].   
 
Evaluation of adverse effects need to consider that children are more susceptible to the 
harmful effects of medicines, and that adverse effects may present much later in children who 
are still undergoing growth and development. Independent Data Monitoring Committees 
(DMCs) or Data Safety Monitoring Boards (DSMBs) safeguard the interests of trial 
participants by monitoring safety and adverse drug reactions (ADRs) and the scientific 
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integrity of the trial for example decisions on interim analysis and early stopping of trials. Not 
all trials require stopping guidelines, interim analyses or a DMC; however it is still important 
for this to be justified in the protocol. DMCs play a pivotal role in the scientific validity, 
results and clinical impact of a trial and are recommended for all appropriate pediatric trials 
[20, 21]. Our study showed 62% of the trials described measurement of harms or unintended 
effects with only 12% indicating long-term safety monitoring. A review of 739 published 
trials in children (1996-2002) showed that 71% of the trials reported an ADRs, 20% reported 
a serious ADRs,  but only 2% of the trials had a DMC [22]. A later review of trials (2005-
2007) showed that 17% reported on DMCs, interim analysis or early stopping [23]. We found 
that 73% of protocols defined the criteria for stopping the trial and 71% of the protocols 
indicated that there was to be a DMC. Although the previous studies reflects published trials 
and our study is of protocols submitted, this data  suggests that trialists are becoming more 
aware of the importance of pharmacovigilance in children and the need to comply with 
scientific standards and a framework for DMCs [16, 23-28].   
 
Completion of the risk of bias domains in the protocols were reported well in comparison to 
previous analysis of published pediatric trials that were judged to have high risk of bias. 
[4],[1]
 
An analysis of published pediatric trials indicated that only 27% (1996-2001) and 17% (2002-
2006) of pediatric trials adequately addressed allocation concealment [4]. It is possible that in 
the publication of trials, the authors may not have reported all aspects due to journal editorial 
practices, although these may have been included in the trial design and conduct [4]. A study 
looking at the risk of bias in RCTs in children (2008-2009) showed improvement in reporting 
with a low risk of bias for random sequence generation (59%) and blinding of outcome 
assessment (63%). Researchers need to comply with standards containing the risk of bias in 
trials in children [29]. There is a need for evidence-informed guidelines on the selection of 
appropriate clinical comparators in trials in children. Our findings indicated that 36% of the 
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comparators of the RCTS used the current standards and 30% used placebo, however we did 
not assess the appropriateness of the comparators. The use of placebos in children poses 
ethical dilemmas. A sound rationale must exist for its use to ensure children are not exposed 
to the risks of placebo or an inferior therapy when better therapies are available [26, 30, 31]. 
 
The child-specific elements of the protocols were poorly described in our study. For example 
age and development specific outcomes, which are important in children, were often not 
included. In our study only 13 trials had randomisation stratified by age. The selection of 
endpoints should be objective, clinically relevant and measurable in a valid and reliable 
method minimising the risk of bias.  There are some initiatives underway looking at selection 
of outcomes in the general population [32-38].Well-defined and reliable trials outcome 
assessments for recording treatment benefit in children in most therapeutic areas, considering 
their different manifestations of diseases and the variable developmental changes are lacking 
[39]. In our study, plans to measure children’s quality of life were only mentioned in 9 (13%) 
of the trials and this has been identified as a gap previously [40]. Although there are some 
initiatives underway to develop patient reported outcomes in the general population, [41] 
there is a need to develop age-appropriate measurement strategy of children and adolescents 
reported outcomes [42].
 
 
 
This study has shown that the reporting of scientific components of protocols of trials in 
children submitted to Ethics Committees is generally comprehensive. However, many key 
domains in trial design and conduct are not reported in the submitted protocols. This may be 
due to the different requirements in the Australian context and the institution ethics 
applications templates or lack of oversight by researchers. Consistency was maximised by a 
standardised, widely used checklist with training and guidance provided for completion of the 
checklist to ensure data validity. Although the study was conducted in Australia where the 
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ethics processes and research standards may be different to other countries, there is potential 
for the findings to be extrapolated to other developed countries. However, there are 
limitations with our study. Due to resourcing and time constraints, only 69 protocols were 
analysed. We used a checklist for reporting of core components of the trial protocols 
submitted to the ethics committees. This is not an analysis of the revised final protocols used 
in practice or an assessment of how well the trials were conducted. Given the issues of 
confidentiality there was no capacity for double extraction of data by the same two 
researchers. However, a previous study demonstrated that there was high interrater agreement 
for reviewers by adherence to a standardised checklist and agreed definitions by reviewers 
[43]. At the time of the study Standard Protocol Items for RCTs (SPIRIT) [44] was not 
available and we therefore used the CONSORT checklist.  
 
Our study findings have implications for policy and clinical practice. We encourage 
improvements in explicit and transparent inclusion of all core elements of paediatric trial 
protocols. This will assist regulators in their critical evaluation, researchers in the conduct and 
registration of the trial, and clinicians in synthesising the evidence potentially improving 
quality and  saving time of all users [45, 46]. In the design of our checklist to assess the 
protocols, we noted inadequacies in the current guidance for protocols and reporting of child-
specific issues in trials in children, but acknowledge some initiatives are underway [21]. Two 
recent systematic reviews gathered evidence and recommendations for including child-
specific items in protocols, SPIRIT-Children (SPIRIT-C) [44, 47] and reporting of trials in 
children CONSORT-Children (CONSORT-C) [15, 48]. It is imperative for stakeholders 
including HRECs and research institutions to collaborate locally and internationally and 
invest in researcher’s training on protocol development. This includes supporting the 
development and use of evidence-based standards and guidance such as standardised protocol 
templates to promote best research practices [13,34].   
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A similar assessment of completion of scientific items in protocols of paediatric trials 
conducted in less developed countries would be useful to determine their specific gaps that 
could be different due to resource constraints. Future research should evaluate the 
completeness of the inclusion of the ethical components of relevance to children in the 
protocols and related trial documents to inform improvements in trial design. We recommend 
further research into the conduct of trials including frequency and procedures for auditing trial 
conduct.  
 
5. 6 Conclusions 
Protocols of clinical trials involving children assessed by Ethics Committees were 
comprehensive and well-described. However, many key domains in trial design and conduct 
remain incompletely reported in protocols and could be improved. These cluster around 
statistical analysis, safety monitoring and child-specific elements, such as appropriate 
randomisation stratified by age. Problems in the design and conduct of clinical trials may lead 
to misleading conclusions in child healthcare. There is a need for development, 
implementation and compliance with standards in the design of protocols that consider the 
unique needs of children. This could help improve the quality of trials in children, minimise 
risk of harm to children and generate reliable results to be implemented in the clinical care of 
children.  
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Table 5.1 Characteristics of included trials (n=69) 
Characteristics of trial Number of trials (%) 
Type of trial  
  Randomised controlled trial 57 (83) 
 Non-randomised controlled trial 13(17) 
Initiated by  
   Industry 36 (52) 
   Investigator 33 (48) 
Phase  
  Phase 1 4 (6) 
  Phase 2  10 (15) 
  Phase 3 51 (74) 
  Phase 4 4(6) 
International Classification of Disease (ICD) 
   Respiratory 18 (26) 
   Neoplasms 9 (13) 
   Haematological and immunological 9 (13) 
   Infectious  8 (12) 
   Endocrine, nutritional and metabolic  5 (7) 
   Environmental     5 (7) 
   Other  15 (22) 
Intervention use 
   Treatment 51 (74) 
   Prevention  17 (25) 
   Diagnosis   1 (1) 
Participants 
   Children (0-18 years) 47 (68) 
   Children and adults  22 (32) 
Recruitment sites
a
 
   Multinational 34 (51) 
   Multi-centre  58 (87) 
   Single centre 9 (13) 
Inclusion of sample size  58 (84) 
   Sample size  of 100 or less participants 44 (76) 
   Sample size of 10 or less participants 24 (41) 
Recruitment methods
b
                                                                                          
   Face-to-face/referral  47 (68) 
   Advertising  9 (13) 
   Mail out/telephone  7 (10) 
   Follow-up trial 3 (4) 
Stratification of treatment
c
                       38 (55) 
  Age  13(34) 
  Gender 10 (26) 
 Previous treatment 4 (11)) 
  Severity of illness  3 (8) 
  Weight  1 (3) 
  Other 13(34) 
Primary and secondary endpoint(s)
b
                
  Efficacy 65 (94) 
  Safety 52 (75) 
  Tolerability    14 (20) 
  Optimum dosage schedule  7 (10) 
  Pharmacokinetics    7 (10) 
  Quality of life (QOL) 7 (10) 
  Other 8 (12) 
Type of comparator                         
   Current standards of patient care  25(36) 
   Placebo 21 (30) 
   Different regimens of same intervention                   13(19) 
   Other  2(3) 
b 
some items were unclear and were excluded from the denominator
 
a 
more than one category permissible 
c 
n is less than 69 as domain did not apply to some trials 
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Figure 5.1 Radar chart of frequency of CONSORT domains in paediatric trial protocols submitted to ethics committees  
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Figure 5.2 Radar chart of frequency of other important domains of paediatric trial protocols submitted to ethics committees 
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Figure 5.3 Risk of bias for paediatric trial protocols submitted to ethics committees 
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6.1 Abstract 
Background: The last decade has seen dramatic changes in the regulatory landscape to 
support more trials involving children, but child-specific challenges and inequitable conduct 
across income regions persist. This study aims to describe the attitudes and opinions of 
stakeholders towards trials in children, to inform additional strategies to promote more high-
quality, relevant paediatric trials across the globe. 
Method: Key informant semi-structured interviews were conducted with stakeholders 
(researchers, regulators and sponsors) who were purposively sampled from low-middle and 
high-income countries. The transcripts were thematically analysed. 
Results: Thirty-five stakeholders from 10 countries were interviewed. We identified five-
major themes: addressing pervasive inequities (paucity of safety and efficacy data, knowledge 
disparities, volatile environment, double-standards, contextual relevance, market-driven 
forces, industry sponsorship bias, prohibitive costs); contending with infrastructural barriers 
(resource constraints, dearth of pediatric trial expertise, logistical complexities); navigating 
complex ethical and regulatory frameworks (“draconian” oversight, ambiguous requirements, 
exploitation, excessive paternalism and unwarranted exclusion, precariousness of coercion vs. 
volunteerism); respecting uniqueness of children (paediatric research paradigms, child-
appropriate approaches, family-centered empowerment) and driving evidence-based child 
health (advocacy, opportunities, treatment access, best practices, research prioritisation).                                                                                                                
Conclusions: Stakeholders acknowledged that changes in the regulatory environment have 
encouraged more trials in children to be undertaken, but they contended that inequities, 
political, regulatory, and resource barriers continue to exist. Embedding trials as part of 
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routine clinical care, addressing the unique needs of children, and streamlining regulatory 
approvals were suggested. Increasing international collaboration, establishing sustainable 
centralised trials infrastructure, and aligning research to child health priorities were suggested 
to encourage more high-quality trials that address global child healthcare needs.  
 
What’s known on this subject  
Conducting trials in children is complex because of safety concerns, stringent regulatory 
requirements, lower prevalence of disease, and lack of commercial interest. Recent changes in 
the regulatory environment have mitigated these challenges somewhat.  
 
What this study adds  
Stakeholder views on mitigating the inequities by addressing children’s unique needs, 
integrating trials into clinical care, streamlining regulatory approvals, building infrastructure, 
increasing international collaboration, and aligning research to child health priorities to 
facilitate the conduct of high-quality relevant paediatric trials.   
 
6.2 Introduction 
The last decade has thus seen major changes in the regulatory framework for clinical trials in 
children, resulting in substantial incentivisation for industry and investigators to rigorously 
evaluate new therapies through the conduct of clinical trials [1-3]. Several pediatric research 
networks have also been established to support trials in children, with variable success [4, 5]. 
Despite these advances, all too often, children remain “therapeutic orphans” as the majority of 
medicines prescribed for children have still not been adequately validated for safety and 
efficacy, and disparities exist compared to adults and by income regions [1].   
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Trials in children are complex and can be challenging due to the unique requirements of 
children, safety concerns, stringent ethical requirements and the lack of commercial interest 
[6, 7]. In low-and middle-income countries (LMICs) there are additional challenges related to 
poverty, fear of exploitation and mistrust [8, 9]. The pharmaceutical industry are  perceived as 
reluctant to conduct trials in children, while pediatricians’ concerns regarding risks are seen as 
barriers [1].  
 
This study aims to describe the attitudes and opinions of researchers, regulators and sponsors 
regarding the conduct of clinical trials in children. A comprehensive understanding of their 
values, beliefs and experiences across different income contexts could inform local and 
international strategies to improve the number, quality and appropriateness of trials conducted 
in children. 
 
6.3 Methods 
We followed the Consolidated Criteria for Reporting Qualitative Research (COREQ) 
framework for interviews and focus groups [10]. 
 
6.3.1 Respondent Selection and Practice Setting 
Respondents were eligible if they were researchers, regulators, or sponsors, who were 
involved in trials in children. The stakeholder groups are defined in Box 6.1.We recruited 
respondents via professional networks who were purposively selected to capture a range of 
age, gender, income settings, and experience in trials. A snowball sampling strategy was also 
used whereby respondents could nominate others who could add a different or important 
viewpoint. The University of Sydney Ethics Committee approved this study. 
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Box 6.1.   Professionala (researcher, regulator and sponsor) stakeholders of clinical trials in 
children  
  
Researchers: academic, administrator, clinicians/paediatrician, clinical pharmacologist, 
investigators/researcher, methodologist, networks/working groups, clinical trials 
center/clinical research facility, trial coordinators/assistants.  
 
Regulators:  Institutional Review Board (IRB) (bioethicist, ethics committee member, ethical 
review bodies, ethics subcommittee/scientific advisory committee member), 
networks/working groups, Data Safety Monitoring Board (DSMB) or Data Monitoring 
Committee (DMC)/local safety monitor, regulatory body, policy makers, research 
governance. 
 
Sponsors: academic sponsor, charitable organisations, clinical research assistants (CRA), 
government funding body, monitors, pharmaceutical industry, Contract Research 
Organization (CRO), consultancy work with sponsors. 
 
aProfessional stakeholders excludes consumers (children, families and the public) 
 
 
6.3.2 Data collection 
The interview guide was based on a systematic review of trials in children and discussion 
among the study team [1].  It focused on the challenges and strategies to improve trials 
relevant to child health (Appendix F1, provided as online supplementary material). From 
October 2013 to August 2014, PDJ conducted face-to-face interviews in offices or meeting 
rooms or via the telephone. Respondent recruitment ceased when theoretical saturation (i.e. 
when little or no new information was being obtained from subsequent interviews) was 
reached [11, 12]. We audio-recorded and transcribed all interviews. 
 
6.3.3 Analysis 
Transcripts were entered into HyperRESEARCH software (ResearchWare Inc, United States, 
Version 3.5.2,). Based on grounded theory [13] and thematic analysis, [12] PDJ coded 
transcripts line-by-line, and translated similar and different concepts into existing or new 
codes, respectively, as they emerged in the data. We grouped similar concepts into themes and 
subthemes, and revised the coding structure until all concepts relating to barriers and enablers 
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of trials in children were captured. We identified relationships and patterns between themes to 
develop a thematic schema. To enhance the comprehensiveness and validity of the thematic 
framework, the preliminary findings were discussed among the research team (investigator 
triangulation) and then emailed to all respondents who were given 2 weeks to include 
additional viewpoints (i.e. member checking). Their feedback was coded and incorporated 
into subsequent revisions of the analytical framework. 
 
6.4 Results 
6.4.1 Study Respondents 
In total, 35 (88%) of the 40 invited stakeholders participated. They were from 10 countries 
[high-income countries (n=20) and LMICs (n=15)] (Table 6.1). Non-participation was due to 
non-availability or institutional restrictions. The duration of the interview ranged from 20 to 
70 minutes. Eight interviews were conducted face-to-face.  
 
6.4.2 Themes 
We identified 5 major themes: addressing pervasive inequities, contending with infrastructural 
barriers, navigating complex regulatory and ethical frameworks, respecting uniqueness of 
children and driving evidence-based child health. These themes are described with illustrative 
quotations in Table 6.2 and Appendix F2. Figure 6.1 shows the conceptual relationships 
among themes and subthemes.   
 
6.4.2.1 Addressing pervasive inequities 
Paucity of safety and efficacy data 
The growth in the number of trials in diseases specific to children was perceived to be less 
than expected. Clinicians were concerned that children could be potentially harmed due to 
“treatment uncertainties” and “practicing un-researched healthcare” as trials were still 
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“skewed” with data from the adult population. In particular, respondents felt there was a 
paucity of safety and efficacy data in diseases with a high burden in resource-poor settings, 
rare childhood diseases, older off-patent medicines, and younger age groups. 
 
Knowledge disparities  
Researchers felt that they were perceived by some pediatricians, the community and 
politicians to be “using” children, and were described as “vampires after your blood.” Some 
respondents believed that parents in the West were “pretty informed and educated,” whilst 
researchers in LMICs had to contend with language barriers and lower health literacy in 
parents. 
 
Volatile environment 
The entrenched social disadvantage, local political instability and corruption in certain LMICs 
were put forward as the main reasons for insecurity and hesitation among local researchers to 
conduct trials in children. Historical fears were believed as damaging public trust of trials 
involving children, for example, the unethical trials conducted during the Second World War 
in Germany.  
 
Challenging double standards 
The “double-standard” of the bureaucratic burden and regulatory requirements to conduct 
trials in children, compared to the ease of using untested interventions in routine clinical care 
was questioned. There was controversy regarding the proposal of using placebos or inferior 
treatments as comparators in trials in LMIC countries, where the international standard of care 
was not routinely available. Regulators in the UK and US queried why it was “illegal” to pay 
children anything beyond trial expenses reimbursements, while in adult trials it was “fair to 
pay” for participation.  
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Ensuring contextual relevance  
A “disconnect” between the paediatric burden of disease and countries where trials were 
conducted was felt by respondents. Researchers thought “data which is not Indigenous” may 
not be relevant to local settings because of “pharmacogenomic differences” and variability in 
healthcare. 
 
Market driven forces  
Respondents believed industry would “leverage their resources” in trials where there was 
greater “financial reward” rather than for “humanitarian reasons.” Clinicians argued that most 
trials were focused on diseases in adults, driven by political and economic influences, and the 
regulatory incentives for involving children in trials only helped to “tie the pediatric caboose 
to the adult marketing train.” They surmised that it had been “a happy marriage between 
industry and regulators” to conduct trials with a large sample size as a “pre-authorization 
marketing tool.”  
 
Industry sponsorship bias 
Industry-sponsored trials were noted to be almost always multinational and of higher quality 
because of adherence to regulatory standards for obtaining marketing authorisation. In 
contrast, investigator-initiated trials were deemed to be of a “poor quality,” “curiosity-driven” 
or for academic promotion. Clinicians suspected that investigators reluctantly participated in 
industry-sponsored trials, so they could “pay the rent” and subsidise their own research. 
Industry sponsors felt that the majority of industry “get tainted in that stigma” by the minority 
of pharmaceutical companies who conduct research unethically. They felt “damned if they do 
and damned if they don’t” involve children from LMICs in trials. 
 
Dissuaded by prohibitive costs  
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The “manifold costs” of regulatory oversight was perceived as a “double-edged sword” for 
investigators who had to conduct trials “on shoestring budgets or no budgets.” Trials in 
children were perceived to be a “financial risk” to industry because of the small pool of 
eligible patients, longer follow-up and the increasing site costs. Industry sponsors were 
polarised regarding the perception that they were “shifting” to the LMICs where it was a 
“cheaper” option. 
 
6.4.2.2 Contending with infrastructural barriers  
Overwhelming resource constraints 
Researchers stated that “funding was the bane of doing research” in children, as paediatric 
trial facilities and resources were scarce, especially in disadvantaged settings.   
 
Dearth of paediatric trial expertise  
Respondents noted a critical lack of expertise in paediatric trials. Some researchers from 
LMICs acknowledged that they developed expertise from participating in industry-sponsored 
trials.  
 
Traversing logistical complexities  
All respondents had to confront logistical complexities such as shipping samples overseas. 
This was particularly challenging in LMICs. For example, researchers in Nigeria had to 
contend with electricity disruptions, unreliable telecommunication, and difficulty in 
following-up respondents who frequently relocated.  
 
6.4.2.3 Navigating complex ethical and regulatory frameworks 
“Draconian” oversight 
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Researchers believed that “draconian” ethical and regulatory oversight were a barrier to 
conducting trials in children. Navigating the long, heterogeneous and duplicative process of 
obtaining multiple approvals was considered “cumbersome,” and the informed consent 
requirements were described as onerous and impractical. Some respondents were frustrated 
that research funds were wasted on “unreasonable bureaucracy,” whilst acknowledging that 
without a “robust governance and safety system we would prejudice our research.” 
 
Ambiguous requirements 
Many felt that the variability in the quality of ethical deliberations and “ambiguous” trial 
guidelines “drives people crazy” and potentially leads to “unequal protection.”  
 
Fear of exploiting the vulnerable  
Some felt that children in LMICs were exploited to address the healthcare needs primarily of 
wealthy nations. Ethics committee members opposed “exposing children to inappropriate 
level of research risk absent of any prospective direct benefit” e.g. inserting a central line for 
placebo administration. The new mandatory requirement of audio-visual consent in India was 
believed to protect respondents, although some felt this was excessive and could stigmatise 
adolescents who preferred to be de-identified. 
 
Excessive paternalism and unwarranted exclusion 
Researchers and sponsors felt that parents and regulators had “paternalistic attitudes” and 
were “over cautious” about including children in trials. However, some argued that excluding 
children was discriminatory as “the way we should protect children is not from research, but 
through research.” Researchers reasoned that ethics committees and guidelines were there to 
protect children from “unreasonable, potential risk.” Some felt that it was easier to justify 
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testing medicines in neonates where there is limited or no clinical practice evidence, than 
trialling treatments which are currently used in children without evidence.  
 
Precariousness of coercion vs. volunteerism 
Researchers were uncertain about the morality surrounding investigator and parent’s 
inducement to participate in trials, particularly in the context of LMICs. Industry sponsors 
maintained that the amount of reimbursement could not be universally standardised and 
should be reflective of the economy, as payment of disproportionately high amounts of 
reimbursement could unduly influence participation.  
 
6.4.2.4 Respecting uniqueness of children  
Embracing paediatric research paradigms   
Respondents advocated for stakeholders to “embrace paediatric paradigms” and consider the 
“uniqueness” of children regarding treatment response, disease pathophysiology and 
expression. Clinicians prioritised impact on quality of life and long-term neurocognitive 
outcomes. Respondents recommended novel, pragmatic trial designs for small populations of 
rare diseases in children. 
 
Considering child-appropriate approaches 
Researchers and ethics committee members thought that industry neglected child-specific 
issues when designing protocols. Respondents proposed that protocols be developed to 
include child-specific considerations such as micro-analysis techniques that require smaller 
volumes of blood. They recommended a child-friendly research environment with distraction 
therapies, and using pictures or audio-visual aids and plain language to explain trials. Some 
suggested that clinical visits or assessments needed to be scheduled to minimise interference 
with school attendance.  
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Facilitating family-centred empowerment  
Involving families in setting child healthcare research priorities, designing and conducting of 
trials was proposed. The clinical team highlighted that when “recruiting a child, you are 
recruiting the whole family.” In the UK, families and children involved in trial networks have 
lobbied to have trial results provided to respondents.  
 
6.4.2.5 Driving evidence-based child health 
Promoting research advocacy  
“Great strides” in benefits of children’s participation in trials was recognised, however further 
behavioral and cultural shifts through a massive awareness campaign was deemed essential. 
The ethical case that “children deserved evidence-based care,” the economic justification of 
return on investment by healthcare cost savings and involving families to obtain “public 
acceptance” and policy-makers support were encouraged. Many felt that clinicians required 
appropriate rewards  and “career pathing” to enhance participation in trials.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
 
Creating and seizing opportunities  
Proponents of trials in children encouraged global “societal commitment” to dedicate funds 
and attract investment in paediatric trials. Respondents felt that strong networking 
opportunities contributed to the success of trials in paediatric oncology. Researchers from 
LMICs welcomed opportunities for participation in international trials. They advocated for 
research improving the health system and philanthropic investment to build local trial and 
healthcare capacity. 
 
Supporting best practice 
Respondents supported the development of consensus trial regulations and resources that 
could be adapted to local contexts. They felt that it would be “utopia” to have one 
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“amalgamated” national ethical review process. However, some regarded this as a “double-
edged sword” as a central ethical review would eliminate the inherent quality control provided 
by multiple reviewers. Many encouraged collaboration and sharing of expertise, and 
emphasised the need for a centralised trials infrastructure with research “intra-operable tools” 
to support a range of study designs. 
 
Improving access to treatment 
Trial participation gave children the opportunity to access new or better treatments that may 
otherwise be “unreachable,” expensive or unavailable. Thus respondents advocated for trials 
to be embedded in clinical care. They endorsed harmonisation and augmentation of 
regulations and stronger partnerships between researchers, regulators and industry to support 
well-designed developmental pipelines for therapeutic agents for children. More efficient 
dissemination, translation and implementation of paediatric research into practice and policy 
was encouraged. 
 
Prioritising research productivity  
Multi-stakeholder collaboration to improve trials in child healthcare globally and reduce 
research waste was deemed crucial. Prioritisation of child healthcare needs based on 
epidemiological or trial registries data analysis was recommended. Burden of disease, 
balanced by scientific opportunities in rare diseases was considered important to justify 
expenditure in prioritising funding universally.  
  
6.5 Discussion 
A broad range of stakeholders involved in the conduct of clinical trials in children recognised 
that much had been done to promote trial-informed clinical care of children, but that large-
scale cultural and behavioral change, coupled with substantial infrastructural enhancement 
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was still required to promote the conduct of more trials, that were of high quality and relevant. 
They felt that there was still a scarcity of child healthcare safety and efficacy data, most 
notably in LMICs, child-specific diseases, neonates, off-patent medicines and child-
appropriate formulations. Challenges and specific paediatric disparities were believed to arise 
from fears of harming children, political and economic influences, lack of resources for 
paediatric trials, and the bureaucratic regulatory framework. Global multi-stakeholder 
collaboration, integration of trials as part of clinical care, sustainable centralised trials 
infrastructure, harmonisation of regulatory approvals and alignment of the pediatric research 
agenda through analysis of trial registries and epidemiological data, were believed to enhance 
global capacities to conduct paediatric trials.  
A recent systematic review of stakeholder views of trials in children in LMICs  identified 
challenges related to social disadvantage, idiosyncratic cultural beliefs and historical 
disempowerment,  with community engagement as the main enabler [14]. In our study, more 
challenges were identified by respondents in LMICs, where few trials are conducted despite 
the enormous paediatric disease burden. Some respondents were concerned about safety and 
exploitation of children, while others maintained that trial participation protects children from 
harm caused by non-evidenced based healthcare [15, 16]. 
 
In addition to the frustration engendered by what was regarded as shortcomings in the 
technical capacity of ethics committees and ambiguities in the regulatory requirements, [17-
19] researchers in our study questioned the legitimacy of being explicit about treatment 
uncertainties and enrolling children in trials as opposed to the ease of giving the same 
untested treatment in routine clinical practice. Some felt that it was unethical and 
discriminatory not to involve children in trials. Stakeholders supported harmonising and 
expediting ethical review and developing local and international standards was recommended 
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[20, 21]. Professional stakeholders were polarised regarding the current regulations forbidding 
payment to children for participation in trials [22].  
 
Stakeholders encouraged regulators worldwide to adopt appropriate regulations for the 
conduct of trials in children. They recognised that market exclusivity incentives supporting 
patent protection were not designed to meet the current needs of children and this was 
corroborated in a recent examination of drugs granted exclusivity [23]. Stakeholders endorsed 
improved regulations and incentives addressing child-specific therapeutic needs, off-patent 
medicines and rare child-hood diseases [24, 25]. To accommodate the low disease prevalence 
in children, innovative and optimum methodologies were suggested [26-28]. 
   
Amalgamated government and philanthropic investment with strengthened multi-stakeholder 
partnership was regarded as necessary to improve drug development for paediatric use. 
Stakeholders supported multi-centre collaborative trials and open disclosure of trial results 
through registries to reduce research waste and increase clinical benefit. Investment in a 
global governance framework of registries was encouraged to assist expedient availability, 
translation and implementation of trial results [29]. Incorporating analysis of epidemiological 
and registries data to inform clinical research needs in children was supported, and integrating 
trials as part of routine clinical care was considered essential to bring interventions to the 
bedside in  a sustainable manner.  
  
There is an apparent urgent need to invest in training and progress investigator-initiated trials 
to regulatory standards with the potential to inform paediatric labelling changes of medicines. 
Guidance and standards to improve paediatric trial design, conduct and reporting has been 
recognised as vital with some initiatives underway [4, 30, 31]. Establishing networks to 
collaborate and support trials was deemed essential. Investing into a centralised trial 
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infrastructure with sustainable funding that could support different studies was considered 
crucial to promote more high-quality trials in children. This infrastructure has been shown to 
be beneficial in the highly-successful UK Medicines for Children Research Network (MCRN) 
[32]. 
 
Our international study highlights a wide spectrum of opinions of paediatric trials experts and 
decision-makers across different income and healthcare settings. We applied member 
checking to ensure the analysis reflected the range and depth of the data collected. Our study 
outlines recommendations to enable more high-quality trials primarily by making more 
explicit and informed decisions concerning child health research priorities (Table 6.3). 
However, there are some potential limitations. The transferability of the findings to countries 
that were not included in our study is uncertain and we recommend extending similar research 
to other countries.   
 
6.6 Conclusions 
Despite an apparent increase in the number of initiatives that have encouraged trials in 
children, disparities still exist, particularly in LMICs, neonates, off-patent medicines and rare 
diseases. Embracing unique paediatric needs and creating a culture of embedding trials as part 
of routine clinical care were recommended. International collaboration, sustainable centralised 
paediatric trials infrastructure, development of paediatric trial expertise and alignment of 
research to child healthcare priorities are suggested to encourage more high-quality, 
appropriate trials that address the healthcare needs of children globally. 
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Table 6.1 Respondent characteristics (n=35) 
Characteristics Number (%)) 
Gender  
   Male 25 (71) 
   Female 10 (29) 
Age group (years)  
   <40  5 (14) 
   40-49  9 (26) 
   50-59  12 (34) 
   60-69 9 (26) 
Country of practice  
   High-income countries    
      Australia 5 (14) 
      Canada  5 (14) 
      Finland  1 (3) 
      France  1 (3) 
      UK  3 (5) 
      USA  5 (14) 
    Low-and middle-income countries (LMICs)                                                                                                
      India  5 (14) 
      Nigeria  4 (11) 
      Papua New Guinea  1 (3) 
      South Africa  5 (14) 
Role
a
   
  Researchers/clinicians  30 (50) 
  Regulators 20 (33) 
  Sponsor 10 (17) 
Speciality area
a
  
  General Paediatrics 13 (21) 
  Subspeciality
b
 46 (72) 
   Other 3 (5) 
Clinical trial experience (years)  
   10  13 (37) 
    10-20  11 (31) 
    21-30  7 (20) 
    >30 4 (11) 
 
a
Numbers do not equal 35 as multiple categories apply to some individuals 
b
Number of respondents in subspecialities: Cardiology (1), Clinical Pharmacology (2), 
Emergency (1), Endocrinology (2), Immunology and infectious disease (8),  Intensive 
care (3),  Haematology (3),   Neonatology (7),  Nutrition (1),  Oncology (8), 
Psychological Medicine or Mental Health (2), Renal (3), Respiratory (4), 
Musculoskeletal or rheumatology (1) Other: ethics (1), methodology (2)
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Table 6.2.  Selected quotes to support each theme 
Subthemes Illustrative quotations
 
                        Addressing pervasive inequities 
Paucity of safety and 
efficacy data  
 We know that children’s health professionals have a background of working without an evidence base, because that is all that they could do up to now. (Researcher, 
research facility, network, UK)  
Knowledge disparities  
 
As a doctor, people tell me just do whatever is good for me; he will not be able to understand the meaning of a clinical trial. He will say, ‘are you trying to use me as, a 
guinea pig or something?’…So the meaning of consent is entirely different for an illiterate patient as compared to an internet savvy, educated one. (Researcher, trial 
coordinator, India) 
Volatile environment  
 
 And it has worsened by...the medical profession also becoming extremely defensive, because they don’t want to get into any trouble and bad media publicity if something 
goes wrong. But this is where actually we really are getting hurt, especially in paediatric research. (IRB, CRO, India)  
The other challenge that one could face in Nigeria is the challenge of conducting studies in places where you have political skirmishes. Where there are such skirmishes it 
can affect research, especially if the investigator is not experienced. (Researcher, IRB, monitor, Nigeria) 
Challenging double 
standards 
For a very simple regimen to treat Burkitt’s lymphoma, it was being done in Malawi...the Ethics committee in Nigeria refused the protocol. Even though the drugs are cheap 
and affordable, it was seen as reduced efficacy than the current standard treatment in the country. (Researcher, paediatrician, Nigeria)  
If I want to treat a child and it is not so much as here take this medicine. If I want to recruit them into a trial and give them the same medicine, I have to give them a 20 page 
information sheet and go through a vast number of hoops. There seems to be double standards which one might argue inappropriate standards for research. (Regulator, 
paediatrician, UK)   
Ensuring contextual 
relevance 
Research in a developing country, it’s like a copy paste thing from the West…a lot of money goes into it and we just replicate research with not many really great outcomes. 
(Researcher, trial coordinator, India)  
I don’t do pie in the sky research. I don’t have the time, to be honest. All my research, everything I prepare, and even published, has clinical relevance…are all based on 
clinical need. (Researcher, IRB, regulator, South Africa) 
Market  
driven forces 
So in most cases those drugs are developed for adults because that is where the biggest need is. And now we have laws that require us to also study those drugs in children. 
And that’s great. But it doesn’t mean that we’re looking carefully to study drugs for a need for children primarily. (Researcher, paediatrician, industry sponsor, US) 
Industry sponsorship 
bias 
 Within the physician environment, definitely industry-sponsored trials are seen as with a bit of bias and real question as to whether or not physicians soil themselves by 
getting involved with industry. (Researcher, IRB, governance, Canada)  
 So even a high quality investigator-initiated study doesn’t change any market authorisation for children or even lead to include other new findings if necessary, unless the 
pharmaceutical company who has the market authorisation for this product is willing to then submit the data for regulatory approval. (Researcher, paediatrician, IRB, 
Finland)   
Dissuaded by 
prohibitive costs 
Investigator-initiated trials were sometimes possible here like the neonatal trials around caffeine for apnoea. But they all cost $5 million each to answer one question and so 
there’s no more money in the public arena to sponsor trials that are that expensive. (Researcher, paediatrician, academic, Canada)   
There are not a lot of rewards for the faculty who are involved, particularly when there are small numbers of patients that would be enrolled at any one site to warrant their 
spending time, very considerable time on putting through the consent forms, the contracts, the IRB approvals and then looking for the one or two patients that they may 
be able to involve. (Researcher, paediatrician, industry sponsor, US)  
                        Contending with infrastructural barriers 
Overwhelming 
resource constraints 
You have brilliant ideas, but the brilliant ideas at the best they end on the desktop because of the lack of funding. Because…issues relating to children tend to be culturally 
very last on the priority list…So where we really have the big need is how to get funding for the Investigator initiated studies. (Researcher, IRB, monitor, Nigeria)   
We have turned downed studies on occasions where we didn’t have the resources to carry them out. (Researcher, IRB, South Africa)  
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Subthemes Illustrative quotations
 
Dearth of pediatric 
trial expertise 
I can’t tell you the number of meetings that I have been in where someone said GCP and somebody goes, ‘what’s that?’ ‘Good Clinical Practice.’  First of all we have no real 
sticks, we have possibly some carrots but we’re sort of neutral on ensuring in a satisfactory fashion that investigators and their staff are qualified and sufficiently 
maintained skills to carry out trials. (Researcher, IRB, governance, Canada)   
When companies submit proposals for paediatric clinical trials for regulatory approval, they don’t get an answer. Because nobody is really able to assess the 
appropriateness of the study. (Researcher, paediatrician, IRB, Finland) 
 They are not robust so the science behind what gets submitted is sometimes not good quality, so people often have not thought about…sample size calculations, 
recruitment, the feasibility of the study and…the practicalities of actually conducting the trials. (Researcher, paediatrician, IRB, Australia)  
Traversing logistical 
complexities 
We have some issues like electricity or power supply which is not very regular and storage facilities to keep specimens are a challenge because of erratic power supply. And 
therefore if you are going to conduct clinical trials here, you would need an alternative source of power to ensure that bio-specimens and other items are kept properly. 
(Researcher, Nigeria) 
So if you need to get samples for central review or for collaborative studies they have to arrive within 24 to 48 hours. That can be logistically impossible from Australia. (Trial 
coordinator, trial center, Australia) 
     Navigating complex regulatory and ethical frameworks 
“Draconian” oversight Some of the regulations around that are quite stringent and that we can’t follow to the letter at the moment because it’s just impractical. For instance, it says the Minister 
has to provide consent for every child that participates in a study. (Researcher, paediatrician, South Africa)   
I mean the 17 page sort of consent forms outlining every conceivable risk is counter-productive to good clinical practice, it’s counter-productive to good science, it’s 
counter-productive to moving things forward and making things better for everyone. (Researcher, regulator, government sponsor, Australia)  
Ambiguous 
requirements 
One area of uncertainty appears to be the definitions of key terms like minimal risk and minor increase over minimal risk, in the paediatric context. (Regulator, IRB, 
governance, US) 
 There are certain South American countries that just won’t allow research with a placebo and there are countries right next door that do. So it’s whatever the local laws 
and regulations govern. (Researcher, paediatrician, industry sponsor, US) 
Fear of  exploiting the 
vulnerable 
 In a developing world context, there’s a greater potential for exploitation and because in a way they’re a vulnerable population - socio-economically they’re vulnerable, 
from a point of view of levels and standards of education they’re vulnerable, from a point of view of access to care their vulnerable…the reduced capacity for authorities 
and ethics committee to deal with these complex issues. (Researcher, paediatrician, South Africa) 
Excessive paternalism  
  and unwarranted  
  exclusion 
If we are convinced of…our basic research that’s phase I, phase II studies and that we’ve done this safely,  crossed our ‘t’ and dotted our ‘i’ and you know it’s safe.  I don’t 
think we need to go adults first and then children...all studies that are safe should be offered to children and adults. This artificial cut off that we are going to do it in 
adults first then children should not exist. (Researcher, IRB, regulator, South Africa)  
Precariousness of                        
   coercion vs. 
volunteerism 
They may offer treatment that is otherwise unreachable by the children in this area, too expensive or not present at all. It may bring equipment to the centers like 
laboratory, x-ray, and ultrasound whatever is needed for the trial that remains there after the trials. But these are ethically very difficult questions. Because it is possible 
that this indirect benefits that benefit the whole health care system…may lead to a situation where children are then allowed to participate in…trials for reasons that are 
not directly for the benefit of themselves but for the benefit of the society. (Researcher, paediatrician, IRB, Finland) 
                  Respecting uniqueness of children 
Embracing paediatric 
research paradigms   
 Regulatory agencies need to move away from a very narrow interpretation of indications in terms of paediatric studies…right now so much of it’s still based on the adult 
indications and the paediatric-intended indications being similar. That’s certainly not always the case, for example, sildenafil is used in adults to treat erectile 
dysfunction and it’s used in premature neonates for pulmonary hypertension. Certainly those two indications are very different as is the populations…So we’re moving 
towards an assessment of effect as a way to bridge data between adults and children…And also moving away from trying to prove in some cases that the disease 
processes are substantially similar,…asthma is asthma but the disease process is very different (Researcher, pharmacologist, US) 
But now the trend has been turning. It probably started with the orphan regulations in Europe where it very quickly became clear that there are no way you can make big 
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Subthemes Illustrative quotations
 
clinical trials in rare diseases…optimally paediatric trials should use methods that are designed for small size clinical trials. (Researcher, paediatrician, IRB, Finland) 
And it is very dangerous to have a comparator that is an unproven treatment and children are exactly in this position because many of the paediatric treatments even if 
they are considered current choice of treatment, have not been well documented.(Researcher, paediatrician, IRB, Finland) 
Considering child-
appropriate 
approaches 
Sometimes we get protocols that are not designed with children in mind so that the assessment periods are too tightly scheduled, or the number of assessments is not 
appropriate for children. So they’ve looked at adult studies and tried to just sort of adapt that to children by just scaling down the dose. And they haven’t really 
thought…kids aren’t going to come in for that many visits and they’ve got school and they’ve got exams. And they’ve got days where they just don’t feel like being poked 
and prodded and they’re just not going to comply. And the protocols are not always written with that flexibility that’s required for working with children in mind. (Trial co-
ordinator, trial centre Australia) 
Facilitating family-
centred   
empowerment 
 
In the oncology arena, the positive aspects are that the parents are always very enthusiastic and very supportive. So, they see it as an opportunity for their child and they’re 
very engaged so we don’t have problems with compliance and follow-up because the parents want to do the right thing and want to contribute. (Trial coordinator, trial 
centre, Australia) 
I think parents, children and young people need to be at the centre of research and that needs to be nurtured. When people are familiar with clinical trials terms, they can 
be very productive, but unless they’re supported it can be a very bruising journey that wastes a lot of time. So there needs to be specific support for children, parents and 
young people which best works with networks. (Researcher, regulator, industry consultant, UK)  
                      Driving evidence-based child health 
Promoting research 
advocacy 
 Use all international forum and collaborations to raise awareness, to show success, demonstrate projects that it is feasible and that it is ethical and it is safe for the 
participant to be in a clinical trial…maybe using international platforms like WHO, maybe others to engage more children, families, clinicians and researchers across the 
world. (Researcher, paediatrician, academic, Canada) 
Creating and seizing 
opportunities 
 The most feasible way today would be in the form of building infrastructure where you can have networks with people who are full-time professionals assisting in the local 
running of the clinical trials. (Researcher, paediatrician, IRB, Finland) 
 They have been very successful because of a top-down funding model by the NHS (National Health Service) to get the Medicines for Children Research Network (MCRN) 
going. And they have accomplished a lot of success.(Researcher, paediatrician, academic, Canada)  
Supporting best 
practice 
Up to 80 or 90% of paediatric clinical trials are at an uncertain or high risk of bias when it to comes to randomisation sequence, allocation concealment, blinding of the 
intervention of the outcome measurers, attrition and second outcome reporting. So bias is a big threat to the validity and inefficiency and impact of trials and so we need 
to start reducing research waste. (Researcher, paediatrician, academic, Canada) 
All research should be demand-driven, by people who live and work in those countries, by Ministries of Health, by institutions of academia or science in those countries. I’ve 
seen it a lot but I don’t believe that outside institutions should come and just set up trials with minimal collaboration… there needs to be very good…non-trial evidence, 
epidemiological evidence showing the burden of the problem. (Researcher, paediatrician, DSMB, Papua New Guinea) 
Improving access to 
treatment 
It …would be unethical not to study the medicines in the children of resource-limited country if they need the medicines and if they are used anyway. (Researcher, 
paediatrician, IRB, Finland) 
 If it was performance indicator of a CEO of a hospital or other things, that would be seen it was desirable that people involve in clinical trials. Funding would flow to it in a 
way that it doesn’t now…it needs to be embedded more at the center of clinical care. (Trial coordinator, IRB, government sponsor, Australia) 
Prioritizing research 
productivity 
More trials to do with targeting where the burden of disease is. It’s always a balancing act. Paediatrics has its fair share of rare diseases in terms of genetic disorders and 
other things that only occur in children. You wouldn’t want to see all the resourcing going towards diseases like diarrhea management, middle ear infection. (Trial 
coordinator, IRB, government sponsor, Australia)   
 Pooling of resources, making sure resources are not focused in rich countries. They need to be universally available…Sexy things get the funding…where they can get 
publicity…there needs to be an appraisal of what research we are doing; what bang for our buck we are getting;…We know the burden of disease…we need to prioritise 
the research in the right way! (Researcher, IRB, regulator, South Africa)  
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 Table 6.3 Implications for practice and policy to address barriers and inequities 
Key Issues Recommendations or suggested research and policy priorities (examples and initiatives underway) 
Advocate for trials in 
children  
 Campaign for children’s participation in trials, using both ethical and economic justification strategies. 
 Analyse health, epidemiological and registries data to inform clinical research needs in children. 
 Align the academic, pharmaceutical sponsor and policy maker’s agendas to prioritise research in response to child health needs through a multinational consortium.  
 Invest and direct prioritisation of trials in children from government. 
 Incentivise trials of off-patent medicines (e.g. priority list of off-patent medicines developed by the US Paediatric Trials Network [33]). 
 Improve initiatives to study rare diseases (e.g. FDA priority review voucher [34], International Rare Diseases Research Consortium (IRDiRC) [35]). 
 Encourage philanthropic approaches to conduct high-quality research that change paediatric labelling. 
 Provide better incentives to encourage clinicians’ participation and enthusiasm. 
Strengthen and develop 
paediatric trial 
capacity 
 
 Invest in sustainable centralised trial infrastructure including dedicated management team of a statistician, research nurse, data manager, and pharmacist to support 
investigators.  
 Establish networks with sustainable funding to collaborate and support trials in children especially non-industry sponsored trials (e.g. MCRN [32]). 
 Develop standards and guidance on trial design, conduct and reporting (such as valid child health outcomes including child-reported outcomes) explicit definitions e.g. 
minimal risk, adequate sample size; selection of appropriate comparators; reduction of risk of bias (e.g. StaR Child Health [36], Toronto Outcomes Research in Child 
Health (TORCH)[37], Enhancing Research Impact in Child Health (ENRICH)[38],  Standard Protocol Items for Randomised Trials-Children (SPIRIT-C) [39], Consolidated 
Standards of Reporting Trials-Children (CONSORT-C) [40] 
 Invest in training and standards for consistency and high-quality review of ethics applications. 
 Develop guidelines for data safety monitoring committees. 
 Implement programs to audit the conduct of trials at sites.  
Mitigate disparities in 
LMICs 
 Increase research and development investment to encourage trials in LMICs. 
 Build expertise in LMICs by encouraging research collaborations with investigators from high-income countries. 
 Share trial resources of high-income countries for adaptation to local contexts. 
 Advocate for philanthropic investment to build local trial and healthcare capacity. 
 Encourage Operational Research (advanced analytical techniques) on improving practices in these difficult contexts. 
 Invest in prevention and curative health services and research to address some of the neglected health burdens.  
 Promote health and health education of the community. 
 Encourage sponsor provision of ongoing supportive medical care post-trial and ancillary care to siblings and other family members. 
Enhance regulatory 
frameworks 
 Adopt paediatric regulations and incentives globally to encourage pharmaceutical industry to trial medicines in children (e.g. the US and EU regulations). 
 Improve paediatric regulations and incentive to encourage trials in child-specific diseases, including trials of off-patent medicines (e.g. Pediatric Trials Network 
initiatives)[33]  
 Establish a global level paediatric medicines regulatory framework under the leadership of WHO to regulate and harmonise country of trials conduct, transferability of 
results, availability of medicines and improve medicine access and reimbursement strategies (e.g. Transcelerate [41] initiative). 
 Create an international network of regulators to manage the regulatory requirements and provide support for less experienced regulators. 
 Develop a log of trials to prevent duplication and identify therapeutic gaps (e.g. enpr-EMA [42], MCRN, Global Research in Paediatrics (GRIP) [43] initiatives). 
Improve evidence-base 
practice 
 Encourage multi-center collaborative trials to reduce research waste. 
 Develop good referral network amongst paediatric clinicians to enhance recruitment.  
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Key Issues Recommendations or suggested research and policy priorities (examples and initiatives underway) 
 Conduct trials of more economically feasible treatment modalities for LMICs, where appropriate. 
 Promote ongoing supplies of successful interventions to participants, while expediting regulatory approvals of paediatric labelling. 
 Invest in developing formulation of medicines appropriate for children in all income regions (e.g. suspensions). 
 Review medicine reimbursement strategies to improve access of medicines addressing paediatric needs. 
 Embed clinical research as part of routine clinical care and in disease specific registries (e.g. Key Performance Indicator of organisation to involve children in trials). 
 Invest in a governance framework of registries to address the evidence gaps in children and monitor expedient availability of trial results. 
 Invest in funding for translation and implementation of effective interventions. 
Embrace child-
appropriate 
approaches 
 Design protocols around paediatric needs with consultation and partnering with the academic, practicing community and families. e.g. UK, Young Peoples Advisory 
Group (YPAG) [44], International Children’s Advisory Network (ICAN)[45]. 
 Develop guidelines to engage children and parents in setting priorities, designing and conducting trials (e.g. feasibility and selection of patient reported outcomes 
review of consent forms, scheduling appointments). 
 Adopt child-appropriate strategies such as reducing pain and discomfort of painful invasive procedures (e.g. distraction techniques such as DVDs). 
 Develop alternative robust strategies to monitor compliance in children (e.g. devices that can monitor use). 
 Further research to develop guidelines on adequate paediatric decision-making (assent).  
 Further research regarding payment to children for participating in optional research that does not offer direct benefit for the child. 
 Provide patient-specific results sheet to families and children who participated.  
Streamline ethical 
review 
 Develop clear ethical review regulations to reduce the ambiguity of current guidelines.  
 Standardise and simplify ethics processes and templates (e.g. consent forms). 
 Clarify definition of key terms like minimal risk and minor increase over minimal risk in the paediatric context. 
 Recommend education and adherence to Data Monitoring Committees (DMC) standards in paediatric trials. (e.g. Star Child Health group DMC  Standard)[46] 
 Harmonise and expedite authorization of paediatric protocols (e.g. MIYCRN (Maternal Infant Youth and Child Research Network [47] and GRIP initiative).  
 Develop guidelines to manage incidental findings of whole genome sequencing that may have lifelong relevance. 
 Develop explicit and shared guidelines for the retention of bio-specimens and how to engage children in consent for the ongoing use of stored specimens once 
children become adults. 
Equity in trial 
participation 
 Develop explicit and shared guidelines on when it is appropriate to conduct phase I clinical trials in children. 
 Support the design and conduct of appropriate trials in pregnancy, obese children, premature infants and newborns [48].  
 Develop explicit and shared policies regarding appropriate incentives for child participation. 
 Investigate payment to children for participating in optional research not offering the possibility of treatment. 
The suggested research and policy priorities were formulated by respondents and discussion among the research team  
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Figure 6.1 Thematic Schema of challenges and enablers of clinical trials in children 
Respecting uniqueness of children 
• Embracing pediatric research paradigms  
• Considering child-appropriate 
approaches
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empowerment 
Contending with infrastructural barriers
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Driving evidence-based child health
• Promoting research advocacy
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• Prioritising research productivity 
Addressing pervasive inequities
• Paucity of safety and efficacy data
• Knowledge disparities
• Volatile environment 
• Challenging double standards
• Ensuring contextual relevance
• Market driven forces 
• Industry sponsorship bias
• Dissuaded by prohibitive costs
Navigating complex regulatory and ethical frameworks
• “Draconian”oversight
• Ambiguous requirements
• Fear of exploiting the vulnerable
• Excessive paternalism and unwarranted exclusion
• Precariousness of coercion vs volunteerism
Enablers
Challenges and disparities
 
 
 
 
 
 
 
 
 
Chapter 6: Researchers’, regulators’ and sponsors’ views on trials in children: a multinational study 
140 
 
6.7 References 
 
1. Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J of Clin Pharmacol. 
2015;79(3):357-69. 
2. Permanand G, Mossialos E, McKee M. The EU's new paediatric medicines legislation: 
Serving children's needs? Arch Dis Child. 2007;92(9):808-11. 
3. Field MJ, Ellinger LK, Boat TF. IOM Review of FDA--approved biologics labeled or 
studied for pediatric use. Pediatrics. 2013;131(2):328-35. 
4. Craig JC, Offringa M, Hartling L, Wittmeier KDM, van der Lee JH, Klassen TP, et al. 
StaR Child Health: developing evidence-based guidance for the design, conduct, and 
reporting of pediatric trials. Clin Pharmacol Ther. 2011;90(5):727-31. 
5. Slora EJ, Harris DL, Bocian AB, Wasserman RC. Pediatric clinical research networks: 
Current status, common challenges, and potential solutions. Pediatrics. 
2010;126(4):740-5. 
6. Rumney P, Anderson JA, Ryan SE. Ethics in pharmacologic research in the child with a 
disability. Paediatr Drugs. 2015;17(1):61-8. 
7. Schechter T, Grant R. The complexity of consenting to clinical research in phase I 
pediatric cancer studies. Paediatr Drugs. 2015;17(1):77-81. 
8. Pathma D Joseph, Patrina HY Caldwell, Allison Tong, Hanson CS, Craig JC. 
Stakeholder views of clinical trials in low and middle-income countries: a systematic 
review  Pediatrics (accepted for publication). 
9. MacLeod SM, Knoppert DC, Stanton-Jean M, Avard D. Pediatric clinical drug trials in 
low-income countries: key ethical issues. Paediatr Drugs. 2015;17(1):83-90. 
10. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. 2007;19(6):349-57. 
11. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in 
reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 
2012;12(1):181-. 
12. Kuper A, Reeves S, Levinson W. Qualitative Research: An Introduction to Reading and 
Appraising Qualitative Research. BMJ. 2008;337(7666):404-7. 
13. Strauss AL, Corbin JM. Basics of qualitative research: techniques and procedures for 
developing grounded theory. Thousand Oaks: Sage Publications; 1998. 
14. Joseph PD, Caldwell PH, Tong A, Craig JC. Stakeholder Views of Clinical Trials in 
Low- and Middle-Income Countries: A Systematic Review. Pediatrics. Accepted for 
publication. 
15. Sammons HM. Avoiding clinical trials in children. Arch Dis Child. 2011;96(3):291-2. 
16. Jenkins T, Wendler D. Children's and Their Parents' Views on Facing Research Risks 
for the Benefit of Others. Arch Pediatr Adolesc Med. 2008;162(1):9-14. 
17. Shah S, Wendler D, Wilfond B, Gensler G, Whittle A. How Do Institutional Review 
Boards Apply the Federal Risk and Benefit Standards for Pediatric Research? JAMA. 
2004;291(4):476-82. 
18. Ezzat H, Ross S, Von Dadelszen P, Morris T, Liston R, Magee LA, et al. Ethics review 
as a component of institutional approval for a multicentre continuous quality 
Chapter 6: Researchers’, regulators’ and sponsors’ views on trials in children: a multinational study 
141 
 
improvement project: The investigator's perspective. BMC Health Serv Res. 
2010;10(1):223-. 
19. Altavilla A, Manfredi C, Baiardi P, Dehlinger-Kremer M, Galletti P, Pozuelo AA, et al. 
Impact of the new european paediatric regulatory framework on ethics committees: 
overview and perspectives. Acta Paediatr. 2012;101(1):e27-32. 
20. Roth-Cline MD, Gerson J, Bright P, Lee CS, RM N, editors. Ethical considerations in 
conducting pediatric research. Available at: 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Ped
iatricAdvisoryCommittee/UCM254315.pdf. Accessed August 28, 2015.1st ed. In press: 
Springer. 
21. Needham AC, Kapadia MZ, Offringa M. Ethics Review of Pediatric Multi-Center Drug 
Trials. Pediatric Drugs. 2014;17(1):23-30. 
22. Tishler CL, Reiss NS. Pediatric drug-trial recruitment: enticement without coercion. 
Pediatrics. 2011;127(5):949-54. 
23. Rivera DR, Hartzema AG. Pediatric exclusivity: evolving legislation and novel 
complexities within pediatric therapeutic development. Ann Pharmacother. 
2014;48(3):369-79. 
24. Giacoia GP, Taylor-Zapata P, Zajicek A. Drug studies in newborns: a therapeutic 
imperative. Clin Perinatol. 2012;39(1):11-23. 
25. Stoyanova-Beninska VV, Wohlfarth T, Isaac M, Kalverdijk LJ, van den Berg H, 
Gispen-de Wied C. The EU paediatric regulation: effects on paediatric 
psychopharmacology in Europe. Eur Neuropsychopharmacol. 2011;21(8):565-70. 
26. Emdin CA, Odutayo A, Hsiao AJ, Shakir M, Hopewell S, Rahimi K, et al. Association 
between randomised trial evidence and global burden of disease: cross sectional study 
(Epidemiological Study of Randomized Trials--ESORT). BMJ (Clinical research ed). 
2015;350(jan28 24):h117-h. 
27. Junker A, Klassen T. Improving standards for paediatric clinical trials. Paediatr Child 
Health. 2011;16(9):539-40. 
28. Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. 
Lancet.376(9737):229-30. 
29. Laughon MM, Benjamin DK, Jr., Capparelli EV, Kearns GL, Berezny K, Paul IM, et al. 
Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 
2011;4(5):643-52. 
30. Baiardi P, Giaquinto C, Girotto S, Manfredi C, Ceci A, Teddy Network of Excellence. 
Innovative study design for paediatric clinical trials. Eur J Clin Pharmacol. 2011;67 
Suppl 1:109-15. 
31. Knibbe CA, Krekels EH, Danhof M. Advances in paediatric pharmacokinetics. Expert 
Opin Drug Metab Toxicol. 2011;7(1):1-8. 
32. UK, Medicines for Children Research Network (MCRN), Clinical Trials Unit. 
Available at: https://www.mcrnctu.org.uk/. Accessed October 20, 2015. 
33. Pediatric Trials Network (PTN). Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD). Available at: http://pediatrictrials.org/. 
Accessed October 22, 2015. 
34. US Food and Drug Administration.  Rare Pediatric Disease Priority Review Voucher 
Program.  Available at: 
Chapter 6: Researchers’, regulators’ and sponsors’ views on trials in children: a multinational study 
142 
 
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/RarePe
diatricDiseasePriorityVoucherProgram/default.htm. Accessed September 25, 2015. 
35. International Rare Diseases Research Consortium (IRDiRC). 2012-2015. Available at: 
http://www.irdirc.org/. Accessed  October 27, 2015. 
36. StaR Child Health. Available at: http://www.starchildhealth.org/. Accessed October 20, 
2015. 
37. Toronto Outcomes Research in Child Health (TORCH).Hospital for Sick Children. 
Available at: http://www.sickkids.ca/Research/EnRICH/Research-Projects-and-
Initiatives/TORCH/index.html. Accessed October 22, 2015. 
38. The Hospital for Sick Children (SickKids), EnRICH Lab: Enhancing Research Impact 
in Child Health. Available at: http://www.sickkids.ca/Research/EnRICH/index.html. 
Accessed October 20, 2015. 
39. Standard Protocol Items for Randomized Trials-children (SPIRIT-C). Available at: 
http://www.sickkids.ca/Research/EnRICH/Research-Projects-and-Initiatives/SPIRIT-
C/index.html. Accessed October 22, 2015. 
40. Consolidated Standards of Reporting Trials-children (CONSORT-C). Available at: 
http://www.sickkids.ca/Research/EnRICH/Research-Projects-and-
Initiatives/CONSORT-C/index.html. Accessed October 20. 
41. Transcelerate Biopharma Inc. Accelerating the development of new medicines. 
Available at:http://www.transceleratebiopharmainc.com/initiatives/pediatric-trial-
efficiencies/.Accessed September 25, 2015. 
42. European Medicines Agency (EMA). Enpr-EMA. Available at: 
http://enprema.ema.europa.eu/enprema/. Accessed October 22, 2015. 
43. Global Research in Paediatrics, Network of excellence. Available at: http://www.grip-
network.org/index.php/cms/en/Home. Accessed September 25, 2015. 
44. UK, Clinical Research Network Children, Young Peoples Advisory Group (YPAG) 
Available at: https://www.crn.nihr.ac.uk/children/pcpie/young-persons-advisory-group/. 
Accessed October 22, 2015. 
45. International Children's Advisory Network (ICAN). Available at: 
http://www.icanresearch.org/. Acessed August 22, 2015. 
46. Ellenberg S, Fernandes RM, Saloojee H, Bassler D, Askie L, Vandermeer B, et al. 
Standard 3: Data monitoring committees. Pediatrics. 2012;129(3):S132-S7. 
47. Maternal Infant Child and Youth Research Network (MICYRN). Research Enabling 
initiatives. Ethics Platform. Available at: 
http://www.micyrn.ca/ResearchEnablingPlatformInitiatives.html. Accessed September 
29, 2015. 
48. Matsui D. Ethics of studies of drugs in pregnancy. Paediatr Drugs. 2015;17(1):31-5. 
 
 
 
 
 143 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7                                                            
 
Discussion and conclusions  
Chapter 7: Discussion and conclusions 
144 
 
Chapter 7: Discussion and conclusions 
7.1 Overview 
 
This chapter summarises how this thesis addresses the overarching research question of 
equity, quality and relevance of clinical trials in children to improve evidence-informed child 
healthcare worldwide. In this thesis, we provide an in-depth understanding of the current 
context of paediatric trials, the challenges, disparities, gaps and the adoption of appropriate 
strategies suggested by key stakeholders through both quantitative and qualitative techniques. 
We showed that there is still a paucity of safety efficacy evidence across most therapeutic 
areas in paediatric healthcare; gross inequities still exist in the number of trials in children 
conducted within income regions and in comparison to adults; and that trials were 
mismatched to paediatric burden of disease. Continued reform and advocacy is crucial to 
encourage more, high-quality, appropriate trials in children. The urgent need for improvement 
of paediatric trial design, conduct and reporting was also highlighted. This thesis is one of the 
first major attempts to comprehensively look at the equity, quality and relevance of clinical 
trials in children to inform better evidence-based child healthcare worldwide. 
 
7.2 Key Findings  
7.2.1 Trial equity and relevance to child health 
A common theme throughout this thesis is the paucity of safety and efficacy evidence of 
treatments in children. The narrative review described some of the medical mishaps and 
fatalities that have resulted from exposing children to untested medicines. These mishaps 
catalysed regulatory change that sought to protect children from untested medicines, but also 
stimulated “draconian,” bureaucratic ethical and regulatory oversight of paediatric trials 
because of fears of harming children. The interviewed professional stakeholders believed that 
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the involvement of children in trials was also hampered by medical mistrust of parents and 
fears of their child being treated as a “guinea-pig.” This was magnified by the clinician’s 
reluctance to involve children because of safety concerns, and a lack of interest from the 
pharmaceutical industry because of poor economic returns. Major strides have occurred in the 
last decade and clinical trials in children have now been recognised as essential in protecting 
children and advancing child healthcare. Although there is advocacy for the need for more 
appropriate testing of pharmaceutical products in children, the stakeholders felt that further 
cultural and behavioural changes are warranted. All stakeholders including parents, the 
public, clinicians and regulators need to embrace the concept that trials in children is crucial 
in protecting children and improving their healthcare. 
 
The concern of the pervasive disparities that exist in trials conducted in children compared to 
adults was present across the narrative review, analyses of trials registered in children, and the 
multinational interview study of professional paediatric trial stakeholders. The analyses of 
registered trials in children showed that children account for 25% of the global burden of 
disease, but represent only 15% of registered trials. We showed that trials in children are more 
challenging than in adults. This is due to the lack of funding and resources; ethical concerns 
of exposing  children to untested medicines in trials; recruitment difficulties because of the 
lower prevalence of childhood diseases and the need for tailored study designs considering the 
heterogeneous age groupings of the paediatric population and their unique needs. The gap 
between the number of trials in children and adults is increasing, driven by political and 
economic factors. There are now approximately five times more trials in adults compared 
with children. It is pleasing to acknowledge several initiatives encouraging more trials in 
children, such as the US and EU paediatric legislation and economic incentives to include 
children in trials. However, the literature, in addition to stakeholder perspectives, suggest that 
these legislations and incentives encourage children’s participation in trials that focus mainly 
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on health issues in adults. Researchers and clinicians stressed that there is a critical need to 
incentivise trials addressing unique childhood diseases, neonatal conditions, medicines that 
are off-patent and to stimulate more trials in LMICs.  
 
The analyses of registered paediatric trials showed that the high-income countries boast the 
majority of trials. Disproportionately few trials (22%) are registered in LMICs in comparison 
to their enormous illness burden (98%). This could be due to the lack of commercial 
incentives for the pharmaceutical industry to invest in this region. The systematic review of 
stakeholder views of trials in children in LMICs showed that another contributing factor to the 
scarcity of trials in these regions are that trials in these contexts are further hindered by 
impoverishment, disempowerment, inequity and idiosyncratic cultural beliefs that have 
created mistrust in clinical research with great fears of exploitation. Engaging the community 
in mobilising and designing trials in LMICs is essential.  Fair distribution of research benefits 
and investment in research infrastructure and regulatory frameworks in LMICs are 
recommended to promote justice and equity. Researchers supported trials being conducted in 
all income regions as data that is not indigenous could be invalid because of 
“pharmacogenomic differences” and variability in healthcare.   
 
In the analyses of registered trials, we showed that there was only a moderate correlation 
between the number of trials and the burden of disease within each region.We found that 
paediatric trial focus was mismatched to disease burden.The high-income countries 
disproportionately had the majority of paediatric trials for most of disease categories in 
comparison to the burden of disease in children. It is crucial that these misaligned research 
priorities be redressed through a global collaborative effort of greater investment and support 
of paediatric trials that addresses child healthcare priorities worldwide.  
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7.2.2 Quality of trial design, conduct and reporting  
The narrative review highlighted some of the special considerations when designing any of 
the four phases of clinical trials in children [1]. Children are mostly involved from phase III 
trials, to protect them from exposure to harm in the early Phase I and II trials. Professional 
stakeholders in our study believed that this may delay children’s access to potentially useful 
medicines. They suggested that this artificial cut-off should not exist for medicines that are 
assessed to be safe and early phase trials should be conducted simultaneously in children. 
Ethics Committees and Data Monitoring Committees are also there to safeguard the interests 
of children’s participation in appropriate early phase trials. Protocols of clinical trials 
involving children assessed by Ethics Committees were comprehensive and well-described. 
However, many key domains in trial design and conduct remain incompletely reported and 
could be improved. Despite widespread recognition of how problems in the design and 
conduct of clinical trials may lead to misleading conclusions, investigators still appear to be 
omitting key elements in trial protocols. Gaps were observed across all domains that could be 
minimised through development of standards in the design of protocols that consider the 
unique needs of children, training and adherence to guidelines [2]. This could help improve 
the quality of trials in children, minimise risk of harm to children and generate reliable results 
to be implemented in the clinical care of children.  
 
In the systematic review and interviews, researchers in LMICs advocated that international 
sponsors needed to understand the severe lack of research infrastructure and capacity when 
planning trials. In these contexts, trials in LMICs should be appropriate, pragmatic, feasible, 
and sustainable. Researchers felt that the rigorous international requirements for level of 
documentation were sometimes too ambitious and impractical for certain LMICs. However, 
they were concerned that if they did not comply with international standards, their research 
quality would not be acceptable in the global paediatric research community. Researchers 
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questioned the “double-standard” of the bureaucratic burden and regulatory requirements to 
conduct trials in children, compared to the ease of using untested treatments in routine clinical 
care of children. Researchers and sponsors felt that excessive paternalism of parents and 
ethics committees still hinders trials and that excluding children from participating in trials is 
discriminatory. From the evidence we gathered, including the key informant interviews of 
researchers, regulators and sponsors we concluded that conducting trials in children is 
challenging and arduous due to logistical, methodological and ethical issues that hinder 
progress of evidence-based child healthcare. Our studies proposed strategies to address this.  
 
7.2.3 Strategies to enhance paediatric trials 
The findings of these studies demonstrate that investment of dedicated, centralised trial 
infrastructure and the development of paediatric specific standards are critical to support trials 
in children. Guidance for paediatric protocol development includes both the scientific and 
ethical components of trials such as SPIRIT-Children and CONSORT-Children for the 
reporting of paediatric issues of relevance was needed [3]. Standards for the ethics application 
and review process, auditing of trials and dissemination of trial results is necessary to enhance 
the evidence base of child health. The harmonisation of ethical and regulatory processes was 
deemed necessary within countries and potentially extended internationally, as most trials are 
multi-centre and increasingly becoming multinational [4]. There was support for stakeholders 
to embrace paediatric research paradigms that consider the uniqueness of children with regard 
to treatment response, disease pathophysiology and expression. Child-appropriate approaches 
in the design and conduct of trials were important. For example, the integration of trials as 
part of core paediatric clinical care in all specialties was suggested. This has already been 
demonstrated to be effective and successful in the paediatric oncology trials in accelerating 
the evidence-base care. The key understandings developed from this thesis are that improving 
evidence-based child healthcare is the responsibility of all stakeholders including children and 
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families, the community, researchers, regulators, sponsors, and policy-makers, through 
engagement and collaboration. There needs to be greater attention at the highest political level 
to advocate for more investment into paediatric trials. Engaging and empowering children and 
adolescents to inform the paediatric research agenda and trial conduct is essential to 
improvements. Collaboration on trials and the developing and sharing of resources were 
deemed essential both locally and internationally to reduce duplication and waste of research 
resources and increase the value of trials in children. 
 
7.3 Strengths of our study 
The work presented here encompasses a narrative review, and original quantitative research, 
qualitative research including a systematic review of qualitative studies (thematic synthesis), 
in-depth face-to-face interviews, and document analysis. The strengths of our studies include 
providing a comprehensive literature review of the important issues of clinical trials in 
children in the current context, and highlighting challenges, disparities and gaps. We also 
proposed strategies informed by key multinational stakeholders to address these issues both 
nationally and on an international level. The WHO International Clinical Trials Registry 
Portal, which is the most comprehensive, robust repository of trials from several registries 
was used to determine trial activity in children and we compared this to the recent DALYs 
data and established Global Health Estimates. Our systematic review of stakeholder views of 
trials in LMICs further explored the challenges and facilitators of testing medicines in 
children in these contexts. We applied member checking to ensure the analysis reflected the 
range and depth of the data collected generating relevant and novel findings and fulfilling the 
study objectives. In our evaluation of the scientific completeness of trial protocols, we used a 
consolidated checklist based on the validated CONSORT and Cochrane Risk of Bias 
measurement tool and incorporated child-specific and other domains of importance in 
protocols. Our international interview study highlights a wide spectrum of opinions of trial 
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experts and decision makers across different income and healthcare settings on paediatric 
trials. We applied member checking to ensure that the analysis reflected the range and depth 
of the data collected. The important strategies summarised in Table 6.3 informed by the 
synthesis of evidence gathered and key stakeholders, has important policy and clinical 
practice implications. 
 
7.4 Problems encountered and study limitations 
Some problems and limitations were encountered with the various studies comprising the 
thesis. Systematically reviewing the clinical trials in children as a topic was broad and 
generated a very large number of titles and abstracts that needed to be reviewed, including the 
hand-searching of relevant articles, which was time-consuming. The restrictions of the WHO 
ICTRP did not permit extraction of data such as sample size or facilitate subgroup analyses of 
commercial versus non-commercial trials, and we recommend investment to enhance the 
capabilities of the WHO ICTRP. The study looking at the completeness of protocols of trials 
in children submitted to the Ethics Committees was constrained by time and the institutional 
requirements, thereby limiting the study to four of the eight paediatric hospitals and 69 trials. 
Obtaining ethics approval to conduct this study from multiple sites with variable ethical and 
site requirements and application forms was a challenge. Confidentiality issues related to 
access of the protocols precluded data validation by having the same two researchers extract 
the data. The interviews of multinational key researcher, regulator and sponsor informants 
were limited by time and resources for all interviews to have been conducted face-to-face. 
Resource constraints also limited the number of countries that could participate in the study.  
 
7.5 Clinical practice and policy implications 
Important clinical practice and policy implications was generated from the various studies. An 
informative summary of the current issues of relevance to trials in children was produced in 
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the comprehensive narrative review, which is helpful to educate all paediatric trial 
stakeholders. The analysis of registered trials in children provides a benchmark for targeting 
trials aligned to paediatric diseases of greatest burden and neglected therapeutic areas in 
appropriate settings. We showed the value of linking trial data and epidemiological 
information to align the paediatric research agenda to child health priorities. The systematic 
review of stakeholder views of trials in LMICs has highlighted the complex issues that 
researchers, regulators and sponsors need to consider when conducting trials in these areas. 
The systematic review also showed the important enablers of trials in LMICs, such as 
community engagement that can inform more successful trials in these regions. The 
assessment of the completeness of essential domains in trial protocols has shown the benefit 
of having paediatric specific checklists for development of protocols of trials in children that 
consolidate items of importance to address the unique considerations in children. Our studies 
helped to identify the current infrastructural and paediatric trial resource gaps that can be 
addressed to support high-quality trials worldwide.  
 
7.6 Future directions of work 
 
Future research and implementation into practice of the findings and recommendations 
presented in this thesis could be helpful to all paediatric trial stakeholders in informing 
improvements of the design, conduct and reporting of appropriate clinical trials in children. 
We recommend analysis of trial registry and epidemiological data to help prioritise paediatric 
research aligned to disease burden and child health priorities like rare diseases. It is hoped that 
the gaps identified in the essential paediatric specific guidance and standards for the trial 
design, for example child and adolescent reported outcomes and definition of the age of assent 
will inform development of these resources. Future investigation should also look at the gaps 
in the conduct and public disclosure of trial results on registries as well as to participants, for 
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example provision of trial results to families that can bring about practice changes. We noted 
the existence of non-conformity in the trial registries, which is an area requiring further 
development to improve the robustness of the data captured on registries, and to facilitate 
aggregate analysis. We recommend increased investment into the WHO International Clinical 
Registries Portal to improve the capabilities of data extraction.  For example, enhancements to 
the portal to facilitate improved analysis, such as size of paediatric trials and sub-group 
analysis of commercial vs. academic research are important. There needs to be greater 
investment to develop and implement mechanisms to monitor and report trials conducted both 
locally and internationally to identify the gaps in the conduct of trials in children that may be 
improved. 
 
We explored researchers’, regulators’ and sponsors’ views of barriers and facilitators of trials; 
however it is important to also explore the views of children and families in light of current 
developments. Further research looking at payment for children’s participation is important to 
inform standards and practice. The perspectives of key informant stakeholders in other 
countries like China where the paediatric research practices may be different would be 
valuable. The poor dissemination of trial results and publication bias stimulated advocacy for 
the prompt reporting and disclosure of trial results to reduce waste and re-align research 
priorities [5,6]. We suggest research in analysing published paediatric trials in the last five 
years using, the clinical trials registry number to determine the current trends in publication of 
trials and to identify gaps to inform further research and practice changes. We determined the 
completeness of scientific protocols of trials in children for the core trial domains; however, 
future research should look at the completeness of inclusion of essential and child-specific 
ethical components, which is complex in children. It will also be useful to assess the quality 
of the conduct of trials in children.   
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7.7 Conclusions 
This thesis provides a comprehensive and detailed understanding of the issues of equity, 
quality and relevance of clinical trials in children in addressing global child healthcare needs. 
The main gaps, challenges and disparities that hinder progress with trials in children were 
identified, such as paucity of trials, mismatched paediatric trial focus to child healthcare needs 
and deficiencies in child specific trial standards and guidance. Our research provides 
important strategies and future research to improve evidence-informed child healthcare, for 
example, the imperative to embed trials as part of core clinical care and the need for dedicated 
centralised paediatric trials infrastructure with sustainable research funding. This thesis 
concludes that more, high quality appropriate trials in children globally, are vital to improve 
evidence-informed child healthcare. All paediatric trial stakeholders need “to protect children 
not from research, but through research!” 
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Appendices  
Appendix A1 - Search strategy for literature review: clinical trials in children 
 
MEDLINE 
 
Embase 
1 Child/ 
2 exp Infant/ 
3 Adolescent/ 
4 child*.tw. 
5 infant*.tw. 
6 girls.tw. 
7 boys.tw. 
8 p?ediatric*.tw. 
9 newborn*.tw. 
10 or/1-9 
11 exp Pharmaceutical Preparations/ 
12 drug*.mp. 
13 medicin*.mp. 
14 11 or 12 or 13 
15 exp Clinical trials as Topic/ 
16 10 and 14 and 15 
17 limit 16 to yr="2000 -Current" 
18 limit 17 to "review articles" 
1 exp Adolescent/ 
2 exp Adolescence/ 
3 exp Child/ 
4 exp Childhood/ 
5 exp Newborn/ 
6 child*.tw. 
7 infant*.tw. 
8 girls.tw. 
9 boys.tw. 
10 p?ediatric*.tw. 
11 newborn*.tw. 
12 or/1-11 
13 exp ANIMAL/ 
14 12 not 13 
15 exp Drug/ 
16 drug*.mp. 
17 medicin*.mp. 
18 15 or 16 or 17 
19 exp Clinical Trial/ 
20 14 and 18 and 19 
21 limit 20 to (phase 1 clinical trial or phase 2 
clinical trial or phase 3 clinical trial or 
phase 4 clinical trial) 
22 20 not 21 
23 limit 22 to yr="2000 -Current" 
24 limit 23 to "review" 
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Appendix B1 - Search strategy for systematic review: stakeholder views of 
clinical trials in LMICs 
 
MEDLINE 
1946 – August Week 3 2014 
Embase 
Week 34 1974 – Week 34 2014 
1 Child/ 
2 exp Infant/ 
3 Adolescent/ 
4 child*.tw. 
5 infant*.tw. 
6 girls.tw. 
7 boys.tw. 
8 p?ediatric*.tw. 
9 newborn*.tw. 
10 or/1-9 
11 exp Clinical trials as Topic/ 
12 10 and 11 
13 developing country/ 
14 underdeveloped.tw. 
15 under-developed.tw. 
16 less developed.tw. 
17 resource limited.tw. 
18 resource constrain*.tw. 
19 resource poor.tw. 
20 third world.tw. 
21 low income.tw. 
22 middle income.tw. 
23 low socioeconomic.tw. 
24 exp africa/ or exp caribbean region/ or exp 
central america/ or latin america/ or south 
america/ or exp asia/ 
25 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
or 22 or 23 or 24 
26 12 and 25 
27 exp qualitative research/ 
28 qualitative.tw. 
29 interview$.tw. 
30 focus group$.tw. 
31 (thematic$ or theme$).tw. 
32 grounded theory.tw. 
33 phenomenol$.tw. 
34 content analysis.tw. 
35 ethnograph$.tw. 
36 exp decision making/ 
37 exp Knowledge/ or Health Knowledge, Attitudes, 
Practice/ 
38 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 
or 36 or 37 
39 26 and 38 
1 exp Adolescent/ 
2 exp Adolescence/ 
3 exp Child/ 
4 exp Childhood/ 
5 exp Newborn/ 
6 child*.tw. 
7 infant*.tw. 
8 girls.tw. 
9 boys.tw. 
10 p?ediatric*.tw. 
11 newborn*.tw. 
12 or/1-11 
13 limit 12 to human 
14 exp Clinical Trial/ 
15 13 and 14 
16 limit 15 to (phase 1 clinical trial or phase 2 clinical 
trial or phase 3 clinical trial or phase 4 clinical trial) 
17 15 not 16 
18 developing country/ 
19 underdeveloped.tw. 
20 under-developed.tw. 
21 less developed.tw. 
22 resource limited.tw. 
23 resource constrain*.tw. 
24 resource poor.tw. 
25 third world.tw. 
26 low income.tw. 
27 middle income.tw. 
28 low socioeconomic.tw. 
29 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25  or 26 or 
27 or 28 
30 17 and 29 
31 exp qualitative research/ 
32 qualitative$.tw. 
33 interview$.tw. 
34 focus group$.tw. 
35 (thematic$ or theme$).tw. 
36 Content analysis.tw. 
37 grounded theory.tw. 
38 phenomenology.tw. 
39 phenomenological$.tw. 
40 ethnograph$.tw. 
41 exp social psychology/ 
42 exp decision making/ 
43 exp illness behavior/ 
44 exp health belief/ or exp social belief/ 
45 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 
40 or 41 or 42 or 43 or 44 
46 30 and 45 
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Appendix C1 - Checklist for reporting of paediatric trial protocol scientific 
domains 
 
Study Trial Number  Initiated by:     □Investigator             □ Industry           □Collaborative group                                                                                   
                            □Other, specify…………………………………………………………………. 
Date of data collection  The trial is being conducted through:  □ CTN                      □CTX 
 
Section/ Topic 
Item 
No 
CONSORT Checklist item 
(STUDY Checklist item) 
YES/NO/ 
Unclear/
NA 
Title 
 1a Descriptive title of the protocol  
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale  
2a (1) Indication of systematic review (where applicable)   
2a(2) Health condition(s) or problem(s) studied (WHO ICD ): 
…………………………………………………………………………………. 
2a(3) Mention of  disease prevalence in children   
2a(4) Impact of the disease in children   
2b Specific objectives or hypotheses  
Methods 
Trial design 3a Description of the trial design (e.g. parallel, cluster, non-
inferiority/equivalence) including allocation ratio 
 
3a(1) 
 
Is this trial design:      
□ Randomised controlled       □ RCT Parallel       □ RCT Cluster                               
□ Nonrandomised   
□ Cross-over              □ Superiority              □  Non-inferiority                                    
□ Equivalence 
3a(2) Indication of  the allocation ratio of the treatment arms  
3a(3) Indication of the phase of trial  
3a(4) Phase of the trial:  □ Phase 1           □ Phase 2            □ Phase 3            □ Phase 4 
Participants 4a Eligibility criteria for participants  
4a(1) Is this a mixed population of adults and children?  
4a(2) Participant age range:…………….. 
4a(3) Participant timeline of enrolment, interventions, assessments and 
visits 
 
4b Settings and locations where the data were collected  
4b(1) Number of recruitment sites: □Single centre     
□ Multi-centre sites……… 4b (2) Inside Australia…………….  
                                              4b (3) Outside Australia…………  
Recruitment  14a Dates defining the periods of recruitment and follow-up  
14a(1) Indication of the period of recruitment  
14a(2) Indication of the follow up period   
14a(3) Description of recruitment process and forms of recruitment   
14a(4) If Yes, which of the following forms of recruitment were used:                                                                                             
□ Face-to-face        □ Mail out        □ Internet        □ Advertising            □ Referral                            
□ Other, specify……………………………………………………………………. 
14a(5) Total duration of the clinical trial:   ………… (years) if included 
Baseline data 15 Indication of collection of baseline demographic and clinical 
characteristics for each group  
 
Interventions  
5 
The interventions for each group with sufficient details to allow 
replication, including how and when they were actually 
administered 
 
5(1) The WHO Anatomical Therapeutic Chemical (ATC) classification 
http://www.whocc.no/atc_ddd_index/  of the Investigational Medicinal 
Product(s) (IMPs):……………………………………………………………………. 
5(2) Registration status of IMP: 
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Section/ Topic 
Item 
No 
CONSORT Checklist item 
(STUDY Checklist item) 
YES/NO/ 
Unclear/
NA 
□ ARTG unregistered   □  (a) Registered in other countries  
                                         □  (b) First Time in Human 
□  ARTG registered, but unlicensed for use in children 
□  ARTG  registered in children, but not for indication trialled (off-label use) 
□  Other: specify……………………………….. 
5(3) Use of the IMP:  □ Diagnosis                      □ Treatment                       □ Prevention       
□ Other…………………………………………………………………… 
5(4) Description of measurement of compliance to the IMP(s)   
5(5) Indication of age, weight or body surface area adjustments of dose  
5(6) If applicable, explanation of why the formulation of the drug is inappropriate 
for use in children............................................................................................. 
5(7) Defined threshold levels (maximum dose or therapeutic levels) for 
IMP. 
 
5(8) Inclusion of safety data e.g. drug interactions, contraindications 
regarding the proposed usage of the IMP. 
 
5(9) Post-trial provision:  Consideration of the ongoing treatment of 
trial subjects should they respond to the pharmaceutical 
product(s) under investigation.  
 
Outcomes 6a Completely defined pre-specified primary and secondary outcome 
measures, including how and when they were assessed 
 
6a(1) Number of primary outcome measures =……………. 
6a(2) Number of secondary outcome measures =………… 
6a(3) Type of endpoint(s): □ Safety        □ Efficacy         □ Optimum dosage schedule              
□ Tolerability     □ QOL      □ Pharmacokinetics     □ Other, specify…………………… 
6a(4) Age and development specific outcomes included  
19 All important harms or unintended effects in each group   
19(1) Description of continuous safety monitoring   
19(2) Description of  long-term (until the child participant reaches 
adulthood) safety monitoring where applicable 
 
19(3) Inclusion of a Data Safety Monitoring Board  
Sample size 7a Description of  sample size estimation  
7a(1) Performance of a sample size calculation  
7a(2) Target sample size for trial:……………. 
7a(3) Target sample size for site:…………….        or              □ Not specified 
7b When applicable, explanation of any interim analyses and 
stopping guidelines 
 
7b(1) Defined rules for stopping the trial earlier  
7b(2) Inclusion of guidelines for the end of study for an individual 
patient 
 
Randomisation 
Sequence 
generation 
8a Method used to generate the random allocation sequence  
8a(1) Adequate generation of the allocation sequence   
8b Type of randomisation; details of any restriction (such as blocking 
and block size) 
 
8b(1) Description of  stratification of treatment  
8b(2)  If YES, indicate the stratification:    □ Age                  □ Weight                □ Gender                              
□ Severity of illness                □ Other, specify………………………………………….. 
Allocation   
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers), describing any steps 
taken to conceal the sequence until interventions were assigned 
 
9(1) Adequate concealment of allocation   
Implementation 10 Who generated the random allocation sequence,  
who enrolled participants, and who assigned participants to 
interventions 
 
Blinding 11a If done, who was blinded after assignment to interventions (for 
example, participants, care providers, those assessing outcomes) 
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Section/ Topic 
Item 
No 
CONSORT Checklist item 
(STUDY Checklist item) 
YES/NO/ 
Unclear/
NA 
and how 
11a(1) Adequate prevention of the knowledge of the allocated 
interventions during the study.*  
 
11a(2) Blinding of randomised controlled trial  
11a(3) If YES, who was blinded: □ Participants   □ Care providers   □ Study personnel          
□ Data analyst        □ Other specify………………………………………………….. 
11a(4) Explanation of why blinding was not done, or was not possible.    
11b If relevant, description of the similarity of interventions  
11b(1) Is the comparator (control treatment arm), if applicable:      □ Placebo                    
□ Current standards of patient care     □ Other, specify……………………. 
11b(2) Rationale for the type of control or placebo used  
Statistical methods 12a Statistical methods used to compare groups for primary and 
secondary outcomes 
 
12a(1) Professional statistical consideration of the trial (is there a 
statistician as part of the study team or has a statistician been 
consulted). 
 
12b Methods for additional analyses, such as subgroup analyses and 
adjusted analyses 
 
12b(1) Outcome measures. Indication of what analysis will be done on 
outcome measures to answer the research question. 
 
12b(2) Numbers analysed. Specification of intention to treat analysis.  
12b(3) Planning of subgroup analysis   
12b(4) If YES, indicate subgroup analysis: □  Age       □ Weight       □ Gender                            
□ Severity of illness    □ Other, specify……………………………………………. 
12b(5) Limitations. Specification of trial limitations, addressing sources of 
potential bias, imprecision, and, if relevant, multiplicity of 
analyses. 
 
Other information 
Registration 23(1) Inclusion of trial  on the WHO International Clinical Trials Registry 
Portal (ICTRP)  
 
23(2) Indication on which clinical trials registry trial is registered 
………………………………………………………………………………….. 
Protocol 24 (1) Conditions for when the protocol may be modified.  
Funding 25 Sources of funding and other support (such as supply of drugs), 
role of funders 
 
25(1) Primary sponsor:  □ Industry    □ Hospital    □ University                                                 
□ Collaborative group            □ Other, specify……………………………………….. 
25(2) Funding for the study:    □ Full          □ Partial        □ None                                                      
□ Pharmaceutical product only     
Reporting 26(1) Reporting:  Details of how the study results will be reported.  
26(2) Indication if results will be published.   
 
*Using Cochrane Risk of Bias 
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Appendix C2 - Descriptive data of ethics and governance processes at 
Children’s Hospitals 
1. Ethics approval processes 
1.1 Human Research Ethics Committee procedures of  pharmaceutical clinical trial review:  
………………………………………………………………………………………………………………………………………………………………. 
………………………………………………………………………………………………………………………………………………………………. 
1.2 Are there HREC guidelines for submitting clinical trials:    □ YES           □ NO 
1.3  Which ethics application form(s) are being used:               
□ NEAF                    □ Site form                   □ Other, specify………………………………………………………………………                                                                                             
1.4 Acceptance of multi-centre ethics approval:                       □ YES           □ NO 
1.5 Is the site an approved Lead Paediatric HREC:                   □ YES           □ NO 
1.6  Is the site accredited under the Streamlined Ethical Review Process (SERP) for the review of clinical 
trials                                                                                            □ YES           □ NO 
1.7  Is the site certified under the NHMRC Harmonisation of Multi-Site Ethical Review (HoMER):                                                                                                                  
□ YES           □ NO 
 
2. Institutional governance approval process of paediatric clinical trials: 
 
…………………………………………………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………………………………………………… 
 
3. Is there training and support of clinical trials ethics submissions and conduct: 
□YES                      □ NO 
If YES, specify:………………………………………………………………………………………………………………………………………………. 
……………………………………………………………………………………………………………………………………………………………………… 
 
4. Clinical trial registration: Institution recommendations/guidelines on trial registration if any: 
           ………………………………………………………………………………………………………………………………………………………………..... 
           …………………………………………………………………………………………………………………………………………………………………… 
 
5. Clinical trials activity: average number of paediatric pharmaceutical trial HREC applications/year:…………… 
 
6. Number of paediatric pharmaceutical trials submitted to the Human Research Ethics Committee (HREC) 
for the period 1 January 2012 – 31 December 2012……………… 
 
7. Number of paediatric pharmaceutical trials submitted for site approval for the period 1 January – 31 
December 2012……………… 
 
8. Any additional information:……………………………………………………………………………………………………………………… 
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Appendix D1 - Professional stakeholder interview invitation 
 
 
 
 
Discipline of Paediatrics and Child Health 
Clinical School 
Faculty of Medicine 
  ABN 15 211 513 464  
 
Dear Colleague, 
 
Interview invitation: “Stakeholder experiences and perspectives of paediatric clinical 
trials” 
 
We are conducting research to improve our understanding of issues faced when conducting paediatric 
clinical trials internationally. As a stakeholder involved with trials in children you are in an ideal position to 
give us valuable first-hand information from your own perspective and experiences. We would like to invite 
you to participate in an interview as part of this study. 
 
There is a research imperative to conduct more quality clinical trials that are relevant to the paediatric 
population. However, there are major barriers which limit the conduct of trials in children in different 
settings. This study will examine paediatric clinical trial stakeholders’ (clinical/investigating team, 
government/ethics/regulators and sponsors) views on clinical trials in children. The study will use 
qualitative methods (key informant interviews or focus groups) to gain a better understanding of the 
experiences and challenges experienced by stakeholders. We hope this study will help to inform strategies 
and provide potential solutions to the challenges faced in the design and conduct of quality paediatric trials 
in different settings.   
 
This study involves stakeholders from the international trials community who are invited to participate in 
one, semi-structured face-to-face or telephone interview about your individual views and personal opinions 
about the issues faced in clinical trials in children. The interview will take about 30 minutes. Being in this 
study is completely voluntary and you are not under any obligation to consent. All aspects of the study, 
including results, will be strictly confidential and only the investigators will have access to information on 
participants. A report of the study will be submitted for publication, but individual participants will not be 
identifiable in such a report. All participants will be sent a final report of the study which may be of interest 
to you in your role or involvement in paediatric trials. You can tell other people about this study, and 
welcome your nomination of additional people who may be interested in taking part in the study that we 
can approach. 
 
If you are willing to participate please suggest the days and times that you are available and we will do our 
best to accommodate your requirements. If you would like to know more at any stage, please feel free to 
contact Pathma D Joseph, PhD candidate, The Discipline of Paediatrics and Child Health, University of 
Sydney  on +61 2 9845 2697 or e-mail: pathma.joseph@health.nsw.gov.au.   
 
We thank you and greatly appreciate your assistance. 
 
 
Dr Patrina Caldwell 
Staff Specialist, Centre for Kidney Research 
Senior Lecturer, Discipline of Paediatrics and Child Health 
The University of Sydney 
The Children's Hospital at Westmead 
Locked Bag 4001 Westmead NSW 2145, Phone: +61 2 9845 3406 
Email: patrina.caldwell@health.nsw.gov.au, Web: http://www.sydney.edu.au 
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Appendix D2 - Participant information statement 
 
 
 
 
Discipline of Paediatrics and Child Health 
Clinical School 
Faculty of Medicine 
  ABN 15 211 513 464  
 Dr Patrina Caldwell 
Staff Specialist, Centre for Kidney Research 
Senior Lecturer, Discipline of Paediatrics and Child Health 
 
The University of Sydney 
The Children's Hospital at Westmead 
Locked Bag 4001 Westmead NSW 2145 
Phone: +61 2 9845 3406 
Email: patrina.caldwell@health.nsw.gov.au  
Web: http://www.sydney.edu.au 
 
Stakeholder experiences and perspectives of paediatric clinical trials 
 
Participant Information Statement: Interview 
 
(1) What is the study about? 
You are invited to participate in a study of your experiences and perspectives of clinical trials in 
children. There is a research imperative to conduct more quality clinical trials that are relevant to the 
paediatric population.  However, there are major barriers which limit the conduct of trials in children 
in different settings. This study will examine paediatric clinical trial stakeholders’ 
(clinical/investigating team, government, ethics/regulators and sponsors) views on clinical trials in 
children. The study will use qualitative methods (key informant interviews /focus groups) to gain a 
better understanding of the experiences and challenges from the perspective of stakeholders 
involved in paediatric clinical trials. We hope this study will help to inform strategies and provide 
potential solutions to the challenges faced in the design and conduct of quality paediatric trials in 
different settings.   
 
(2) Who is carrying out the study? 
The study is being conducted by Ms Pathma D Joseph, Senior Pharmacist and Clinical Lecturer and 
will form the basis for the degree of Doctor of Philosophy at The University of Sydney under the 
supervision of Dr Patrina Caldwell, Staff Specialist and Senior Lecturer. 
 
(3) What does the study involve? 
You have been approached because we want to talk with stakeholders involved in clinical trials in 
children. This study involves participating in one, semi-structured face-to-face or telephone interview 
about your individual views and personal opinions about the issues in the conduct of clinical trials in 
children, which will be audio recorded.  The interview will be either face-to-face or via the telephone. 
Face-to-face interviews will take place at a suitable date, time and location nominated by you. 
Telephone interviews will be pre-arranged at a suitable date and time nominated by you. 
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(4) How much time will the study take? 
We expect that the interview to take approximately half to one hour to complete  
  
(5) Can I withdraw from the study? 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you 
do consent - you can withdraw at any time without affecting your relationship with The University of 
Sydney. 
You may stop the interview at any time if you do not wish to continue, the audio recording will be 
erased and the information provided will not be included in the study. 
 
(6) Will anyone else know the results? 
All aspects of the study, including results, will be strictly confidential and only the researchers will 
have access to information on participants. A report of the study will be submitted for publication, 
but individual participants will not be identifiable in such a report. 
 
(7) Will the study benefit me? 
All participants will be sent a final report of the study which may be of interest to you in your role or 
involvement in paediatric trials.  
 
(8) Can I tell other people about the study? 
You can tell other people about this study, and welcome your nomination of additional people who 
may be interested in taking part in the study that we can approach.  
 
(9) What if I require further information about the study or my involvement in it? 
When you have read this information, Pathma D Joseph will discuss it with you further and answer 
any questions you may have.  If you would like to know more at any stage, please feel free to contact 
Pathma D Joseph, PhD candidate, The Discipline of Paediatrics and Child Health, University of Sydney  
on +61 2 9845 2697 or e-mail: pathma.joseph@health.nsw.gov.au.   
 
(10) What if I have a complaint or any concerns? 
Any person with concerns or complaints about the conduct of a research study can contact The 
Manager, Human Ethics Administration, University of Sydney on +61 2 8627 8176 (Telephone); +61 2 
8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
 
This information sheet is for you to keep 
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Appendix D3 - Participant consent form for interview 
 
 
 
 
Discipline of Paediatrics and Child Health 
Clinical School 
Faculty of Medicine 
  ABN 15 211 513 464  
 Dr Patrina Caldwell 
Staff Specialist, Centre for Kidney Research 
Senior Lecturer, Discipline of Paediatrics and Child Health 
 
The University of Sydney 
The Children's Hospital at Westmead 
Locked Bag 4001 Westmead NSW 2145 
Phone: +61 2 9845 3406 
Email: patrina.caldwell@health.nsw.gov.au  
Web: http://www.sydney.edu.au 
 
Participant consent form for interview 
 
I, ...........................................................................................[PRINT NAME], give consent to my 
participation in the research project 
 
Title: Stakeholder Experiences and Perspectives of Paediatric Clinical Trials 
 
In giving my consent I acknowledge that: 
 
1. The procedures required for the project and the time involved have been explained to me, and 
any questions I have about the project have been answered to my satisfaction. 
 
 
2. I have read the Participant Information Statement and have been given the opportunity to discuss 
the information and my involvement in the project with the researcher/s. 
 
 
3. I understand that being in this study is completely voluntary – I am not under any obligation to 
consent. 
 
 
4. I understand that my involvement is strictly confidential. I understand that any research data 
gathered from the results of the study may be published however no information about me will be 
used in any way that is identifiable. 
 
 
5. I understand that I can withdraw from the study at any time, without affecting my relationship 
with the researcher(s) or the University of Sydney now or in the future. 
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6. I understand that I can stop the interview at any time if I do not wish to continue, the audio 
recording will be erased and the information provided will not be included in the study. 
 
7. I consent to:  
 
 Audio-recording YES  NO  
 
 Receiving Feedback YES  NO  
 
If you answered YES to the “Receiving Feedback” question, please provide your details i.e. mailing 
address, email address. 
 
 
Feedback Option 
 
Address:  …………………………………………………………………………………………………… 
 
                       …………………………………………………………………………………………………… 
 
Email: …………………………………………………………………………………………………… 
 
 
 
 
 
 
 
............................................................................................. 
Signature  
 
 
 
............................................................................................. 
Please PRINT name 
 
 
............................................................................................. 
 
Date 
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Appendix D4 - Participant (Professional stakeholders) demographics 
 
 
   Country:…………………………………………………………                                               State:………………………………………………………………. 
 
Gender: □ Male □ Female 
 
   
Age group: □ 20s □ 30s □ 40s □ 50s □ 60s       □ 70s 
 
 
Experience in 
trials in children 
(years): 
□ ≤2 □ 2-5 □ 6-10 □  11-20 □  21-30      □ >30 
 
 
 
Current role(s) in 
trials 
 
 
 
Clinical/investigating team 
□ Investigator 
□ Trial co-ordinator 
□ Pharmacist 
□ Paediatrician 
□ Academic 
□ Other:……………………………. 
 
 
 
Ethics/regulators 
□ Bioethicist/ ethics 
  committee member 
□ Scientific Advisory 
  committee member 
□ Research Governance 
□ Regulator/policy-makers 
□ Other:…………………………… 
 
 
 
Sponsor/industry/funding/bodies 
□ Clinical research assistants 
□ Monitors 
□ Sponsor/industry 
□ Other:…………………………………… 
 
 
Clinical trial 
speciality  area(s) 
 
 
□ Cardiology  
□ Emergency 
□ Endocrinology  
□ Immunology and infectious disease  
□ Intensive care 
□ Neonates  
 
□ Neonatology  
□ Oncology  
□ Psychological Medicine/Mental Health  
□ Renal  
□ Respiratory  
□ Musculoskeletal/rheumatology  
□ Other:…………………………………….. 
 
 
Main type of 
studies you have 
experience with: 
 
□ Investigator initiated     
                
□ All types  
 
 
 
 
 
 
□ Pharma sponsored 
 
□ Collaborative groups 
 
□ Funding bodies 
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Appendix E1 - Frequency of CONSORT domains in paediatric trial protocols 
(n=69)  
 
Section/Topic 
Item 
No CONSORT Checklist item                                                                                                Yes (%) No (% ) Unclear (% ) 
Title and abstract 1a Descriptive trial of the protocol 36 (52) 33 (48) 0 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 66 (96) 2(3) 1 ( 1) 
2b Specific objectives or hypotheses 67 (97) 1 (1) 1 ( 1) 
Methods 
Trial design 
3a 
Description of trial design (such as parallel, factorial) 
including allocation ratio 68 (97) 0 1 (1) 
Participants 
4a Eligibility criteria for participants 62 (90) 3 (4) 4 (6) 
4b Settings and locations of data collection 63 (91) 3 (4) 3 (4) 
Recruitment                  
14a 
Dates defining the periods of recruitment and follow-
up 58 (84) 4 (6) 7 (10) 
Interventions 
5 
The interventions for each group with sufficient details 
to allow replication, including how and when they 
were actually administered 68 (99) 1 (1) 0 
Outcomes 
6a 
Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were assessed 67 (97) 1 (1) 1 (1) 
Harms or 
unintended effects 19 
All important harms or unintended effects in each 
group
a
  56 (82) 8 (12) 4 (6) 
Sample size 
7a How sample size was determined 56 (81) 6 (9) 7 (10) 
7b 
When applicable, explanation of any interim analyses 
and stopping guidelines 50 (73) 18 (26) 1 (1) 
Randomization: 
Sequence 
generation 
8a 
Method used to generate the random allocation 
sequence
a
 44 (85) 4 (8) 4 (8) 
8b 
Type of randomisation; details of any restriction (such 
as blocking and block size) 43 (86) 7 (10) 0 
Allocation 
concealment 
mechanism 
9 
Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence 
until interventions were assigned 37 (76) 8 (16) 4 (6) 
 Implementation 
10 
Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants to 
interventions
a
 42 (84) 3 (6) 5 (1) 
Blinding 11a 
If done, who was blinded after assignment to 
interventions (for example, participants, care 
providers, those assessing outcomes) and how
a
 34 (92) 0 3 (4) 
11b 
If relevant, description of the similarity of 
interventions 50 (72) 5 (7) 0 
Statistical methods 
12a 
Statistical methods used to compare groups for 
primary and secondary outcomes
a
 58 (87) 6 (9) 3 (5) 
12b 
Methods for additional analyses, such as subgroup 
analyses and adjusted analyzes 40 (58) 15 (22) 6 (9) 
Other information       
Funding 25 
Sources of funding and other support (such as supply 
of drugs), role of funders
a
 67 (99) 0 1 (2) 
 a
n is less than 69 as domain did not apply to some trials 
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Appendix E2 - Frequency of child-specific and other important domains in trial 
protocols (n=69)  
 
Child-specific and other important domains Yes (% ) No (%) Unclear (%) 
Background and objectives 
  Indication of systematic review (where applicable) 33 (48) 13 (19) 23 (33) 
  Description  of  disease prevalence in children 60 (87) 9 (13) 0 
  Description of impact of the disease in children 52 (75) 17 (25) 0 
Participants 
  Participant timeline of enrolment, interventions, assessments and visits 53 (77) 16 (23) 0 
Intervention 
  Measurement of compliance of the therapeutic intervention
a
 44 (92) 1 (2) 3 (6) 
  Age, weight or body surface area adjustments of dose 43 (62) 26 (38 0 
  Threshold levels (maximum dose or therapeutic levels) for therapeutic 
  intervention
a
 
64 (94) 4 (6) 0 
  Safety data on the therapeutic interventions  63 (91) 5 (7) 1 (1) 
  Post-trial provision of successful interventions
a
 20 (39) 27 (53) 4 (8) 
Outcomes 
  Age and development specific outcomes 33 (48) 36 (52) 0 
  Description of continuous safety monitoring  60(87) 9(12) 0 
  Long-term safety monitoring
a
 8 (12) 59 (87) 1 (1.5) 
  Data Safety Monitoring Board included 45 (71) 20 (26) 4 (3) 
  Conditions when the protocol may be modified 37 (54) 31 (45) 1 (2) 
  Planned reporting of study results 52 (75) 17 (25) 0 
a
These items did not apply to certain trials  
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Appendix F1 - Interview guide 
 
Interview guide* 
1. Issues with clinical trials in children in (name of respondent’s country) 
a) In your opinion, what are positive aspects of doing trials in children in (name of respondent’s country)? 
b) On the other hand, what do you believe are the main concerns(s) with the conduct of trials in children in (name of respondent’s country)? Can you describe these 
issues and its impact on the conduct of pediatric trials? (recruitment, resources, ethics approval, operational issues, safety monitoring).  
c) Can you think of ways of addressing the challenges you mentioned with trials in children in (name of respondents country)? (training, funding) 
d)  In your view what are the different issues with investigator initiated, collaborative or pharma sponsored pediatric trials? How can these issues be addressed?  
e) What is your view on registration and reporting of trials in children?  Is there a need for paediatric specific registries or disease specific registries? 
f) Do you feel that the trials conducted in (name of respondent’s country) are meeting the needs of the children in the country?  Why? (number, quality, relevance). 
Any suggestions on how this can be addressed or improved to meet the needs of children? 
g) In an ideal world if you have unlimited resources what would be the one or two things you would change in trials in children in (name of respondents country). 
h) Is there anything else you feel would be important to add about clinical trials in children in (name of respondent’s country)? 
 
2. Issues with clinical trials in children worldwide. 
a) In your opinion what are some of the positive aspects of clinical trials in children that’s occurring globally? (advocacy, recruitment, poor study designs) 
b) What do you consider to be the international concerns or challenges with the conduct of trials in children? (protocol design, ethical, regulatory, operational, 
recruitment and retention challenges, resources). 
c) In your view, what are the different issues (advantages or challenges) in trials in children in low-and middle- income countries compared to the wealthy nations? 
d) Any suggestions or strategies on how the global challenges in trials in children can be overcome. 
e) In an ideal world, if you have unlimited resources, what will be the one or two things you would change in trials in children? 
 
* NB. This question guide includes questions relating to challenges and enablers in the respondent’s country and globally. The complete interview guide is available on request 
from the authors. 
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Appendix F2 - Supplementary additional quotations 
 
Sub-themes Illustrative quotations 
 
Addressing pervasive inequities 
Paucity of safety and 
efficacy data  
 We want to increase access of children and adolescents with relapsed malignancies which is not curable with current treatment. We want to seek access for these patients 
to more active compounds… to increase the number of phase 1 and phase 2 trials. (Researcher, paediatrician, academic sponsor, France) 
All diseases are understudied…all other fields outside paediatric oncology are lacking enough trials and qualitatively, good trials. (Researcher, paediatrician, academic, 
Canada) 
 So there’s just a mismatch based on where you can put the incentives and the fact that there are many older products…in neonatology in particular…that are off-label and 
are off-patent and are not subject to those incentives. (Researcher, IRB, regulator, US) 
Knowledge disparities  
 
In my experience…the parents who are more educated and understand the needs of the clinical trial better, tend to comply better than those who are less educated, who 
tend to get lost to follow-up and drop out. (Researcher, paediatrician, Nigeria) 
I think that language is somewhat of a barrier in that if you are dealing with children who come from particularly rural areas or places where literacy levels are low. 
(Researcher, paediatrician, South Africa) 
Volatile environment  
 
 You have opened the Pandora’s Box…I belong to a local organization. But there is politics. I also belong to International organization, with virtually non-existent 
politics…the local politics. It suffices to say it is filthy. (Researcher, Nigeria) 
We need to nominate or appoint certain staff from that lab to be part of the clinical trial. And sometimes other staff in the same labs that are not part of the clinical trial 
can see that the scientists being part of the trial being given some extra material or extra money. And try to make things difficult for them… I am not sure whether to call 
it envy or rivalry…is also a major logistical problem in conducting the trial. (Researcher, paediatrician, Nigeria)  
 The ethos...research is not a paying thing. There is a driving force from the university to undertake the research…But it’s not a system that incentivise. It’s actually a stick 
tackle approach you don’t do it, you don’t get this. It’s quite abrasive in ways. They are actually very harsh and rude...they actually destroy people rather than build on 
them…in that way actually young people don’t want even to come into the research fold because they just know that the people and the politics behind it, is quite 
challenging. So I think that’s a huge limitation in this space. (Researcher, IRB, regulator, South Africa) 
Challenging double 
standards 
The agency also registers the traditional drugs by alternative medicines practitioners. When we, orthodox doctors challenged this action, we were educated that 
toxicological tests on the drugs didn’t show any toxicity or whatever. So, NAFDAC [National Agency for Food and Drug Administration and Control] is only interested in 
the safety according to them, but not interested in the efficacy and effectiveness. (Researcher, Nigeria)  
Families shouldn’t be out of pocket...We have a problem that the current EU clinical trial regulation and our national trial regulation seems to suggest that it is illegal to pay 
children anything beyond those expenses and reimbursements. I think that’s probably an unethical position and that there’s a better way for the administrator to judge 
whether the proposed remunerations isn’t an undue influence…in adult practice it seems fair to pay…we accept we pay people to take part in particular research 
projects. Yet we seem to be saying, we can’t pay children and that seems a little bit odd… ethically it would be reasonable to pay. But it seems that legally, there is a 
serious question over the legality of paying. (Regulator, paediatrician, UK)  
But distinctly say that not for years, there’s no standard of care because normally a person can’t afford standard of care because you live in a poor population. That is not 
appropriate because you are now doing a study, the study has to give whatever is the standard of care for that particular disease whether it’s something that the 
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Sub-themes Illustrative quotations 
 
population would normally be going out and purchasing for themselves or be able to get at a hospital at a cost. You can’t simply say, well they don’t normally do anything 
and so we leave it at that. Earlier there were a lot more placebo trials. Now there are much fewer placebo trials because we’ve insisted at least the standard of care 
being given to the control. (Researcher, paediatrician, IRB, India)  
Ensuring contextual 
relevance 
Trials should only be done if they fulfil a local need and they address a local question and they build capacity among local people. They should not be coming in so-called 
developing countries simply because disease burdens are greatest so therefore you can get an answer quicker. (Researcher, paediatrician, DSMB, Papua New Guinea) 
 We’re not providing what would internationally be regarded as best clinical practice...there are certain studies where very expensive drugs are being used and it’s unlikely 
that the study population where the study’s being done would eventually get to benefit from the drug once it’s licensed, just  because it’s too expensive. One example 
was a prophylaxis against respiratory syncytial virus where they get monoclonal antibodies for a group at risk like premature babies or babies with congenital heart 
disease. (Researcher, IRB, South Africa)  
Pharmaceutical companies are conducting trials in these low income countries because it’s easier to get ethics approval and it’s easy to conduct trials and is cheaper and 
it’s not necessarily meeting the needs of the children in that area. (Researcher, paediatrician, IRB, Australia) 
I think there will be issues at times if you’re conducting trials in health care settings where there may be a high degree of variability and the background clinical care that’s 
provided. That it might be difficult to know whether the effects that you’re seeing from the product that you’re studying will be reproducible in a different setting. I think 
that cuts both ways, but one questions any time there’s data that comes in from outside of the United States site would be, to what extent is it applicable to the US 
population. Not only from the standpoint of any changes…from pharmacogenomics differences or within the population, but also in the actual delivery of the 
background care to the patients that are enrolled. (Researcher, IRB, regulator, US) 
Market  
driven forces 
There’s an attitude of people being used to do trials on medicines that don’t become available within that country and people know about that. I think that’s partly to do 
with the politics within those countries…I think there’s reasonable case that medicine should be tested on a broad spectrum of humanity, if they get to be used in a 
board spectrum of humanity. So I can see why companies might want to do research in resource-poor countries because one day their medicines might be used there. I 
think also the value of infrastructure within well-resourced countries is that it does overcome the need for countries to go to less-resourced countries to actually do the 
recruitment. So in the UK we’ve had a progressive rise in a number of phase 3 studies being conducted on children in the UK, and a rise in the number of children being 
recruited to these studies in the UK. Which means there’s less need for sponsors to find more challenging situations, more ethically ambivalent situations? (Researcher, 
regulator, industry consultant, UK)  
In terms of whether it meets children’s needs, I think there’s a real gap here both in the EU and the US because the legislative drivers for research in children are filling in 
the gaps from adults to children. These are driven to make sure that the medicines they sell to adults can be used in children. And that’s a different perspective from 
developing medicines that children need. And that’s been a big barrier and I think it’s a result of the political pressures that were compromised when the medicines 
registration was set up. (Researcher, regulator, industry consultant, UK) 
We recruit from any country where there is a need for the drug in paediatrics and where our company has a footprint. We intend to make the drug available or market the 
drug in that country. If we are not going to go to that country to market that drug, we would not do research there. (Researcher, paediatrician, industry sponsor, US) 
Industry sponsorship 
bias 
There are trials done by academic institutions, trials involving drugs and devices or done in academic institutions outside the sponsorship by industry. But in those 
cases…the data from those studies cannot be used in a regulatory context…so if it’s done by a pure academic then the people who regulate drugs licencing, may not be 
able to use the information. (Researcher, pharmacologist, US) 
  A pragmatic study will only answer certain questions reliant upon you knowing quite a lot about the intervention and certainly in the UK there’s a lot of funding for 
pragmatic studies and so people do them in many contexts when they’re inappropriate. So a lot of people to avoid registration studies are actually doing quite poor 
Appendices 
172 
 
Sub-themes Illustrative quotations 
 
quality studies in terms of internal validity and external validity. So there’s that big mash in between the curiosity-driven investigator study that’s generally poor and the 
studies which are leading to marketing authorization which are generally of high quality. (Researcher, regulator, industry consultant, UK)  
 In terms of ethics there is a little higher moral ground from the collaborative research. Primary investigator driven research we always put patients first. (Researcher, IRB, 
regulator, South Africa)    
Dissuaded by 
prohibitive costs 
Small biotechnology is scraping through every single dollar they can get to be able to bring the product to market. It is very expensive to do that. If they are forced to 
provide the drug, that is still unproven post-initial clinical trial, then they might not physically have the funds to do that. Because besides providing the drug they have an 
obligation to monitor those patients. And it becomes a very big expense or potentially could be a big expense and that’s typical for them not having the funding for that. 
(Industry sponsor, CRO, monitor, Australia) 
And in South Africa, we have some of the highest radiology prices in the world because, we don’t know why, we just get exploited basically. So that pushes up the price of 
clinical trials involving oncology and radiology so it does become a bit of a money issue where they want to get paid more and more and more. (Industry CRA, monitor, 
South Africa) 
Some of the drugs are just not available in Australia or the drug companies won’t let Australian sites participate because they don’t want to be bothered with shipping 
drugs down here. So they stick with the sites in the Northern Hemisphere…and then compared to countries like India and China, the employment costs are more 
expensive as well. (Trial co-ordinator, trial center, Australia) 
It’s so pricey to go and just go and audit a place and expect for the sponsor to pay for it. So at the moment, the ethics we’re using there’re not doing that. (Industry 
monitor, South Africa) 
Contending with infrastructural barriers 
Overwhelming resource 
constraints 
In terms of Nigeria, not all institutions have an ethics committee. Not all institutions have IRBs. Most of the teaching institutions do. So this is an issue if you want to start a 
clinical trial.  (Researcher, paediatrician, Nigeria)  
Insufficient. We get a little bit of money from New South Wales Cancer Institute but it’s more just politically. They couldn’t be seen not to support paediatrics. So we get a 
little bit of funding but most of our study coordinators are funded through donated funds. And that’s all the money we get. We get enough to cover probably one salary 
and this aren’t enough? (Trial coordinator, trial centre, Australia) 
 The general system of power in most of the developed countries where there has been a need to cut resources allocated to health care. That has meant  that at all levels 
of health care and for all people working in the health care, any other time that they can freely allocate something they would like to do has been drastically, 
dramatically reduced to the extent that it has practically disappeared for instance in Finland. And that means that in the old times whether you call them bad or good 
times is subjective assessment, but it was for a paediatrician or a doctor treating children at a hospital or even in rehabilitatory care, you could allocate some of your 
time for doing research. (Researcher, paediatrician, IRB, Finland)  
I am employed by the university. If I had to get a grant and that grant goes to the university and I am then allowed to use it, but I don’t have carte blanche to use it in any 
way I think it’s the most appropriate. And if by some chance you have actually been efficient and ran the study well and you’ve got left over funds, the university takes it 
away. So you really don’t have money to come up with the next study…It’s a huge challenge. (Researcher, IRB, regulator, South Africa)  
The pharma company would prefer to get all samples frozen, send them to US or wherever and have them analysed there. Where it would have been actually better for a 
developing country to do everything local. But then again…the developing country hasn’t got all the same assays they run, all the same machinery to do the sampling or 
to do the analysis. (Industry monitor, South Africa) 
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The heavy administrative burden and increasing costs that really jeopardized or delayed the activation of these clinical trials in children with cancer across Europe. 
(Researcher, paediatrician, academic sponsor, France)  
Dearth of pediatric trial 
expertise 
Our work has shown that up to 90% of trials have either unclear or high risk bias…it’s outrageous that we’re doing research that may be high risk of bias or not even dealing 
with these issues when we have the knowledge how to do it. So I think that’s an urgent agenda item that, we shouldn’t be allowing people to do trials unless they have 
the know-how and show they know how to design and implement trials. (Researcher, paediatrician, research governance, Canada) 
Because the very basic aspects about conducting research is not a general curriculum in most of our academics or as a medical student, neither me nor anyone for that 
matter. It’s really not part of academics, so people really are not exposed to research methodologies so there are deep flaws in the research methodologies. Because I 
am a firm believer in the dictum that bad science is bad ethics. (IRB, CRO, India) 
Lack of accountability. Because all of a sudden everybody gets MCC [Medicine Control Council] inspections, FDA inspections, they’re running around like chickens without 
heads. They manage to pull it off for one or two inspections but meanwhile they are sort of crumbling and crumbling further. Eventually these types of government 
institutions implode because they just can’t keep up with the demand of the pharmaceutical industry…if you make a doctor a manager you just kill them completely 
because that’s not what they study to be and they shouldn’t be expected to have business acumen. But we actually do need them to be business managers. So it’s the 
doctors in private practice, who have a bit of business background, or MBA or whatever just even a financial accounting course to understand how things work better, 
they see the bigger picture. (Industry CRA, monitor, South Africa) 
Some of the issues haven’t been answered that might be in the actual day-to-day running, particularly from investigator driven studies, quite a few issues may not have 
been addressed in the protocols. May not be as detailed as one would expect to ensure that they run equally across all sites, or some of the products provided may not 
have as much supporting information as we sometimes expect. (Pharmacist, IRB, Australia) 
 And people don’t necessarily know a lot about the details, other than wanting to do a randomised control trial. They know it should be random, but there’s kind of a limit 
on the knowledge in a lot of cases. (Academic, methodologist, Canada) 
There are new clinicians, investigators but it is very hard to get well-trained people and most of them are not really familiar with how trials are conducted and it ends up 
being a lot of our own personal time and personal supervision. So it’s actually a real big problem and we don’t get dedicated time to do the work. (Researcher, 
paediatrician, industry sponsor, US)  
Traversing logistical 
complexities 
I think the other major challenge for research participants in South Africa is distances that they have to travel, particularly if they’re not living in the city or they’re living in 
informal settlements further away from the hospital. Because as you know most of these research studies happen in larger academic centers, whereas people live out in 
quite far off communities, and it becomes quite a costly exercise to travel. (Researcher, paediatrician, South Africa) 
Heterogeneity in terms of resources because patients are paying from their own pockets so that the quality of care and of the treatment is often not trial-based, but is 
often patient-based. Funding, time, the ability for the clinician, manpower. (Researcher, trial coordinator, India) 
Navigating complex regulatory and ethical frameworks 
“Draconian” oversight I suppose my main issue about the funding and research is that it is a frighteningly bleak one. I get upset when I see that public and private funds, funding for research are 
being spent on bureaucracy and applications to R and D [Research and Development] Departments to hospital trust. And really quite a significant amount of money is 
being spent even before you start to near recruit the first patient. And that is where I feel it’s unethical. People are raising funds for research which then has to be spent 
on unreasonable bureaucracy. (Regulator, paediatrician, UK)  
Bio-banking, I think is a low risk enterprise for the most part, but is something people feel strongly about once an element of choice. Again, some research going on in that 
particular domain but that’s going to remain a challenging one to not overburden investigators with tracking people down and getting consent while at the same time 
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maintaining trust and the research enterprise, I think that’s the main conflict there. (Regulator, IRB, governance, US) 
The other problem is that a lot of doctors don’t like to do clinical research because it’s incredibly laborious and has such admin issues and we want every‘t’ crossed and 
every ‘i’ dotted. We want it perfect and it’s getting worse so the GCP requirements are becoming more, they haven’t changed, but people are requiring that investigators 
stick to it more. Time is a problem; capacity in terms of staff is a problem, qualified staff. (Industry CRA, monitor, South Africa) 
 Too long and cumbersome. From the forms, from the processes, the number of hoops you have to go through, the level of complexity, it’s just got to the point where I 
don’t think it actually helps protect children or childhood experiences. It can sometimes overall hinder them, because less trials get done when you spend so much time 
getting one trial up. (Trial coordinator, IRB, government sponsor, Australia) 
I think their [Medicine Control Council] bureaucracy is inadequate to cope. (Researcher, IRB, South Africa)  
 Perhaps the pendulum has swung to an ethical approach that puts undue limitations on some trials in some aspects and makes it very hard for researchers to conduct 
trials in industrialized countries. (Researcher, paediatrician, DSMB, Papua New Guinea)  
Ambiguous 
requirements 
People struggle…what kinds of incentives are appropriate. Sometimes pencils are. You know, people are just unsure of things to present to ethics committees. What’s 
acceptable and what’s not. At times is not necessarily consistent. (Trial coordinator, network, Canada) 
You have to give the insurance and you have to know how much you’re going to be compensating for what kind of things. The rules right now are very vague. (Researcher, 
paediatrician, IRB, India) 
A bit of gray area is the use of consent and assent forms…But it seems at this stage to be ethics committees specific and then not even mandatory to use. So mandatory to 
write them but not to use them and it’s just seems like an inefficient use of time at the moment.  (Trial coordinator, trial center, Australia) 
Fear of  exploiting the 
vulnerable 
So you can’t go to a third world country and exploit the cheap labor and use those children for your clinical trial and then pack up and leave again. The supportive care and 
the sought of long term follow-up needs to be offered to those participants. (Trial coordinator, trial center, Australia) 
 Actually, in the media, somehow it always gets projected like Indians are being used for international trials. So I think the last few years, Indian government has made it 
very difficult to do international trials in India. (Researcher, trial coordinator, India) 
 You’ve got to be very careful not to exploit the vulnerable population, and children are deemed vulnerable population, because obviously they are not 18 yet and they 
don’t really necessarily 100% understand what’s going on...Because I don’t think you can rely on governments in certain countries to be as sensitive to the needs of the 
children as you would want them to be. (Industry CRA, monitor, South Africa) 
It was a trial that was done on girls in Gujarat and that I thought was again a huge oversight because the children who were enrolled in the study were tribal girls who were 
studying in a boarding school. And we all know that children in India are a vulnerable population and tribal are an even more vulnerable population…it just didn’t make 
sense. I mean you could do the study in a different population; you didn’t have to go to this population. And unfortunately because there were a few deaths, it put the 
whole cervical cancer vaccine into jeopardy which was really quite ridiculous and I felt very careless of the researchers. If they did it in a better way they could have 
gotten the same results and in a properly conducted and ethical study. (Researcher, paediatrician, IRB, India) 
Excessive paternalism  
  and unwarranted  
  exclusion 
Lots of the things one does in a neonatal intensive care are (considered funded) not experimental but considered we haven’t done it before.  It’s more problematic when 
you’re trying to run or test already used drugs or therapies in some older groups in paediatrics. It is actually harder to convince an ethics committee ‘why’ children should 
be randomised to one treatment or another when they’re both being used in clinical practice albeit not with any evidence base. (Trial coordinator, regulator, government 
sponsor, Australia)   
 And so people are extremely defensive and they just don’t want to really have no part, any kind of research, where even a little risk is involved. So we are now extremely 
risk-averse which is a big problem especially conducting clinical research in India and also though the paediatricians and clinicians are extremely good, because of this 
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general, bad negative publicity and background that is prevailing…they are also not keen on taking up a lot of research because the caregivers and parents are also 
extremely apprehensive about participating or allowing their kids to participate in these research. (IRB, CRO, India) 
Precariousness of                        
   coercion 
vs.volunteerism 
A barrier in India is that often if the family is presented at trial by the doctors or the other people who treat patients. They often feel that there may be a compulsion to 
participate in the trial and even if you tell them no, that it is entirely voluntary and it’s up to you there is a sort of feeling that they may have to participate. (Researcher, 
paediatrician, IRB, India) 
I have spoken to people in developing countries. And they say that they are so desperate for research and so desperate for funding that they are prepared to take any 
research. Because it puts funding, training and some help for those people in their country that might be suffering with that particular condition that will be helped by 
the study, even though it’s not meeting sort of the overall needs of all children in that country. So, I mean, they are in such a desperate situation that they are more 
willing to accept studies which may not be the best study to be conducted in that country. (Researcher, paediatrician, IRB, Australia) 
 I think that one needs to be careful that parents aren’t enrolling their kids in the clinical trials in order to pocket the money. (Researcher, IRB, regulator, US)  
If we’re paying a certain amount in the United States and a certain amount in whatever third world country-disadvantaged country. It isn’t the money that’s the issue, it’s 
basically you don’t want to be coercive. (Researcher, paediatrician, industry sponsor, US) 
Respecting uniqueness of children 
Embracing paediatric 
research paradigms   
Because you have to deal with childish behaviours and you have to deal with parents who are struggling with the concept that they have a sick child. If you’re doing trials in 
sick children, so you need a lot more time and resources to manage a child on a study than an adult on a study. So I think that poses problems if funding bodies or drug 
companies think that budgets and performance metrics that are appropriate for adult studies, if they try and impose those onto paediatric studies, then it’s a problem. 
(Trial coordinator, trial center, Australia) 
So from critically appraising the results and putting them into practice. Now I’ve moved into appraising and enhancing methods used in trials with kids, with the aim to 
make the trials more relevant, more valid and more efficient, i.e. faster results, more valid results that can inform decisions tomorrow or maybe next week. And 
exploring new methodologies that will do smarter job without putting children at risk if they participate. (Researcher, paediatrician, academic, Canada) 
The other challenge in paediatrics particularly when you get into the neonatal, infant and the young child stage is that if there are products that may have neurocognitive 
consequences, they are unknown. But potentially of concern is the length of trial you then need to do to see any of that, it’s quite expensive and we would extend way 
past what would be considered a meaningful timeline for a product to be studied to get into the market given the constraints of patents and so on and so forth. 
(Researcher, IRB, regulator, US) 
Considering child-
appropriate 
approaches 
We eventually found that the patients were lying and they weren’t completing their diaries as they were supposed to and because at the end of study, if you look at their 
compliance with the study drug and it, turned out to be, less on the e-diary than normal with the actual device, because you can do the estimate on the device as 
well...They’re kids!  And I think they want to sleep late over holidays and they don’t want to answer these things [e-diaries] that are prompting them to answer. And I 
think parents aren’t always there to guide the children.  (Industry monitor, South Africa) 
Another major challenge has been the fact that many of these children have lost their parents so their primary caregivers then are people who are usually not formally 
recognized as legal guardians. (Researcher, paediatrician, South Africa)  
You are enrolling somebody who may not be able to give consent and you are relying on a second or third party, i.e. parents to give permission. So the issues about 
ensuring they understand the proposal and then making sure that, if you are getting permission from the parents, you also are under our regulations, ensure that the 
child to the best of…his developmental capacity can understand what you propose to do …assent then to have the safeguard of recognizing if the child objects. Is that 
objection sufficiently significant to say well actually I don’t think you should be a part of the trial anymore. (Regulator, paediatrician, UK)   
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 When it’s appropriate to conduct, a phase I oncology trial in particular, in children, is an ethical challenge…the whole domain of whole genome sequencing and the 
management of incidental findings is a very hot topic right now. The retention of bio-specimens and how to engage children in consent for the ongoing use of those 
specimens once the kids become adults is an interesting issue. And I think the whole assent process still is challenging to try to make sure kids are given an adequate 
decision-making role in their participation and research. (Regulator, IRB, research governance, US) 
Facilitating family-
centered   
empowerment 
 
When you are recruiting a kid, you are recruiting a whole family really, especially with the longitudinal studies where there’s multiple visits. So there’s a lot of loss to follow 
up which I know happens in the adult population, but I think happens even more so in kids. (Trial coordinator, network, Canada)  
We need to improve the input of families and parents and children in setting up priorities and in designing studies and then conducting studies. (Researcher, regulator, 
industry consultant, UK) 
Parents usually want to see that their children are treated well and recover from their illness so they do co-operate...I haven’t seen major problems coming from parents of 
children who participated in the research. (Researcher, IRB, monitor, Nigeria) 
Driving evidence-based child health 
Promoting research 
advocacy 
I suppose there’s a particular great need for us all to sign up to the idea that research isn’t an optional extra, it should be a part of everyday care. And that’s difficult for 
professionals and I think it’s also difficult sometimes for families and children to understand.(Regulator, paediatrician, UK)  
Very clear top-down direction from the highest level of government that this is a priority and that priority is accompanied by token amounts of money that can be spent 
directly on children’s research. That then has to be met by a level of committed management who share that focus, share that vision and can turn it into effective 
operational issues and then that has to meet with the enthusiasm of researchers…And I think you do need that business case, hard dollars and cents and how many 
people does it cost to run a network, how many trials can you get done, how many medicines can you study? I think that’s the essential part. And the emotional and 
moral case is only a small part of it. You have to really play the same game as everyone else plays when they’re helping politicians for money. (Researcher, regulator, 
industry consultant, UK)  
There would be 100 news against the trials which are going on. And there would be hardly one news which is for it…So media needs to be structured-needs to give a 
neutral perspective on this rather than over doing it. (Trial centre administrator, India)   
In Nigeria, before you enter a community there are some people you need to go to. You have the traditional rulers like the local, and then you have the chief local 
government chairman… the power and local stakeholders. They will help with mobilization. So there will be some organization ahead of time to let the people know and 
these are the things involved. So the people are already aware. We also have some special programs from outside Europe that dump on the people. The people now 
encourage a lot of active participation.  When they realize the importance we need to coerce them with jobs, voluntary work and that will be. (Paediatrician, safety 
monitor, Nigeria) 
 I would like to see a huge campaign with children, parents, researchers, the public, to explain why we research, what we see the benefits of research, how it’s currently 
regulated to ensure that it is safe. So that we can all ultimately have a fair view of the place of research in health care and a fair view of its benefits and risks. That’s 
utopia. (Regulator, paediatrician, UK) 
Creating and seizing 
opportunities 
The current clinical research, infrastructure, experience and process has immensely benefitted from a lot of best practices which has come from the western populations 
and countries. So, even now, I am sure even though our regulators and adults may not accept it, we still look up to a lot of well-accepted and respected processes, SOPs 
and guidelines and rules which are already being used in US, Europe or Australia or other countries. (IRB, CRO, India) 
We need to support the philanthropy approaches. But I guess I have a concern that those philanthropic approaches are isolated and not really taking advantage of the 
opportunities for high quality research now being developed in the ICH jurisdictions. So it would be helpful if there’s a way to sort of reach out to those philanthropic 
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developments and make sure they are being done to high quality. Because the host countries for research don’t have the regulatory apparatus to ensure that. 
(Researcher, regulator, industry consultant, UK)  
 We have a first-world infrastructure and have third-world burden of disease. So we actually have an ability to answer in detail difficult questions with the patient 
population rather than, spending time on animal models and things like that. We have the patients with the problem and we try and resolve those as part of the clinical 
practice which in time relates to clinical research. (Researcher, IRB, regulator, South Africa) 
In 2013 in the first nine months of that financial year, the NIHR [National Institute of Health Research] across all specialities children and adult were able to recruit 25 first 
global patients, that means in a commercial study opening across the international at the same time point; in 25 of those studies the first patient recruited was in 
England. And of those 25, 11 were in the children’s network. So it shows that that’s an international competitive metric. And I think that plus the sense of collaboration 
that has allowed investigators in this case, paediatricians or other children’s health professionals, to work equitably and collaboratively, has allowed us to develop that 
work and taken away some of the academic tension and pressures that can sometimes get in the way there. And make it attractive to industry to undertake research 
studies of new medicines in children. (Researcher, research facility, network, UK)  
Supporting best practice In Europe, it is a rather good continent to implement clinical research; it’s for sure because we have this longstanding networking experience and activity with all paediatric 
oncologists and hematologists across the Union. (Researcher, paediatrician, academic sponsor, France) 
That people have different jurisdictions and they want slightly different information so it’s getting all the stakeholders together to agree on some common core data items 
and then the registries will want some additional information as will the ethics committees, as will the TGA [Therapeutic Goods Administration], but at least your 
common core data set could be entered just once. (Trial coordinator, IRB, government sponsor, Australia)    
Harmonization of terminology is needed; I think inter-operability of trial processes and databases are needed.  I think that quite a lot of training is needed, but all of that 
needs to be done in an intelligent, pragmatic way that takes account of reality rather than having a one size fits all other regulatory design or ethical level. (Researcher, 
regulator, industry consultant, UK) 
 There’s a lot of work that needs to be done to optimize the design of clinical trials, particularly helping people make intelligent, justifiable choices about how to do their 
phase I studies, how to do their phase II studies, how to do their phase III studies. And there are issues about comparators, there are issues about Fujian extrapolation, 
there are issues about PK [pharmacokinetic] modeling, about population PK, about blood sampling, about the developing and optimization of formulations and testing of 
formulations. There’s a whole strand of methodology that needs to be incorporated into research so that people designing their studies not in an abstract, academic 
way, but based upon the experiences of experts and of clinicians and networks that are built up share memory about these things. So there’s quite a lot that can be done 
to improve the way clinical trials are operationalized.   (Researcher, regulator, industry consultant, UK) 
The interaction of…global initiatives and country implementation. These are often a challenge. When countries don’t have good health systems where there’s mistrust 
between the academics and the health professionals, governments then go to international bodies to say what we should do. And that’s become the problem because 
they may be advising incorrectly because they are coming from what’s good for Zambia or Zimbabwe rather than what’s good for South Africa, so I think there is that 
concern that WHO, UNICEF, all these organisations shouldn’t have more say than people that working on the ground. They should be inputting into people on the ground 
exactly what they are doing. It’s almost as though some of these programs are run internationally for South Africa. They are not even run by South Africa. (Researcher, 
IRB, regulator, South Africa) 
Improving access to 
treatment 
One reason companies don’t put medicines into other markets is that they don’t get paid what they think they deserve, or they can get the money without having to 
register the medicine. So people who feel they’re not getting access to medicines need to review carefully what their reimbursement strategies are and to make sure 
that if they are going to reimburse then the agent does meet a proper need. And I think that health technology assessments are described not very early in drug 
developments because this demonstrating efficacy doesn’t demonstrate value for money. And value for money studies is different from traditional drug development. 
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(Researcher, regulator, industry consultant, UK) 
From Nigeria, cost is not really the issue a lot of time this is availability. Availability that is hampered by lack of experience and inability to acquire some of those products is 
really the problem… just because these products may be unavailable because we are poor. I think that we need to change that. (Researcher, IRB, monitor, Nigeria)  
So the collaboration between pharma and academic research needs to be really fine-tuned, improved, clearly defining together the best way to develop a drug and the 
best way to introduce these drugs into standard care. And finally the best way to follow surviving patients after having been exposed to these drugs on the long term. 
(Researcher, paediatrician, academic sponsor, France)  
The trials that I’ve been involved in have been run on limited, very lean budgets and that can have some benefits I see, in that if the trial itself is more integrated within,  
normal, structures and it’s run in a way where the results are more sustainable. If you’ve got a heavily funded clinical trial, the interpretation and generalizability of those 
results can be limited because the funding for implementation of whatever the result is not always available. (Researcher, paediatrician, DSMB, Papua New Guinea)  
In paediatric oncology we have long standing record, have a strong way of conducting clinical trials, meaning that clinical research is integrated into care. And more than 
50-60% of children with leukemia or malignant tumours participates into clinical trials, phase III, phase II and phase I. (Researcher, paediatrician, academic sponsor, 
France) 
Prioritizing research 
productivity 
The life of a child is important anywhere in the world whether in Nigeria or anywhere. Life is sacred, it is a gift from God and I think that all hands need to be on deck to 
ensure that these children’s needs are met. We do realize now that the world is a global village. People in developed nations should not just sit back and that we have 
finished dealing with all the problems in our nation and we don’t have any problems…somebody else has a problem in a developing nation, this should be a cause of 
concerns and I think we should all should try and join hands together.(Paediatrician, safety monitor, Nigeria) 
The problems of children in Nigeria are many and are valid. Nigeria has a lot of people from different backgrounds and their unique backgrounds are not uniform across 
the country. The epidemiology of disease is different from one part of country to another. I would like to see that we address our issues of children more with research 
than politics.(Researcher, IRB, monitor, Nigeria) 
Clinical trials could address the major disease burden issues and address the issues of equity and inequity. I think that’s very important and not just focus on I would say, 
medical intervention but be broader than that. Should have a balanced focus on prevention and curative health services, to address some of neglected disease burdens. 
But not to forget that many of the poorest countries still are bedeviled by some old problems that still have not been resolved. And so much of the focus, I think, of 
clinical trials  shouldn’t be about necessarily finding some new treatment approach but actually be operational research on how to do things better in difficult contexts. 
(Researcher, paediatrician, DSMB, Papua New Guinea) 
 We need to look at the use of our health data, that’s our held records, our social care records, our demographics and again with public leadership, not just agreement, we 
need to find a responsible way of using what I would call big data, to help us perform better and quicker research. (Researcher, research facility, network, UK) 
 Stop mass production of research but to have research more coordinated…I have articles saying ‘yes’ and articles saying ‘no’ and unless we don’t stop this mad rush to 
publish or perish, we’re going to end up with more confusion than actually answering questions. (Researcher, IRB, regulator, South Africa)  
Have a critical mass of investigators support the necessary changes so that they can lead to culture change, but culture change by itself is just a sociologic phenomenon. 
What we really want to look at is culture change that is supportive of new logistical implementation, operational and business practices. (Research institute, regulator, 
government sponsor, US) 
 If it is a multinational collaborative effort it will have a much stronger research question. Ensuring that trials are done in a more rigorous manner and ensuring quality 
control. So obviously there is some funding for these things. (Researcher, IRB, India) 
 
